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Abstract
In Staphylococcus aureus, the accessory gene regulator (Agr) system controls the
expression of toxins that damage the host. Agr is required for bacterial survival in
a range of animal infection models, although its role during bacteraemia is poorly
understood. Agr is also important for survival of S. aureus in the presence of neu-
trophils in vitro, but there is paradoxical clinical evidence that loss of Agr (either
via agr mutations or mutations that result in the small colony variant [SCV] phe-
notype) promotes bacterial survival during bacteraemia. Therefore, the aim of this
thesis was to decipher the role of Agr in the survival of S. aureus in blood. Mutants
with deletions in the agr operon or in genes that confer the SCV phenotype were
tested alongside their isogenic wildtype strain in an ex vivo whole human blood
model. Functional Agr was shown to be important for maximal survival of wild-
type S. aureus in blood. However, S. aureus could survive in an Agr-independent
manner as an SCV, the survival of which was much higher in blood than wildtype
bacteria. This elevated SCV survival in blood was due to increased resistance to the
neutrophil oxidative burst. For one SCV type, this was partly due to increased cata-
lase activity, although this was not the case for the other type of SCV examined,
suggesting additional mechanisms of oxidative stress resistance. Inductively cou-
pled plasma mass-spectrometry revealed that SCVs had reduced levels of iron and
increased levels of manganese relative to the wildtype, which could protect against
exposure to reactive oxygen species. In conclusion, the data within this thesis sup-
port the importance of Agr for S. aureus survival in the blood, as well as revealing
a novel Agr-independent mechanism by which S. aureus can persist in the host.
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Roads go ever ever on,
Over rock and under tree,
By caves where never sun has shone,
By streams that never nd the sea;
Over snow by winter sown,
And through the merry owers of June,
Over grass and over stone,
And under mountains in the moon.
Roads go ever ever on
Under cloud and under star,
Yet feet that wandering have gone
Turn at last to home afar.
Eyes that re and sword have seen
And horror in the halls of stone
Look at last on meadows green
And trees and hills they long have known
- The Hobbit: An Unexpected Journey
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Glossary
AdsA Adenosine synthase.
Agr Accessory gene regulator.
AhpC Alkyl hydroperoxide reductase.
AIP Auto-inducing peptide.
AMPs Antimicrobial peptides.
APC Antigen-presenting cell.
ApoB Apolipoprotein B.
Bcp Bacterioferritin comigratory protein.
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eDNA Extracellular DNA.
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FLIPr FPR-like 1 inhibitory proteins.
FnBP Fibronectin-binding protein.
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Ftn Ferritin.
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uorescent protein.
gIIA-PLA2 Group II phospholipase A2.
GPCRs G protein-coupled receptors.
H2O2 Hydrogen peroxide.
HA-MRSA Hospital-associated methicillin-resistant Staphylococcus aureus.
HBSS Hanks' Balanced Salt Solution.
Hla -toxin.
Hlb -toxin.
Hld -toxin.
HOCl Hypochlorous acid.
HQNO 4-hydroxy-2- heptylquinoline-N-oxide.
hVISA Heterogenous vancomycin-intermediate Staphylococcus aureus.
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ICP-MS Inductively Coupled Plasma Mass Spectrometry.
IE Infective endocarditis.
IR Intergenic region.
KatA Catalase.
kDa Kilodalton.
LB Lysogeny Broth.
LPS Lipopolysaccharide.
LTA Lipoteichoic acid.
MHC Major histocompatibility complex.
MIC Minimum inhibitory concentration.
MPO Myeloperoxidase.
MRSA Methicillin-resistant Staphylococcus aureus.
MSA Mannitol salt agar.
MSCRAMMs Microbial Surface Components Recognizing Adhesive Matrix Molecules.
Msr Methionine sulfoxide reductases.
MSSA Methicillin-sensitive Staphylococcus aureus.
NADPH Nicotinamide adenine dinucleotide phosphate.
NEB New England Biolabs.
NETs Neutrophil extracellular traps.
NLRs Nod-like receptors.
Nuc Staphylococcal nuclease.
O 2 Superoxide.
OD Optical density.
PAMPs Pathogen-associated molecular patterns.
PBMCs Peripheral blood mononuclear cells.
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PBP Penicillin-binding protein.
PCR Polymerase chain reaction.
PerR Peroxide responsive repressor.
PerR-Fe Iron-bound PerR.
PerR-Mn Manganese-bound PerR.
PFA Paraformaldehyde.
PIA Polysaccharide intercellular adhesin.
PMNs Polymorphonuclear leukocytes.
PRRs Pathogen recognition receptors.
PSMs Phenol-soluble modulins.
PVL Panton-Valentine leukocidin.
qPCR Quantitative real-time PCR.
QS Quorum-sensing.
RFU Relative uorescence unit.
ROS Reactive oxygen species.
Rot Repressor of toxins.
SAB S. aureus bacteraemia.
SAK Staphylokinase.
Sbi Staphylococcal IgG binding molecule.
SCCmec Staphylococcal Cassette Chromosome mec element.
SCIN Staphylococcal complement inhibitor.
SCVs Small colony variants.
SD Shine-Dalgarno.
SERAMs Secretable Expanded Repertoire Adhesive Molecules.
Sod Superoxide dismutase.
SOK Surface factor promoting resistance to oxidative killing molecule.
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Spa Protein A.
SSC Side scatter.
SSS Scalded skin syndrome.
SSTI Skin and soft tissue infection.
STX Staphyloxanthin.
SXT Trimethoprim-sulfamethoxazole.
TCA Tricarboxylic acid.
TCR T cell receptor.
TCS Two-component system.
TD-SCVs Thymidine-dependent small colony variants.
TLRs Toll-like receptors.
tPMP Thrombin-induced platelet microbicidal protein.
TSA Tryptic soy agar.
TSB Tryptic Soy Broth.
TSST Toxic shock syndrome toxin.
VISA Vancomycin intermediate-resistant Staphylococcus aureus.
VLT Vesicle lysis test.
VRSA Vancomycin-resistant Staphylococcus aureus.
vWbp von-Willebrand factor-binding protein.
vWF von Willebrand factor.
WT Wildtype.
WTA Wall teichoic-acid.
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1 Introduction
1.1 The pathogen Staphylococcus aureus
1.1.1 General characteristics of S. aureus
The bacterium Staphylococcus aureus is a member of the Micrococcaceae family, with
molecular taxonomics specically placing it in the Bacillus-Lactobacillus-Streptococcus
cluster [1]. The S. aureus genome is 2.8 megabase pairs in size with a GC content of 36%,
having acquired approximately 15% of its genome via horizontal gene transfer [2, 3].
S. aureus is a facultative anaerobe and can be identied in the diagnostic laboratory
as being Gram-positive and a producer of both coagulase and catalase [4]. It produces
highly-pigmented golden colonies when grown on agar plates and individual bacteria
are coccus-shaped when observed under a microscope [5]. It can be dierentiated from
related non-pathogenic species by plating onto mannitol salt agar (MSA) [6]. The high
salt content selects for members of the Micrococcaceae family and the mannitol can
generally only be fermented by pathogenic Staphylococci, resulting in a colour change in
the agar from red to yellow due to the presence of a pH indicator [6].
1.1.2 Infections caused by S. aureus
S. aureus was rst described by Sir Alexander Ogston in 1882 who observed grape-
like clusters of cocci-shaped bacteria associated with abscesses [5]. Ogston was able to
recreate a similar infection in mice by injecting the animals with pus derived from these
abscesses, thereby demonstrating that S. aureus was the causative agent of the infection
[5].
Abscess formation is only one of the many manifestations of S. aureus infection. In
fact, S. aureus is able to cause a wide range of dierent types of infections. These may
be relatively minor such as a skin and soft tissue infection (SSTI) or, when S. aureus is
able to overcome the skin barrier, it may cause much more serious and invasive infections
such as bacteraemia, osteomyelitis, meningitis, septic arthritis and endocarditis [4, 7].
Rare cases of necrotising fasciitis and necrotising pneumonia caused by S. aureus have
also been described [8, 9]. The entry site of the bacterium and host-specic factors both
inuence how the infection manifests [4]. As well as causing infections in humans, S.
aureus is also capable of infecting animals and its ability to cause bovine mastitis is a
signicant problem in the dairy industry [10].
1.1.3 Carriage of S. aureus
Whilst S. aureus can be extremely harmful to humans, it primarily exists as a com-
mensal organism, colonising regions of the body such as the perineum, chest, axillae,
hand and gastrointestinal tract [11]. However, the most common site of colonisation
is approximately 1{2 cm into the nasal cavity, on the squamous epithelium of the an-
terior nares [11{13]. At least 20% of the population are persistent nasal carriers of S.
aureus and at least a further 30% are transiently colonised [11, 14]. The remaining 50%
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are not colonised by S. aureus, although this is likely an overestimate as reports are
often based on one culture-negative swab [11, 14, 15]. There do, however, appear to be
clear dierences in the ability of S. aureus to colonise certain individuals. Whilst some
individuals are colonised persistently ( 154 days), others are colonised for very short
periods (4{14 days) [16]. This ability to colonise is not associated with geographic lo-
cation as numerous studies have found carriers world-wide regardless of how remote the
region is, indicating that there is a genetic basis for carriage [17]. Particular individuals
are certainly more susceptible, however, with HIV and diabetes patients more likely to
be carriers [14].
Colonisation by S. aureus occurs early in life, with newborns rapidly becoming car-
riers [18]. These rates of carriage decline sharply within the rst year of life, then peak
in children aged 6{12, before declining by the age of 18 [18]. Whilst some of this early
colonisation is likely due to transmission from the mother, the environment is an im-
portant contributing factor [19]. Transmission from the environment to the hands and
nally the nose appears to be a common route [20]. The nose of carriers may then act
as source for the transmission of S. aureus back into the environment [21].
1.1.4 Antibiotic resistance of S. aureus
The availability of penicillin G in the 1940s sparked optimism around the world and it was
thought that this would nally put an end to the high numbers of deaths attributed to
bacterial infection. Penicillin is a -lactam antibiotic produced by Penicillium moulds,
which kills bacteria by acting as a structural mimic of the D-alanine D-alanine (D-
Ala D-Ala) substrate targeted by transpeptidases during the process of peptidoglycan
synthesis [22]. Binding of the -lactam by the transpeptidase instead of its normal
substrate prevents growth of the bacterium as peptidoglycan synthesis is blocked and
this eventually leads to bacterial lysis [23].
The optimistic view that penicillin would be a permanent solution to the problem
of bacterial infection was rapidly crushed only two years after its rst use in hospitals,
when reports of penicillin-resistant organisms started to appear [24, 25]. S. aureus was
one of the rst organisms to acquire resistance to penicillin and by the 1960s, 80% of
isolates were resistant to the antibiotic [26]. Resistance was attributed to the presence of
a -lactamase enzyme encoded by the blaZ gene, that was able to hydrolyse the -lactam
ring of penicillin, thereby rendering the antibiotic inactive [27].
Resistance to penicillin spurred the development of a new, semi-synthetic -lactam
antibiotic called methicillin that was resistant to hydrolysis by -lactamases [26, 28].
However, following its introduction in 1959, it took just one year for methicillin-resistant
S. aureus (MRSA) to emerge. [29, 30]. Resistance was the result of horizontal gene
transfer of an element termed the Staphylococcal Chromosome Cassette mec element
(SCCmec) from a related staphyloccal species, reported to either be Staphylococcus sci-
uri or Staphylococcus euretti [28, 31, 32]. The SCCmec element contains the gene
mecA, which encodes a penicillin binding protein (PBP2a/PBP2') that functions as
a transglycosylase and transpeptidase involved in peptidoglycan biosynthesis [33, 34].
Importantly, PBP2a/PBP2' binds methicillin with very low anity, meaning peptido-
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glycan synthesis can continue even in the presence of the antibiotic [33, 34]. To date,
eleven SCCmec elements have been described, with elements I-IV most commonly found
in S. aureus isolated from infections [35]. Screening for these elements by polymerase
chain reaction (PCR) provides a quick method to determine if an isolate is resistant to
methicillin [35, 36].
The acquisition of the SCCmec element renders MRSA resistant to all -lactam
antibiotics, carbapenems and all but a recent generation of cephalosporins [28]. This
has led to the increased use of the antibiotic vancomycin in hospitals and a subsequent
selection for vancomycin-resistant isolates [37, 38]. Vancomycin is a glycopeptide that
also targets peptidoglycan synthesis. Rather than acting as a structural mimic like the
-lactams, vancomycin binds to the D-Ala D-Ala substrate and prevents its transpepti-
dation [39]. Resistance to vancomycin has arisen in two forms, resulting in vancomycin-
resistant S. aureus (VRSA) and vancomycin intermediate-resistant (i.e. insensitive) S.
aureus (VISA) [37, 38]. VISA strains may also exist as a sub-population of a strain
otherwise sensitive to vancomycin, referred to as heterogenous VISA (hVISA) [40]. The
minimum inhibitory concentration (MIC) of vancomycin required to inhibit growth in
VISA strains is  4{8 g ml 1, compared to  2 g ml 1 in sensitive strains [41]. VISA
strains originate after exposure to vancomycin, via the accumulation of adaptive muta-
tions that result in increased peptidoglycan synthesis and thick cell walls, where excess
D-Ala D-Ala residues are thought to trap vancomycin and prevent it from aecting pep-
tidoglycan synthesis in the deeper layers [40]. VRSA strains are dened as having an
MIC of  16 g ml 1 and some strains have even been isolated with MICs of over 128
g ml 1 [41, 42]. VRSA strains acquire their resistance by horizontal gene transfer of
vanA from Enterococcus faecalis, which enables S. aureus to switch to using the D-Ala
D-Lac peptide rather than D-Ala D-Ala [43]. As vancomycin has a reduced anity for
the D-Ala D-Lac substrate, this enables S. aureus to continue peptidogylcan synthesis
[26]. In addition, genes transferred along with vanA are thought to increase subsequent
rates of conjugation and this may enable S. aureus to acquire further antibiotic resis-
tance genes from other organisms [44]. Vancomycin is used as a last-resort antibiotic at
present and VRSA strains are therefore relatively rare [45]. However, the increasing use
of vancomycin, will likely result in ever greater selection for strains with the vanA gene.
Although newer drugs such as daptomycin, ceftaroline, and tigecycline now exist,
which can be used against MRSA, resistance is already emerging [46, 47].
1.1.5 The emergence of community-associated MRSA
Antibiotic usage in the hospital environment selected for hospital-associated MRSA (HA-
MRSA), which mainly infected immunocompromised individuals with long or frequent
stays in the hospitals, such as HIV patients or individuals with diabetes [48]. One of the
most prevalent HA-MRSA strains in Europe, including the UK, is EMRSA-16. After its
appearance in 1991, it has since spread to the United States, establishing itself as the
second most common HA-MRSA strain [48, 49]. However, since 2003, the numbers of
infections caused by EMRSA-16 in the USA have declined following the emergence of
strains such as the Southwest Pacic clone and USA300 (see below) [48, 50].
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In the 1990s, MRSA capable of infecting healthy individuals in the community
(community-associated MRSA; CA-MRSA) emerged [48]. CA-MRSA was initially iso-
lated from indigenous populations but strains rapidly spread across the world [51, 52].
Although not always true, CA-MRSA strains are generally more virulent than HA-MRSA
strains, enabling them to infect healthy individuals [53]. The presence of the type IV
SCCmec element, as opposed to the type II element commonly found in HA-MRSA,
is also thought to contribute to the overall tness of CA-MRSA as this element is the
smallest of all the types resulting in a lower tness cost to the organism [54].
One particular CA-MRSA strain that has dominated the United States is USA300,
which is highly-transmissible and resistant to many antibiotics, including erythromycin,
tetracycline, mupirocin and lindamycin [55{57]. Although the distinction between HA-
MRSA and CA-MRSA was initially very clear cut, CA-MRSA have now entered the
hospital and horizontal gene transfer between these two groups has caused this distinction
to become blurred [55, 58].
1.2 S. aureus virulence factors and the Agr two-component system
1.2.1 The accessory gene regulator system
The ability of S. aureus to colonise a host but not cause infection suggests that it is
able to control the production of virulence factors, such as toxins, that would normally
cause damage to the host. S. aureus has at least 16 two-component regulatory systems
(TCS) that enable it to sense environmental factors and control the expression of genes
[59]. The accessory gene regulator (Agr) system is one of the best characterised and
is the dominant TCS involved in controlling the expression of many of the virulence
factors identied in S. aureus [60, 61]. It is, therefore, not too surprising that Agr has
been shown to be important for virulence in a wide range of in vivo animal models
of infections. For example, Agr has been shown to contribute to SSTIs, pneumomia,
osteomyelitis, infective endocarditis, bacteraemia and abscess formation [4, 62{69].
The Agr TCS was rst identied as a result of strains identied with mutations
located between the purB and ilv loci of the S. aureus genome [70]. These mutants
lacked expression of a number of toxins normally produced by S. aureus such as -toxin
(Hla) and toxic shock syndrome toxin (TSST-1), and showed up-regulation of surface
proteins such as Protein A (Spa) [70, 71]. Ji et al. (1995) later determined that Agr
functions as a quorum-sensing (QS) system that is able to regulate expression of a number
of genes in response to cell density and the concentration of a signalling molecule [72].
QS systems have been identied in both Gram-positive and Gram-negative bacteria
[73]. Whilst Gram-negatives generally utilise N-acyl-homoserine lactones that are de-
tected by an intracellular receptor, Gram-positives utilise peptides that are secreted from
the cell and sensed by an extracellular receptor [61]. S. aureus produces a 7{9 residue
cyclic peptide called auto-inducing peptide (AIP), which harbours a 5-residue lactone
or thiolactone ring formed between a cysteine and carboxyl group, which is essential
for activation of the Agr system [74{76]. Binding of AIP to the AgrC receptor on the
bacterial cell surface results in activation of the Agr system and increased production of
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AIP [77]. Therefore, activation of Agr relies on high levels of AIP in the environment
and so tends to occur when bacterial cell density is high [77].
The Agr system is encoded by the agr operon, consisting of agrBDCA (encoding the
QS system) and RNAIII (encoding a regulatory RNA that acts as the primary eector
molecule of the agr system and also encodes -toxin [Hld]) [70, 72, 77]. The agr operon
is divergently transcribed, with RNAII under the control of promoter P2 and RNAIII
under the control of promoter P3 (Figure 1.1) [77]. A basal level of transcription of
the agr system prior to exponential phase growth is controlled by the binding of the
activator SarA to the intergenic (IR) region of RNAII and RNAIII [64, 78]. This leads
to the production of AgrD, which encodes a pro-peptide that is processed to form AIP
[60, 61]. The AgrD pro-peptide contains an N-terminal amphipathic leader sequence
that directs it to the membrane where the SpsB type I peptidase is thought to cleave
o the N-terminal leader [79]. AgrB is a transmembrane protein that likely acts as a
cysteine protease to cleave the C-terminal tail of AgrD [79{81]. Through an unknown
process, likely to be carried out by AgrB, formation of the nal AIP molecule is achieved
by generation of the lactone or thiolactone ring and this processed molecule is then
exported from the bacterial cell into the extracellular milleu [72].
The cyclic ring of AIP is thought to target the molecule to the AgrC receptor, a
histidine kinase that is likely activated by the tail region of the AIP molecule [82].
There are four types of AIP found in S. aureus strains (AIP1, AIP2, AIP3 and AIP4),
with each strain capable of producing only one type of AIP [60]. This variation is a
result of a hypervariable region that spans agrBDC [83]. Each AIP type has evolved
to only activate its corresponding or cognate receptor [84, 85]. Binding of an AIP to
a receptor other than its cognate receptor prevents Agr activation, except with Agr-
1 which can be weakly activated by AIP4 as it only diers from AIP1 by one amino
acid [84]. This competitive antagonism between the dierent AIP types, referred to as
`interference', is reversible as the antagonist can be displaced upon exposure to an AIP
of the corresponding Agr type [82, 85].
AgrC is a transmembrane protein that appears to act like conventional homodimeric
sensor kinases [60, 61]. It has been suggested that the second transmembrane loop of
AgrC is involved in binding the AIP molecule, whilst the rst transmembrane loop is
involved in Agr activation after binding to the N-terminal tail of AIP [86, 87]. AIP
binding results in autophosphorylation of a histidine residue within AgrC, enabling it
to activate the Agr system by transferring its phosphate to an aspartic residue on the
response regulator AgrA [60].
AgrA is member of the LytTR family of transcription factors and completes the au-
toactivation circuit of the Agr system by binding to the IR region of the agr operon [88].
This leads to full activation of the Agr system during late- to post-exponential phase
as AgrA is a stronger activator than SarA and, compared to production in exponential
phase bacteria, levels of RNAIII double upon the production of active AgrA [89]. Al-
though AgrA is the response regulator of the system, the main eector that regulates
the expression of adhesins and toxins is RNAIII [90]. AgrA does, however, regulate a
subset of genes including downregulation of genes involved in carbohydrate and amino
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Figure 1.1: The Agr system. During exponential phase growth, the Agr system
is switched o, resulting in a high expression of adhesins and low expression of toxins,
thereby promoting the colonisation of S. aureus. Towards late- to post-exponential
phase, the Agr system is switched on, with increased expression of agrBDCA (RNAII)
leading to the increased production of autoinducing peptide (AIP). AIP is sensed by
AgrC, which activates AgrA, the response regulator of the system. AgrA activates
expression of the PSMs and metabolic genes, as well as completing the autoactivation
circuit by activating further expression of RNAII and RNAIII. RNAIII, the RNA eector
molecule, activates the expression of toxins and represses the expression of adhesins.
acid metabolism and staphyloxanthin (STX) biosynthesis, and upregulation of a group
of small cytolytic toxins called the phenol-soluble modulins (PSMs) [91].
The RNAIII component of the Agr system comprises the coding sequence for Hld
and the RNA eector molecule RNAIII. The RNAIII transcript is 514 nucleotides in
length and comprises 14 hairpins and 3 other domains that enable it to function as both
a post-transcriptional activator and repressor [70, 92, 93]. Once expressed, RNAIII has
a half-life of approximately 45 minutes and positively or negatively regulates by either
revealing or masking the Shine-Dalgarno (SD) sequence, respectively, on specic target
mRNAs [94]. The SD sequence is required for the 16S ribosomal subunit to recognise
mRNA and initiate its translation into protein [95]. For example, binding of RNAIII to
the 5' untranslated region of the mRNA encoding Hla, causes RNAIII to relieve a hairpin
structure that normally masks the SD sequence and therefore prevents translation [90].
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RNAIII also indirectly regulates gene expression through its negative regulation of
the repressor of toxins (Rot) protein, which upregulates the expression of adhesins such
as Spa and downregulates toxins such as Hla [92, 96]. RNAIII also acts in concert with
RNase III, which degrades mRNAs that it is targeted to, thereby reducing their half-life
[94]. Both Spa and Rot are examples of RNase III targets [94].
The Agr system is able to control a wide range of genes including toxins, immune
evasion molecules and genes involved in metabolism, using AgrA and RNAIII to control
gene expression in response to the signalling molecule AIP. Overall, activation of agr is
thought to mark a distinct shift in the expression prole of S. aureus and enable it to
switch from an organism that is highly adapted to adherence to host tissues, to one that
is capable of causing signicant damage to the host tissues, allowing it to gain access to
nutrients and proliferate [97]. The next two sections will describe the two major classes
of virulence factors that are inuenced by agr : the surface proteins, downregulated by
agr and involved in adhesion, and the toxins upregulated by agr and involved in host
damage.
1.2.2 Adhesins
S. aureus encodes over twenty dierent proteins that have been implicated in promoting
adhesion to host tissues or proteins (Figure 1.2A) [98]. Although these were previously
categorised into MSCRAMMs (Microbial Surface Components Recognizing Adhesive
Matrix Molecules) and SERAMs (Secretable Expanded Repertoire Adhesive Molecules),
it is now known that many of these molecules have additional functions aside from
adhesion [99{101]. Therefore, it is better to describe adhesins as either being cell wall-
associated or secreted surface proteins.
Adhesins that are cell-wall associated are generally secreted via the Sec translocon
and covalently bound to peptidogylcan by the sortase enzyme, which recognises, cleaves
and anchors proteins containing an LPXTG motif [102]. In most cases, this is done using
sortase A, although a second sortase, sortase B, specically processes the adhesin IsdC
[103]. Cell-wall associated adhesins include clumping factors A and B (ClfA and ClfB),
collagen adhesin (Cna), bronectin-binding proteins A and B (FnBP-A and FnBP-B)
and Spa [99, 100]. In each case, the specic adhesins bind to host extracellular matrix
(ECM) molecules. ClfA and ClfB bind brinogen, Cna binds collagen, FnBP-A and
FnBP-B bind bronectin and Spa binds von Willebrand factor (vWF) [104{107]. Al-
though adhesins have primary targets that they bind with high eciency, adhesins often
bind multiple ECM molecules, such as the FnBPs that are capable of binding brinogen
and elastin as well as bronectin [108]. Eap, a secreted adhesin, can bind bronectin,
vitronectin, prothrombin and brinogen and this enables it to adhere to host cells [98].
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Figure 1.2: The adhesins and toxins of S. aureus. (A) Adhesin molecules known to be
important during S. aureus infection are shown with their host targets listed. In addition to
attachment, S. aureus can invade host cells by forming a bronectin bridge between the 51
integrins and the FnBPs. (B) The toxins produced by S. aureus and their targets are shown.
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Adhesins have been implicated in numerous infections including skin abscesses, en-
docarditis, bacteraemia, septic arthritis and sepsis [98, 109{115]. Adhesion to the tissue
enables bacteria to colonise the host and establish an infection. For example, colonisa-
tion of the nasopharynx is aided by ClfB, which binds to cytokeratin 10 on epithelial cells
and other adhesins, such as SasG, wall-teichoic acid, IsdA and SdrG, are also thought
to contribute [98, 116{118]. In addition, skin colonisation is facilitated by the FnBPs,
which can bind ECM proteins such as bronectin and brinogen that are exposed upon
skin damage [112, 119]. ClfA and the FnBPs are also involved in the colonisation of
cardiac vegetations, which become coated in ECM proteins [100, 113].
Adhesion is also a pre-requisite for S. aureus to invade host cells [120]. Although S.
aureus generally functions as an extracellular pathogen, numerous studies have shown
that it can invade and persist in a wide range of non-professional phagocytes [121{125].
Survival inside host cells enables S. aureus to evade immune surveillance and may provide
a way for the pathogen to disseminate to other parts of the body [126, 127]. Uptake has
mainly been shown through the binding of FnBPs to 51 integrins on host cells, which
stimulates actin rearrangement and engulfment of the bacterium [128{132].
S. aureus can adhere to damaged tissue, heart valves and medical devices (such as
intravenous catheters and prosthetic joints), which become coated in host proteins, and
accumulate to form biolms [133]. Due to the diculty of eradicating biolms, they
cause signicant problems in hospitals, often leading to persistent infections [134]. At
least two types of S. aureus biolms exist, polysaccharide intercellular adhesin (PIA)
mediated biolms and those mediated by protein adhesins [135]. PIA-dependent biolms
are generally formed by methicillin-sensitive S. aureus (MSSA) strains and are induced
by sodium chloride, resulting in the production of PIA, a polysaccharide with a positive
charge that enables S. aureus to adhere to inert surfaces [135, 136]. The PIA-independent
biolms are often formed by MRSA strains and are induced by glucose, which acidies
the growth medium [137]. Autolysins such as Atl are implicated in PIA-independent
biolms, with autolysis and the release of extracellular DNA (eDNA) required for biolm
formation [138]. Other adhesins may have roles in biolm formation such as SasG and
FnBPs, although it is not known if biolms formed by these adhesins are distinct from
the autolysin-dependent biolms [139]. Previous work has shown that down-regulation
of Agr is important for the initial steps of biolm formation, with agr expression associ-
ated with biolm dispersal [140]. However, this appears to be a gross oversimplication
as bacteria within a planktonic biolm all express agr, albeit to varying degrees [141].
Clearly, more research is needed to fully understand biolm formation as dierent com-
ponents may be more or less important depending on the the host niche, for example;
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ow, nutrients and the type of surface may inuence outcomes.
Although agr downregulation is often associated with the increased expression of
adhesins, so far, negative regulation directly by agr has only been described for the
FnBPs, Spa, capsule and Aaa [60]. However, it is known that Rot, which is negatively
regulated by RNAIII, positively regulates the expression of additional adhesins such as
ClfB [142].
1.2.3 Toxins
The Agr system regulates the production of a large range of dierent toxins that cause
damage to the host, either by directly lysing cells, or by causing massive activation of
the immune system, which can lead to septic shock (Figure 1.2) [143]. The majority
of these toxins are regulated by RNAIII, except the PSMs, which are regulated directly
by AgrA [91]. Interestingly, CA-MRSA strains are known to have higher levels of Agr
expression than HA-MRSA strains, which is thought to contribute to their increased
virulence [144, 145]. Each of the major toxins produced by S. aureus is discussed briey
below.
Hla is a 33 kDa -barrel protein that binds to certain host cells, where it oligomerises
to form 11.4 A heptameric pores [146, 147]. Pore formation leads to the eux of ATP
and potassium ions and an inux of calcium, resulting in lysis of the host cell [148{150].
Although Hla was initially identied via a transposon mutant that lacked haemolytic
activity when grown on CBA, Hla is also capable of lysing monocytes, platelets, epithe-
lial cells, broblasts, macrophages and lymphocytes, as well as erythrocytes [151{154].
Hla binds to host cells via the ADAM10 receptor, a zinc-dependent metalloprotease,
involved in maintaining cell-cell adhesion and integrity [155]. Binding to ADAM10 on
endothelial and epithelial cells results in the cleavage of e-cadherin, which leads to degra-
dation of adherens junctions and the disruption of focal adhesion complexes, culminating
in detachment of the basal membrane [155]. This results in increased membrane per-
meability and may enable S. aureus to invade the surrounding tissue [146, 147]. Hla
has been shown to be important in animal models of SSTIs, pneumonia, sepsis, bacter-
aemia, peritonitis and during infections that aect the cornea, central nervous system
and mammary glands [66, 68, 156{161].
-toxin (Hlb) is a sphingomyelinase that is able to cause hot-cold lysis on CBA,
degrading the sphingomyelin in erythrocytes at 37C but only causing full haemolysis
after subsequent incubation at 4C [162]. In the majority of human clinical strains, the
hlb gene is disrupted by a prophage (Sa3), rendering it inactive [163, 164]. However,
exposure to oxidative stress may trigger loss of the phage and production of functional
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toxin [165{167]. Hlb is mainly active in isolates derived from infected animals and is
capable of lysing sheep erythrocytes and human monocytes [162, 164, 168{170]. Synergy
of -toxin with -toxin may also contribute to the intracellular survival of S. aureus in
non-professional human phagocytes [171].
The leukocidins are a group of receptor-mediated toxins capable of lysing leukocytes
such as macrophages, monocytes and neutrophils and some are also capable of lysing
erythrocytes [172]. Leukotoxins consist of two components, the class F protein (HlgB,
LukF, LukD, LukF', LukA/G) and the class S protein (HlgA, HlgC, LukS, LukM, LukE,
LukB/H) [143]. Each class F protein has a corresponding class S protein, although
HlgB can bind either HlgA or HlgC [173]. The toxins function by binding to specic
receptors on the host cell, which stimulates the oligomerisation of octameric -barrel
pores consisting of alternating F and S subunits [174{176]. Whilst the dierent F and S
subunits may combine outside of their corresponding classes to function synergistically,
certain combinations may actually reduce the ability of S. aureus to lyse host cells by
forming inactive combinations [177, 178]. It has been dicult to assess the importance
of each of the leukotoxins during infection as some of the toxins bind specic host
cell receptors that restrict it to certain species. For example, both Panton-Valentine
leukocidin (PVL) and LukAB/GH are able to lyse cells within humans and rabbits but
not mice [179, 180]. This means that many of the studies that have evaluated the role
of PVL in mice may not accurately reect what happens in humans. Additionally,
expression of the leukotoxins is highly inuenced by the medium used to grow S. aureus,
with toxin expression lowest in tryptic soy broth, one of the most commonly used growth
media [181]. Each of the leukotoxins that have been identied and their targets during
infection are summarised in Table 1.1.
30
Table 1.1: The S. aureus leukotoxins
Toxin Target cells killed Host specicity Diseases
PVL (LukFS) Monocytes, neutrophils, macrophages [179,
182, 183]
Human, rabbit [179] SSTIs, osteomyelitis, necrotising pneumonia,
bacteraemia [184{188]
HlgAB Erythrocytes (mainly), leukocytes [178] Broad [172] Septic arthritis, ocular infections, acute sep-
sis, endophthalmitis, bacteraemia [180, 189{
191]
HlgCB Erythrocytes, leukocytes (mainly) [178] Broad [172] Septic arthritis, ocular infections, acute sep-
sis, endophthalmitis, bacteraemia [180, 189{
191]
LukAB/GH Neutrophils, macrophages, monocytes, den-
dritic cells [180, 192, 193]
Human, rabbit [180, 194] SSTIs, renal abscesses [180, 192]
LukED Neutrophils, monocytes, macrophages, T
cells, dendritic cells, NK cells [195, 196]
Broad [195, 197] Acute sepsis, renal abscesses, bacteraemia
[195{197]
LukF'M Bovine neutrophils, macrophages [198, 199] Bovine [199] Bovine mastitis [200]31
The enterotoxins are a group of 20{30 kDa proteins, that cause food poisoning, toxic
shock syndrome and inammation of the skin and airways [143]. Foreign antigens are
taken up by antigen presenting cells (APCs) and presented to T cells via the major
histocompatibility complex (MHC) class II molecule [201]. T cells are activated upon
interaction of the T cell receptor (TCR) with an MHC class molecule containing the
processed antigen [201]. Some enterotoxins act as superantigens and bind to the V
region of the TCR and the MHC class II molecule, leading to activation of up to 20-50%
of the host's T cells [202]. This makes the host highly susceptible to antigens such as
lipopolysaccharide (LPS), a common component of the microbiota, which results in the
production of a large amount of cytokines [203]. This `cytokine storm' leads to toxic
shock, which is often fatal [204]. Production of the cytokine storm may also result in T
cells becoming anergic and even death of the T cell, preventing the host from developing
immunity to future S. aureus infections [205, 206].
Scalded skin syndrome (SSS) and bullous impetigo are serious SSTIs, caused by S.
aureus, that typically aect neonates and infants [207]. These infections are caused by
the expression of exfoliative toxins (mainly Eta or Etb), which are serine proteases that
degrade desmoglein 1, which is found in the supercial layers of skin and is required for
the cell-cell adhesion of keratinocytes [208]. Degradation of desmoglein 1 leads to SSS,
which manifests as a rash, followed by the production of blisters that burst, making the
individual susceptible to secondary infections by other pathogens [207]. There is also
evidence to suggest that the exfoliative toxins may also act as superantigens to activate
T cells, although their action is much weaker than TSST-1, another Agr-regulated toxin
[71, 209].
Finally, the PSMs are a group of -helical, cytolytic peptides that have reported roles
in SSTIs and bacteraemia [210]. The PSMs are separated into two groups: the 20{26
amino acid long -PSMs and the 43{44 amino acid long, -PSMs [210]. Hld, which is
co-transcribed with RNAIII, is similar to the -PSMs. Five -PSMs have been identied
(including Hld), which are capable of lysing both erythrocytes and leukocytes [210]. In
addition to killing host cells, the PSMs are also involved in the formation of biolms
due to their surfactant-like properties and their ability to form amyloid bers [211, 212].
Recent evidence has also shown that the N-terminal leader peptide of AgrD (the AIP
pro-peptide) functions like the PSMs and can lyse both erythrocytes and neutrophils,
and can form amyloid bres that may contribute to biolm formation [213, 214].
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1.2.4 Regulators of the Agr system
Many of the regulatory systems in S. aureus are interconnected, making it very dicult
to dissect which transcription factors regulate Agr [215]. Levels of agr mRNA are con-
trolled by the RNA helicase, ensuring that the agr system is not fully activated until
AIP levels are suciently high [216].
So far, SarA is the only regulator that has been shown to directly bind to the IR
region of the agr operon and positively regulate expression [217]. Although a number
of other regulators (SarU, SarX, SigB, SrrAB, ClpP, MgrA, Msa, CcpA, ArlRS, CrfA)
have all been linked to regulating agr expression, this appears to occur as an indirect
mechanism [61].
1.3 S. aureus bloodstream infections
After the coagulase-negative staphylococci, S. aureus is reported to be the most common
cause of bacteraemia [218]. In 2013/14, 10,152 cases of S. aureus bacteraemia (SAB)
were reported in the UK, with the majority of these cases (92%) caused by MSSA [219].
Whilst cases of MSSA appear to be on the rise, cases of MRSA are declining in the UK
[219].
Individuals most at risk of acquiring SAB include the elderly, those frequently in
hospital (for example, haemodialysis patients) and patients that have one or more co-
morbidities such as alcoholism or immunosuppression (including HIV patients) [220].
Identication of SAB is by a positive blood culture and is dened as community-
associated if the culture is positive less than 48 h after admission, or healthcare-associated
if the culture is positive more than 48 h after admission [220]. S. aureus colonises wounds
and catheters and this provides a direct route to the bloodstream, resulting in SAB [221].
Surgery involving prosthetic joints or devices also places individuals at risk for SAB be-
cause of the ability of S. aureus to form biolms on abiotic surfaces [222]. In the majority
of cases, SAB is caused by bacteria derived from the nasopharynx that are transferred
to a vulnerable body site where the strain can enter the bloodstream [223]. Healthcare
workers and patients that are in the hospital for prolonged periods are known to be
frequent carriers of S. aureus and so transmission is high within nosocomial settings
[21].
During SAB, approximately a third of infections will become metastatic, with S.
aureus disseminating to other sites of the body, where it can cause serious infections
such as infective endocarditis (IE), septic arthritis, osteomyelitis and tissue abscesses
[7, 224]. Cases of SAB are dened as either being simple, uncomplicated or complicated
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[7]. Complicated SAB occurs in approximately 40% of SAB cases and is identied as
the patient having a secondary infection, a recurrent infection (after a 12 week follow
up), attributable mortality or embolic stroke [7]. Mortality of SAB is in the range of 13{
30%, although it becomes much higher when the infection is complicated, particularly
when a patient develops IE [225, 226]. Although carriers of S. aureus tend to be more
susceptible to developing bacteraemia, they tend to have better outcomes than non-
carriers and this may be because carriers produce partially protective antibodies against
S. aureus [223, 227, 228].
After identication of a SAB case, the patient is treated by removing the focus of
infection (such as a catheter or prostheses) if easily-identiable and removable, before
treatment with antibiotics [229]. When SAB is caused by an MSSA strain, the patient
is commonly treated with semi-synthetic penicillins such as cefazidin or ucloxacillin,
or daptomycin if the patient is allergic to penicillin [229, 230]. For MRSA SAB cases,
patients are typically treated with either vancomycin or daptomycin, although other
antibiotics such as linezolid, teicoplanin or trimethoprim-sulfomethoxazole (SXT) may
be used [229]. Vancomycin has been associated with worse outcomes than -lactams
when used to treat SAB caused by MSSA [230]. Antibiotic treatment is usually continued
for up to 14 days during uncomplicated SAB but may be extended to six weeks or more
when the infection is complicated or deep-seated [221, 231].
1.4 Immune targeting of S. aureus in the bloodstream
1.4.1 Opsonisation of S. aureus
Host recognition of S. aureus in the bloodstream involves a number of dierent immune
cells and mechanisms, as shown in Figure 1.3. The immune system initially recog-
nises S. aureus via antibodies and the complement system, which both function to coat
the bacteria in a process known as opsonisation, which promotes the phagocytosis and
clearance of bacteria by immune cells [201].
During an S. aureus infection, antibodies may be generated against antigens such
as Hla and IsdB [232, 233]. By binding to Hla, antibodies are able to neutralise the
toxin as well as signal to other immune cells that there is an infection [234]. Signalling
occurs by immune cells recognising the constant region of antibodies via Fc receptors
[201]. Additionally, APCs may engulf the antibody and present the antigen to T cells,
which can assist in killing and are involved in the development of immune memory that
helps prevent future infections [201]. Interestingly, despite the ability of humans to
produce antibodies against S. aureus, these rarely prevent subsequent infection and this
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Figure 1.3: Recognition of S. aureus in the bloodstream. Immune cells such
as neutrophils express a number of receptors on their cell surface that enable them to
recognise S. aureus. As well as the Fc receptors that recognise antibodies that have
bound antigens, neutrophils express GPCRs (such as FPR1 and FPR2), TLRs (such
as TLR4 and TLR2) and complement receptors (such as C5aR). In addition to sensing
extracellular signals, neutrophils can sense the presence of S. aureus in the phagosome
via the Nod2 receptor and TLR9.
is thought to be one of the reasons why vaccine attempts against S. aureus have so far
been unsuccessful [235].
The complement system is made up of more than 20 proteins that, upon binding to
a pathogen, activate a cascade enabling the detection of pathogens even when numbers
are very low [201]. There are three dierent complement pathways that all converge to
activate the C3 complement protein [236]. The classical pathway is activated after one
of the early complement proteins (C1) binds to bacteria or to an antibody. The alter-
native pathway is always switched on at a low level, leading to the continual production
of C3 that will only activate the complement system fully after binding to a bacterium.
The lectin pathway is activated after proteases from the complement system recognise
carbohydrate-binding proteins such as mannose-binding lectin that have bound to spe-
cic carbohydrates on bacteria. Activation of the C3 protein results in the production of
opsonins (such as C3b) that coat the bacteria and anaphylatoxins (such as C3a), which
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contribute to inammation and attract immune cells [237].
1.4.2 Priming and activation of immune cells in the bloodstream
The bloodstream contains a large number of circulating immune cells, including mono-
cytes (precursors to macrophages that largely reside in tissue), neutrophils and dendritic
cells (DCs), that are capable of recognising and engulng S. aureus. These APCs are
able to recognise foreign organisms by detecting `non-self' molecules, such as peptido-
glycan and unmethylated cytosine-phosphate-guanosine motifs (CpG) on DNA, which
are referred to as pathogen-associated molecular patterns (PAMPs) [238]. PAMPs are
recognised by dedicated receptors (pattern recognition receptors or PRRs) on host cells
and PRR binding primes immune cells for phagocytosis and stimulates the production
of cytokines and chemokines that lead to the recruitment and activation of additional
immune cells [201]. Several dierent PRRs enable host cells to detect diverse PAMPs.
The Toll-like receptors (TLRs) are one family of PRRs, which consist of ten dierent
receptors that each recognise dierent PAMPs [239]. TLRs may be either extracellular
or intracellular, enabling the recognition of both extracellular pathogens, and pathogens
that have been engulfed by phagocytic immune cells [201]. S. aureus is recognised
by TLRs such as TLR2 (via peptidogylcan), TLR4 (via the leukocidins), TLR9 (via
unmethylated CpG motifs on DNA) and the TLR2/6 heterodimers (via the diacylated
groups on lipoproteins) [240{243]. The Nod-like receptors (NLRs) are another family
of PRRs, although their functions are less well-understood. The NLRs are particularly
important at recognising bacteria with Nod1 generally involved in the recognition of
Gram-negatives (through binding meso-diaminopimelic acid), whilst Nod2 recognises
muramyl dipeptides and is important in the recognition of Gram-positives such as S.
aureus (Figure 1.3) [244{247].
1.4.3 Recruitment of neutrophils to the site of infection
Recognition of S. aureus by PRRs and receptors that bind antibody or complement
stimulates a downstream signalling cascade in APCs. For example, activation of TLRs
and NLRs leads to the intracellular recruitment of proteins that enables the transcription
factor NF-B to enter the nucleus and activate expression of the cytokines TNF-, IL-
1 and IL-6 [201]. The release of cytokines results in inammation and the recruitment
and activation of additional immune cells. Chemokines such as the complement pro-
tein C5a and CXCL8 (produced by APCs, epithelial and endothelial cells after pathogen
recognition) specically recruits neutrophils, professional phagocytes that are highly spe-
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cialised at killing pathogens [248]. Neutrophils also express the formyl peptide receptors
(FPRs), FPR1 and FPR2, which are G protein-coupled receptors (GPCRs) that are
involved in the recognition of S. aureus [239]. FPR1 recognises N-formylated peptides
that are secreted upon bacterial growth and FPR2 is capable of recognising the PSMs
[249, 250]. FPR1 or FPR2 binding also leads to the recruitment of neutrophils to the
site of infection.
1.4.4 Killing of S. aureus by neutrophils
Neutrophils are derived from pluripotent haematopoietic stem cells that mature for 6.5
days in the bone marrow before entering the bloodstream [251]. After entry into the
bloodstream, neutrophils circulate for only 10{12 hours before extravasation into tis-
sues where they undergo apoptosis [251]. Dead neutrophils are then cleared away by
macrophages via a process known as eerocytosis [252]. Approximately 3   6  106
neutrophils are found within 1 ml of human blood, which enables the host to respond
quickly to infection [253]. In addition, upon infection, neutrophil production increases
[254]. Whilst neutrophils are normally short-lived, the release of pro-inammatory cy-
tokines such as TNF- and IL-1 and TLR2 recognition of lipoteichoic acids (LTA) from
S. aureus delay apoptosis [255]. This ensures that a large number of neutrophils are able
to contribute to the clearance of an infection.
The importance of neutrophils in combating S. aureus infection is highlighted by
the recurrent staphylococcal infections that are suered by patients with neutropenia or
individuals with disorders that aect neutrophil function [255]. For example, neutrophils
derived from patients with chronic granulomatous disease (CGD) or Chediak-Higashi
syndrome are unable to kill as eectively [256{258].
After neutrophils arrive at the site of infection, bacteria are taken up in a process
known as phagocytosis, which was rst observed by Elie Metchniko in the 1880s. The
bacteria become enclosed in the phagosome, a 1.2 m compartment derived from the
plasma membrane [259, 260]. Nutrients are highly restricted in the phagosome by the
host proteins lactoferrin and calprotectin, which sequester iron and zinc and manganese,
respectively [261]. Since these elements are important for the bacterial metabolism, the
majority of bacteria (including S. aureus) are unable to grow in this environment [262].
Neutrophils store several dierent antimicrobial molecules within granules when they
are inactive. This enables rapid release upon exposure to pathogens. There are three
types of granules found within neutrophils, the primary or azurophilic granules, the sec-
ondary granules and the tertiary granules [263]. The primary granules contain lysozyme,
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bactericidal/permeability-increasing protein (BPI), defensins and proteases such as elas-
tase, cathepsin G and proteinase 3. The secondary granules contain lactoferrin, NGAL,
hCAP-18, lysozyme, collagenase, azurocidin and a number of chemokines and cytokines.
Finally, the tertiary granules contain metalloproteases, such as gelatinase. Phagocytosis
leads to degranulation, with each of the granules rapidly fusing with the phagosome to
form the phagolysosome (Figure 1.4) [263]. The phagosome swells upon granule fu-
sion but the contents remains highly concentrated [264]. Whilst initially the pH of the
phagosome is 7.4{7.8, this lowers to a pH of 6{6.5 within one hour after phagocytosis
[259].
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Figure 1.4: Host defence against S. aureus in the bloodstream. There are a number
of dierent mechanisms that the host employs to defend against S. aureus infection. Firstly,
neutrophils can undergo NETosis (A), releasing their plasma membrane, chromatin, histones
and granules into the extracellular environment to trap bacteria and neutralise their toxins.
Secondly, platelets in response to bacteria can activate and form a brin clot (B), thereby
trapping bacteria and exposing them to high concentrations of tPMPs. Finally, neutrophils can
phagocytose S. aureus (C) and in the phagosome, bacteria are exposed to ROS and proteins
released from granules.
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Some of the antimicrobial molecules found within the granules can kill S. aureus,
for example, hCAP-18 and cathepsin G [265, 266]. Furthermore, the production of
defensins and elastase may neutralise the eects of some of the staphylococcal toxins
[261, 267]. However, unlike Escherichia coli and Streptococcus pneumoniae, S. aureus is
highly resistant to many of the antimicrobial molecules generated by neutrophils [268].
Therefore, neutrophils employ a second mechanism of killing microbes, through the
generation of a respiratory burst, which is active against S. aureus [261].
The respiratory burst occurs within the phagosome 20{90 min after phagocytosis
and involves the generation of reactive oxygen species (ROS) [259, 269]. Generation of
ROS requires the action of the nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase or Nox-2, which binds to the phagosomal membrane and transfers electrons from
cytosolic NADPH through an FAD molecule and two cytochrome b hemes to oxygen in
the phagosome [264]. Continual NADPH oxidase activity requires the hexose monophos-
phate shunt pathway to regenerate NADPH [259]. Individuals with CGD do not produce
active NADPH oxidase and the frequent staphylococcal infections that these individuals
suer highlights the importance of this enzyme in killing S. aureus [257]. In addition,
deletion of the NADPH oxidase in mice is associated with increased susceptibility to S.
aureus infections [270].
Flavocytochrome b558 (consisting of gp91
phox or Nox2 and p22phox) is a signicant
component of NADPH oxidase and is located bound to the membrane of secretory vesi-
cles and the secondary granules prior to neutrophil activation [271]. After phagocytosis,
additional components of the NADPH oxidase (p45phox, p67phox, p40phox and rac2)
translocate from the cytosol and associate with avocytochrome b558 to form active
NADPH oxidase [271].
Electron transfer to oxygen within the phagosome by the NADPH oxidase generates
superoxide (O 2 ) [269]. Due to the charged nature of O
{
2 , it is unable to cross the phago-
some membrane. However, despite its low permability, it remains at a low concentration
(25 M) within the phagosome and most of it is rapidly dismutated to hydrogen per-
oxide (H2O2) [269]. O
{
2 may react with iron-sulfur clusters found in bacteria to release
iron and copper and these elements may react with H2O2 (via the Fenton reaction; see
Figure 1.5). Hydroxyl radicals, hydroxide and ferric iron are generated during the
Fenton reaction, when H2O2 reacts with ferrous iron [272]. The intermediate products
of this reaction are ferryl radicals, which dissociate to form ferric iron [273]. It is these
ferryl radicals, along with hydroxyl radicals, that may kill bacteria by reacting with, and
damaging, DNA [272, 274, 275].
H2O2 is consumed by an enzyme called myeloperoxidase (MPO) to generate further
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Figure 1.5: The Fenton reaction. In the Fenton reaction, H2O2 reacts with ferrous
iron (Fe2+), leading to the generation of hydroxyl radicals (OH ), hydroxide (HO{) and
ferric iron (Fe3+).
ROS [259, 269]. MPO is a 150 kDa protein that forms a dimer of dimers and consumes
H2O2 and chloride (Cl) to generate hypochlorous acid (HOCl) [264, 271]. It is stored in
the azurophilic granules and up to 1 105 molecules accumulate in the phagosome as it
matures [276, 277]. It is thought that the majority of the oxygen within the phagosome
(70%) is converted to HOCl via MPO, with most of it unable to diuse out into the
cytosol [278]. The production of HOCl is extremely bactericidal as it reacts with and
oxidises sulfur and amine residues in amino acids, polyunsaturated lipids and methionine
residues, causing damage to iron-sulfur proteins, membrane transport proteins, ATP-
generating proteins and DNA [260]. Reactions of HOCl with proteins can generate
ammonia chloramines that are bactericidal and the ability of MPO to directly bind to the
bacterial cell may facilitate killing [259, 279]. Therefore, it has been proposed that HOCl
is the main ROS responsible for killing bacteria and that MPO is an essential protein
required for its generation [269]. Interestingly, although 1/4000 people suer from MPO
deciency, these individuals are only more susceptible to infections by Candida, with no
increase in the frequency of S. aureus infections [264]. This is in marked contrast to CGD
patients and could suggest that MPO is not required for killing of S. aureus. However,
MPO decient neutrophils are much slower at killing S. aureus than normal neutrophils
(24 minutes to kill 50% of the inoculum versus 10 min for normal neutrophils), although
not as slow as NADPH oxidase decient neutrophils (38 min) [280].
Secondary reactions of HOCl with H2O2 can generate further ROS such as hydroxyl
radicals, singlet oxygen and hydroperoxyl radical [269]. However these secondary ROS
are dicult to detect and are thought to be at such low levels that they may not con-
tribute much to killing. ROS such as the hydroxyl radicals that arise in the phagosome
are also much more likely to react with other neutrophil proteins before encountering a
bacterium [259].
Neutrophils undergo phagocytosis-induced cell death shortly after uptake of bacteria,
which facilitates the clearance of the pathogen and reduces inammation [255]. Neu-
trophils may also undergo another type of cell death, referred to as NETosis (Figure
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1.4), which is phagocytosis-independent and is stimulated by IL-8, LPS, bacteria and
the staphylococcal toxins LukGH and PVL [281{283].
During NETosis, the neutrophil expels its plasma membrane, granules, histones and
chromatin to form neutrophil extracellular traps (NETs) that are able to ensnare bacteria
[284]. The production of NETs is dependent upon ROS production since neutrophils
from CGD patients are unable to form NETs [285]. S. aureus has been shown to induce
10-fold more NETs than other bacteria and these NETs may be contribute to S. aureus
killing [283]. However, this is controversial, and it may be that NETs serve to prevent
bacteria from dissemination and proliferation, rather than exert bactericidal activity
[281, 284]. Additionally, they may neutralise toxins, with histones and BPI capable of
degrading Hla [286].
1.4.5 Other defence mechanisms against S. aureus in the bloodstream
In addition to actively killing pathogens, the host restricts bacterial growth by severely
limiting the amount of circulating iron [262, 287]. This is known as nutritional immunity.
Since many important proteins utilised by bacteria make use of iron-sulfur clusters, such
as proteins involved in the electron transport chain (ETC), this makes iron an essential
nutrient required by bacteria [287]. The importance of iron homoeostasis in preventing
infections is highlighted in patients with thalassaemia, who have increased levels of free
iron, and are more susceptible to fatal infections [287]. Most of the iron (80%) in the
host is found complexed to haem and in haemoproteins such as haemoglobin, myoglobin
and haptoglobin, so is not easily utilised by most bacteria [288]. Free haem is also
sequestered by the protein haemopexin [262]. However, more than 90% of the iron in
the body is intracellular, with any free iron rapidly taken up by macrophages where it is
used, retained in a bound state to the storage protein ferritin or exported by ferroportin
[262, 289]. As iron is insoluble in blood, due to the aerobic environment and neutral
pH, it is transported bound to transferrin [288]. These molecules are only ever saturated
between 30{40%, meaning free iron is rapidly captured [262]. Iron can then be taken up
by the transferrin receptor and uptake of iron in the liver is an important mechanism by
which the host regulates iron levels [289].
Platelets are an important component of the blood, functioning to stop blood ow
after vessel damage [286]. Approximately 1 5108 platelets are present in 1 ml of blood.
Upon blood vessel damage, platelets adhere to the site of damage by binding to ECM
proteins through platelet receptors such as 2 and GPVI for collagen and GPIIb/IIIa
for brinogen [290]. Adhesion stimulates platelet activation, triggering a globular shape
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and the release of granules containing serotonin, ADP and thromboxane A. This leads to
the recruitment of further platelets that adhere and activate, resulting in the formation
of a platelet plug at the damaged site. Platelet activation also leads to the initiation of
coagulation, with prothrombin converted to thrombin, which in turn converts brinogen
to brin. Aggregation of brin traps platelets and erythrocytes, culminating in the
formation of a thrombus. Platelets are also involved in host immunity as they display
receptors such as the FcRIIa and TLRs, enabling them to recognise some PAMPs and
activate complement and circulating immune cells such as neutrophils through these
receptor interactions. Platelet interactions between CD62P and neutrophils leads to
neutrophil activation, whilst interactions with TLR4 can stimulate the formation of
NETs [291, 292]. Additionally, platelets can release phospholipid vesicles that contain
cytokines sych as IL-1 to activate distant immune cells [286].
S. aureus interacts with a number of dierent platelet receptors via several adhesins
- ClfA/FnBP-A bind indirectly to GPIIb-IIIa via brinogen or bronectin, Spa binds
directly to FcRIIIa and indirectly to GPIb via vWF, Eap binds glycosaminogly-
cans and SSL5 binds GPIb and GPIV [293{297]. Interactions involving binding of the
GPIIb/IIIa and FcRIIa receptors results in fast activation or slow activation if FcRIIa
binding occurs simultaneously with binding of the complement receptor to complement-
opsonised bacteria [290]. Upon activation, platelets may also contribute to bacterial
killing by internalising microbes and by the release of thrombin-inducible platelet mi-
crobicidal proteins (tPMPs; Figure 1.4). Upon activation by thrombin, tPMPs can kill
bacteria by disrupting cell wall permeability [298]. Thus, although activation of platelets
can lead to thrombus formation that enables S. aureus to escape antibiotics and cause
diseases such as IE, the release of tPMPs may help control the infection [290]. Whilst
Hla has been shown to lyse platelets, at sub-lytic concentrations the toxin can also ac-
tivate platelets, resulting in exposure of S. aureus to tPMPs, meaning Hla production
may not benet the pathogen in an infection such as endocarditis [158]. The interaction
of S. aureus with platelets is therefore multifaceted and has diverse outcomes for both
host and pathogen.
Group IIA phospholipase A2 (gIIA-PLA2) is found in plasma, tears and platelets
[299]. Upon infection, the concentration of gIIA-PLA2 increases 100-fold (200{400 ng
ml 1), with it capable of killing S. aureus at a concentration of 5-100 ng ml 1 in serum
[271, 300, 301]. gIIA-PLA2 inserts into the peptidoglycan layer of bacteria due to its
positive charge, where it is able to degrade phospholipids in the membrane [299]. Killing
of bacteria is thought to be due to the activation of autolysins that cause cell lysis
[299]. Interestingly, gIIA-PLA2 has been shown to act synergistically with the NADPH
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oxidase, despite being an extracellular enzyme [302]. It is hypothesised that the NADPH
oxidase may act to damage the bacterial membrane, revealing additional phospholipids
that can subsequently be targeted by gIIA-PLA2 [271]. This highlights the importance
of assessing all of the components within blood when trying to understand how the host
combats infection, rather than simply examining one component in isolation.
1.5 Resistance of S. aureus to killing in the bloodstream
To avoid being killed by immune cells, S. aureus has evolved numerous strategies, ranging
from evading uptake by immune cells to actively secreting toxins that lyse phagocytes
(Figure 1.6).
1.5.1 Evasion of neutrophil phagocytosis
Recruitment of immune cells to the site of an infection is an important step in preventing
serious host damage. This recruitment needs to be fast as the longer a pathogen remains
in the host, the more time it has to do serious damage and disseminate to other parts
of the body. Although S. aureus secretes a number of PAMPs that act to signal the
recruitment of immune cells, it has also evolved a number of strategies that act to
counteract these. For example, S. aureus secretes molecules that target many of the
receptors that are involved in neutrophil chemotaxis, including, SSL10, which binds to
the receptors CXCL12 and CXCR4 [303]. Additionally, the FPR1 and FPR2 GPCRs
found on neutrophils are also targets of S. aureus evasion molecules. SSL5 binds the
N-terminus of both FPR1 and FPR2 to prevent neutrophils from sensing formylated
peptides and the PSMs [304]. The Chemotaxis Inhibitory Protein of Staphylococcus
(CHIPs) is able to block both FPR1 and C5aR [305]. A search for homologous genes to
CHIPs led to the discovery of the FPR-like 1 inhibitory proteins (FLIPr) and FLIPr-like
[306]. FLIPr and FLIPr-like can both block FPR2, whilst only FLIPr-like can block
FPR1 [306]. In addition to blocking receptors, S. aureus also produces staphopain,
which cleaves the N-terminus of CXCR2 to inhibit neutrophil chemotaxis [307].
S. aureus can evade phagocytosis by interfering with complement and antibody
binding that facilitate uptake by phagocytes. The staphylococcal complement inhibitor
(SCIN) blocks all of the complement pathways (classical, alternative and lectin) by sta-
bilising the C3 convertase (C3bBb or C4bC2a), which prevents the cleavage of C3 and
the formation of the later complement molecules such as the opsonin C3a [308]. This
occurs via a number of molecules that target C3. For example, Extracellular brinogen-
binding protein (Efb) and Extracellular complement-binding protein (Ecb) both bind
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Figure 1.6: S. aureus evasion of killing in the bloodstream. S. aureus has devel-
oped a number of strategies to evade killing in the bloodstream. Firstly, S. aureus can
prevent the recruitment of immune cells to the site of infection by inhibiting chemotaxis.
Secondly, S. aureus can evade complement by inhibiting various steps in the cascade,
such as cleavage of C3 to C3a and C3b. Thirdly, S. aureus can evade phagocytosis by
coating itself in host proteins and preventing recognition by antibodies. Finally, after
phagocytosis by neutrophils, S. aureus can protect itself from killing via ROS and AMP
resistance mechanisms and by secreting toxins that lyse the host cell from within.
C3 to prevent its cleavage, whilst aureolysin cleaves C3 into inactive C3a' and C3b'
[309, 310]. The surface protein SdrE specically targets the alternative pathway of com-
plement by binding to Factor H, which normally regulates the alternative pathway by
accelerating the decay of the C3bBb convertase [201, 311]. Inactivation of Factor H leads
to the consumption of C3, preventing full activation of the pathway [312].
S. aureus can also prevent phagocytosis mediated by antibody [261]. Spa binds
the Fc region of immunoglobulins, preventing recognition by Fc receptors on immune
cells [313, 314]. Staphylococcal IgG binding molecule (Sbi) also binds the Fc region
of immunoglobulins through its N-terminus to prevent opsonisation, whilst downstream
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domains in Sbi can bind C3 [315, 316]. Loss of Sbi leads to reduced survival of S.
aureus in blood [317]. Staphylokinase (SAK) is a serine protease that also targets both
antibody and complement by cleaving C3b or the Fc region to prevent phagocytosis
[318]. Many strains of S. aureus also produce a capsule that prevents complement and
antibody components being deposited on the cell surface and therefore, reduced uptake
by phagocytes [319].
Another mechanism S. aureus employs to evade phagocytosis is to coat itself in host
proteins. For example, ClfA and ClfB, FnBPs and von-Willebrand factor-binding protein
(vWbp) all bind to the ECM proteins present in serum [99]. ClfA, ClfB and FnBPs
bind bronogen, the FnBPs bind bronectin and vWbp binds vWF [105, 107, 129]. S.
aureus can also hijack the coagulation cascade through the production of two coagulases
(Coa and vWbp) that bind and activate prothrombin to cleave brinogen into brin
[320]. The formation of brin clots is stimulated by the binding of ClfA as well as
through the activation of platelets [290]. This leads to aggregation within the clots and
whilst neutrophils are attracted to the clots, they are unable to phagocytose the bacteria
[321]. The importance of these clots are highlighted in cases of sepsis, where clots are
capable of blocking blood vessels and causing cardiac arrest [322{324]. Interestingly,
SAK can convert plasminogen into plasmin, which degrades brin clots [325]. SAK is
only expressed in some strains of S. aureus and has been shown to be involved in biolm
dispersal and spreading during skin infections [326, 327]. However, it is unknown how
SAK contributes during bacteraemia currently.
1.5.2 Resistance to neutrophil killing mechanisms
Despite the vast array of molecules that S. aureus produces to evade phagocytosis,
the majority of bacteria are rapidly taken up by neutrophils [328{331]. In a paper by
Schwartz et al. (2009), it was established, through the use of green uorescent protein
(GFP)-labelled bacteria, that killing of S. aureus occurs after neutrophil uptake [329].
Killing was evident by bleaching of the GFP uorescence, which correlated well with
CFU counts [329]. This bleaching was due to bacteria being exposed to ROS produced
by the NADPH oxidase [329]. Approximately 80% of the bacteria were killed after 120
min, with all of the bacteria still enclosed in the phagosome [329]. This means that there
was a signicant proportion (20%) that were still viable, suggesting that S. aureus is to
some extent able to resist neutrophil killing [329, 331, 332].
Upon phagocytosis, S. aureus alters its gene expression prole to adapt to the toxic
environment within the phagosome [331, 333]. Approximately a third of the S. aureus
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genome is dierentially-regulated after exposure to the phagosome, with many of these
changes attributed to exposure to ROS (H2O2 or HOCl) or neutrophil granules [331, 333].
To resist killing, S. aureus up-regulates oxidative stress resistance genes, toxins and
capsule production, whilst genes involved in bacterial growth are down-regulated [331].
The nutrient restrictions within the phagosome also triggers the stringent response within
S. aureus, which promotes S. aureus survival in the phagosome [334].
Killing of S. aureus in neutrophils is mainly the result of ROS, which suggests that
S. aureus is largely resistant to the enzymes and peptides released into the phagosome
from neutrophil granules. Indeed, S. aureus has adapted to resist many of the antimicro-
bial peptides (AMPs) by sensing their presence through the GraXSR three-component
regulatory system and the VraFG transporter [335]. In response, S. aureus reduces the
negative-charge of its cell wall [335]. Since many of the AMPs are cationic peptides,
they require a negative-charge to attract them to bacteria [336]. S. aureus reduces its
negative charge by lysylinylation of phosphotidylglycerol residues and D-alanylation of
teichoic acids such as wall-teichoic acid (WTA) and LTA [337, 338]. Production of STX,
a carotenoid pigment that is responsible for the characteristic golden colour of S. au-
reus colonies, increases the cell wall rigidity of the bacterium and this also increases its
resistance to AMPs [339]. S. aureus can also secrete enzymes such as aureolysin and
SAK that cleave and inactivate the AMPs LL-37 and -defensins, respectively [340, 341].
Resistance to the muramidase, lysozyme, which is found in neutrophil granules as well
as in human uids such as tears and saliva is attributed to peptidoglycan modication
of N-acetyl muramic acid by O-acetylation [342]
STX also provides resistance to ROS, acting as an anti-oxidant and protecting S. au-
reus in the neutrophil through its ability to quench both singlet oxygen and free-radicals
[343]. Resistance to singlet oxygen is also provided by the Surface factor promoting
resistance to oxidative killing molecule (SOK) [344]. S. aureus is also capable of break-
ing down a number of dierent ROS to escape damage. The superoxide dismutases
(SodA and SodM) are enzymes that dismutate O 2 , generated from internal and exter-
nal sources, respectively [345{347]. SodA is a manganese-dependent enzyme and SodM
is also thought to rely on manganese for its activity [346, 348]. Manganese can also
act as a non-enzymatic superoxide dismutase and although neutrophils sequester man-
ganese within the phagosome using calprotectin, S. aureus uses the MntABC and MntH
transport systems to scavenge manganese [349]. Loss of these transporters results in
increased killing within neutrophils [350]. The dismutation of O 2 leads to the produc-
tion of water and H2O2, another ROS that S. aureus breaks down to oxygen and water,
using one of two enzymes (KatA or AhpC) [351]. One of the ways ROS kill bacteria is
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to generate harmful damage to DNA, therefore S. aureus has a number of DNA repair
systems [352]. The methionine sulfoxide reductases (Msr) have also been implicated in
repairing damage caused by oxidative stress by reversing the oxidation of methionine
residues [353]. As a result, Msr mutants appear to be more susceptible to neutrophil
killing [353].
The Agr system has been shown to be important for S. aureus to avoid neutrophil
killing and the enclosed environment of the phagosome means that a single bacterium is
capable of activating its own Agr system [334, 354{356]. However, whilst some studies
have shown that agr is switched on after phagocytosis, other studies have shown that agr
is repressed [328, 331, 333]. Some of this agr repression may be due to ROS, as oxidation
of cysteine residues within AgrA causes the transcriptional regulator to dissociate from
DNA [357]. AIP1 can also be inactivated by oxidation of its methionine residue to
methionine sulfoxide, meaning that agr could be switched o in strains of agr type I
[358]. Agr is likely only important post-phagocytosis as the system is inhibited when
the bacterium is in serum [359{361].
To escape neutrophil killing, S. aureus is also capable of triggering neutrophil cell
death, either by apoptosis or pyroptosis [330, 362]. Apoptosis is characterised by round-
ing of the cell, chromatin and nuclear condensation, membrane blebbing and a reduction
in cell volume [363]. Whilst pyroptosis is characterised by formation of the inamma-
some and cell swelling, in addition to the nuclear degradation seen in apoptotic cells. It
is not understood how each type of cell death is triggered by S. aureus.
Only two toxins, LukAB/GH and the -PSMs, have been shown to be capable of
lysing the neutrophil from within the phagosome and triggering cell death [181, 364].
Although these are both agr -regulated toxins and some reports have shown agr to be
repressed, both LukAB/GH and the PSMs, appear to be up-regulated after phagocytosis
[331, 333]. Activation of the stringent response after uptake also leads to up-regulation
of the PSMs through an unknown mechanism involving (p)ppGpp that is synthesised by
the RelA/SpoT homologue protein to repress protein synthesis [334]. The expression of
the PSMs also requires the presence of AgrA. It is currently unknown how LukAB/GH
and the PSMs lyse neutrophils from inside the phagosome as the membrane is in the
wrong orientation for the toxins to form a pore and so it is hypothesised that they could
function synergistically to lyse the neutrophil via an unknown mechanism [181, 362].
Interestingly, neutrophils are also killed in the absence of toxins and this may be a result
of phagocytosis-induced cell death, a type of programmed-cell death that neutrophils
undergo after the uptake of all bacteria, not just S. aureus [255]. Although at other body
sites, extracellular toxins are likely to be very important for killing immune cells, during
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a bloodstream infection the concentration of S. aureus is low and the volume of blood
high, suggesting that they are very unlikely to contribute signicantly to bacteraemia.
In addition to avoiding killing after neutrophil uptake, S. aureus can escape the ac-
tion of NETs through the secretion of nuclease (Nuc) and adenosine synthase (AdsA)
[365, 366]. The staphylococcal nuclease acts as an endonuclease and exonuclease, cleav-
ing the phosphodiester bonds both within, and at the end of, a polynuclotide chain
[365]. Whilst AdsA is thought to act as a 5'-nucleotidase [366]. Although NETs do not
contribute signicantly to killing, by degrading NETs, S. aureus could disseminate to
other parts of the body rather than being trapped in a localised area [284]. AdsA is also
capable of converting the 5-monophosphate-deoxyadenosine released from NETs into
deoxyadenosine, which induces macrophage death and protects S. aureus from these
professional phagocytes [366]. S. aureus can also use AdsA to convert the adenosine
triphosphate that is released at sites of inammation into adenosine and this molecule
can down-regulate activation of immune cells such as macrophages and DCs [367].
1.5.3 Resistance to other immune defences in blood
S. aureus is able to sense iron levels in the environment through the Ferric uptake
regulator (Fur) and sensor MntR [350, 368]. Both Fur and MntR repress iron acquisition
genes when iron is present, but in the blood, repression is relieved because free iron levels
are low [287]. In response to low iron, S. aureus secretes haemolysins (HlgABC) that
are able to lyse erythrocytes to release haem [328]. S. aureus preferentially uses haem
over iron and this can be utilised directly by membrane proteins on the surface of the
bacterium or it can be taken up by the haem uptake system, Isd [262]. The Isd system
consists of a haemoglobin receptor (IsdB), a haemoglobin-haptoglobin receptor (IsdH)
and two proteins (IsdA and IsdC) that can bind haem. These proteins capture either
free haem or haem complexed as haemoglobin with or without haptoglobin and shuttle
it to the transporter IsdEF for uptake. Under low iron conditions, S. aureus also reduces
the tricarboxylic acid (TCA) cycle that utilises proteins such as cytochromes that rely
heavily on iron [369]. This leads to an increase in the production of lactate that increases
the acidity of the surrounding environment and this can cause host transferrin to release
iron [369]. S. aureus also produces two iron scavengers (or siderophores), Staphyloferrin
A and Staphyloferrin B, that can both capture free iron and transfer it to the transporters
HtsABC and SirABC, respectively, for uptake [370, 371]. There is also evidence that S.
aureus can take up xenosiderophores, siderophores derived from other bacteria, although
this is only relevant to polymicrobial bacteraemia [372].
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As mentioned earlier, S. aureus can hijack the coagulation pathway to produce
thrombi consisting of bacterial aggregates and brin, to escape neutrophil phagocy-
tosis. S. aureus can inhibit platelet activation via Efb, which alters the presentation of
brinogen, preventing platelets being able to bind [373]. S. aureus can also avoid platelet
activation by binding to PRRs through Spa. For example, Spa can interact with platelet
receptor GPIb to inhibit platelet activation [286]. Spa also prevents platelet activation
by preventing FcRIIa recognition of S. aureus [374]. By preventing platelet activation,
S. aureus also stops the release of tPMPs that are bactericidal [298]. S. aureus can
also lyse platelets by Hla and resist the eects of tPMPs using similar mechanisms that
lead to AMP resistance - by decreasing membrane potential and increasing positively-
charged residues on the cell membrane [290]. Reduction of the cell membrane charge
also increases the resistance to the positively-charged gIIA-PLA2 [299].
S. aureus is able to invade non-professional phagocytes (keratinocytes, osteocytes,
chondrocytes, mesothelial cells, epithelial cells and endothelial cells) by binding to the
host 51 integrins via FnBP [124, 125, 128{132, 329, 375{379]. Using intra-vital uo-
rescence microscopy in a dorsal skin fold model, it was shown that over 99% of S. aureus
adheres to the microvasculature within 20 minutes of inoculation [380]. It then takes
approximately 45{60 minutes for invasion of the endothelium to occur after integrin
binding [381]. The intracellular environment in non-professional phagocytes is more
habitable than in neutrophils and it has been shown that S. aureus can escape into
the cytosol by Hla-dependent lysis of the phagosome [122, 382, 383]. Therefore, during
a bloodstream infection, invasion into non-professional phagocytes such as endothelial
cells could provide a niche that facilitates S. aureus survival by enabling it to evade the
immune system [384].
1.6 Persistent S. aureus bacteraemia
In up to 38% of S. aureus bacteraemia (SAB) cases, patients will develop a persistent
infection, dened as an infection that lasts for more than a week after appropriate an-
tibiotic treatment is initiated [385, 385{389]. However, it should be noted that some
studies also deem a case of SAB to be persistent after three days [387, 388]. Cases of
persistent SAB take on average 7{9 days to resolve, although the longer the patient has
bacteraemia, the more likely it is that the infection will metastasise [220]. In patients
with persistent SAB for more than 10 days, just under half (45%) suer from secondary
infections; such as endocarditis, septic arthritis and osteomyelitis [388, 389]. Unsurpris-
ingly, persistent SAB is associated with increased mortality [220]. Even in those patients
50
that appear to rapidly clear the infection, approximately 16% will suer from a recur-
rent infection within 12 weeks after the initial case [7]. In the majority of these cases
(> 80%), this infection is attributed to the same strain that caused the initial infection
[390].
The reasons for persistent SAB are complicated and are likely to be multi-faceted,
involving both host and bacterial factors, as well as requiring S. aureus to overcome
antibiotic therapy. It is, therefore, unsurprising that inappropriate antibiotic treatment
or a delay in treatment or removal of eradicable-foci are factors associated with persistent
SAB [221, 385]. Infections as a result of non-eradicable foci such as septic arthritis
and endocarditis can also lead to persistent SAB due to the diculty associated with
treating these infections [391]. However, the fact that persistent SAB may occur even
after appropriate antibiotic treatment in patients with eradicable foci suggests that S.
aureus may also adapt to enable persistence [386]. In many cases, this persistence is
associated with the acquisition of mutations, although it is also known that S. aureus can
form persisters [392]. Persisters are a small sub-population (< 1%) of bacterial cells that
are evident after a bacterial culture is subjected to antibiotic treatment at the MIC for
the strain being tested. These persisters are not resistant, rather, they appear to switch
to a dormant state, shutting down RNA and protein synthesis, making them insensitive
to the actions of antibiotics [393]. When conditions become favourable, these persisters
may reactivate RNA and protein synthesis, making them sensitive to antibiotics again
[392].
1.7 The association between agr and persistent S. aureus bacteraemia
1.7.1 Agr activity in the bloodstream
A number of studies have shown that after S. aureus enters the bloodstream, agr is down-
regulated [328, 394]. Some of this repression has been attributed to haemoglobin, which
interferes with agr activation in an unknown manner that involves the  and  chains
of haemoglobin [395, 396]. Hla production may also be reduced in the presence of haem
through the repression of the Sae regulatory system that, along with agr, acts to activate
toxin production [397]. Most of the agr suppression, however, is due to the action of
the serum protein apolipoprotein B (ApoB), a major component of low-density and very
low-density lipoproteins (Figure 1.7) [360]. ApoB prevents agr activation by binding
to the thiolactone ring of AIP and sequestering it [360]. Constitutive activation of AgrC
can overcome ApoB inhibition, meaning that ApoB only prevents AgrC activation and
does not aect the agr operon downstream of AgrC [359]. However, it has been shown
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that S. aureus can activate agr in serum within microcolonies, which are impenetrable
to ApoB [398]. Therefore, expression of agr -regulated virulence factors may be possible
after thrombus formation.
Figure 1.7: Agr expression is repressed in blood. In the bloodstream, host ApoB
sequesters AIP, thereby preventing Agr activation. The PSMs are also inactivated by
lipoproteins found in serum. After uptake, Agr may be switched on due to the absence
of ApoB and the enclosed environment of the phagosome enables a single bacterium to
activate its own system. Although full activation is prevented by ROS, which can oxidise
the methionine residue in AIP1, toxin production can occur resulting in neutrophil lysis.
As agr is repressed in the bloodstream, it may be that its activity is more important
after uptake by neutrophils. Serum also inactivates the agr -regulated PSMs, through
binding of the PSMs to the lipid portion of high-density, low-density and very-low density
lipoproteins (Figure 1.7) [399]. Therefore, even if agr could be switched on the blood
via aggregates, it may not be useful to switch it on until after uptake when the PSMs
could lyse the neutrophil from within [364].
1.7.2 Mutations in agr are associated with persistent SAB
The production of virulence factors can be extremely costly to bacteria and is high-
lighted by the fact that mutations within agr are commonly found after serial passage
of S. aureus in vitro [400]. During S. aureus abscess and wound infections, loss of agr
occasionally occurs in sub-populations of bacteria and the agr -negative strains can take
advantage of the virulence factors produced by their agr -positive counterparts without
the negative eect that virulence factor production has on growth [401]. This is referred
to as `cheating'. In this situation, agr -negative strains may out-compete the agr -positive
strains [401, 402].
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The association between agr dysfunction and persistent SAB was rst identied in
a 2004 study by Fowler et al. [403]. In this prospective study of 39 patients with
either persistent or resolving SAB, Fowler et al. found that 71.4% of the strains isolated
from patients with persistent SAB had lost agr function, compared to only 38.9% in
the resolving SAB group [403]. Since then, a number of groups from dierent parts
of the world have also linked agr dysfunction to SAB [385, 386, 404{415]. In most
of these studies, agr dysfunction was tested using the CAMP assay, which was initially
developed by Christie, Atkins and Munch-Peterson in 1944 for the identication of group
B streptococci [416]. In the CAMP assay, the strain is tested for Hld production by
cross-steaking it from a Hlb-producing strain (such as RN4220) on Columbia blood agar
(CBA). Production of Hld from the test strain is evident by the synergistic haemolysis
caused by Hld with the Hlb from RN4220, which occurs where the two strains intersect.
Since Hld is encoded within RNAIII, the presence of the toxin is a good surrogate for
Agr activity.
In 3-82% of SAB cases, agr -defective isolates are recovered and in 70% of cases, a
corresponding agr -defective strain is found in the nasopharynx [412, 417]. This suggests
that agr mutations typically occur within the nose before the strain goes on to cause
bacteraemia [412]. Individuals harbouring an agr defective isolate are more likely to
have visited a hospital within the last six months or been in close contact with someone
hospitalised [405]. Whilst patients with identical agr -negative strains are evident within
the hospital, this is rare and suggests that agr negative strains can only be transmitted
between patients with severely compromised immune systems [405, 412]. Individuals
with agr -defective strains in their nasopharynx are just as likely to develop bacteraemia
as carriers with agr -positive S. aureus, which suggests that whilst agr -defective strains
are no more infective than the wildtype (WT), they are still just as capable of causing
an infection, at least in the hospital setting [412].
Of the agr mutants isolated from cases of SAB, many of these appear to belong
to agr group II, although agr mutants from all of the agr groups have been detected
[385, 404, 407, 409, 414]. Disruption of the agr system tends to occur via mutations
aecting either agrA or agrC, the two largest genes within the operson, suggesting that
the agrCA genes are a mutational hotspot [407]. Inactivation of these genes results
in a complete shutdown of the system, with bacteria unable to respond to signalling
peptide [61]. By contrast, mutations within either agrB and agrD would only prevent S.
aureus producing AIP but not responding to signal generated by other members of the
population. agr mutants isolated from SAB cases harbour a diverse set of mutations,
ranging from insertions/deletions leading to nonsense mutations (resulting in a truncated
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protein) and missense mutations (resulting in a non-functional protein due to an amino
acid change) [405, 407]. One common mutation that inactivates AgrA occurs as a run
of seven adenines at the 3' end of the gene that occurs as a result of slipped-strand
mispairing [404, 418]. This mutation is found in the laboratory strain RN4220 and
strains with longer runs of adenines also disrupt function, with a run of eight adenines
shown to delay RNAIII synthesis, which prevents translation of Hla and Hld [418].
Slipped-strand mispairing can also cause a run of thymidines at position 313 of AgrA
that disrupts agr function. Occasionally no obvious mutation is found within the agr
operon suggesting other mutations could act to disrupt agr function [407, 419]. However,
it is also worth noting that the CAMP assay is not very sensitive and may occasionally
overestimate agr dysfunction [415].
Dysfunction of the agr system has also been associated in some studies with increased
MICs to vancomycin and resistance to tPMPs [385, 406, 414]. The molecular basis for
this association is not well understood, although it appears to be due to alterations to the
cell wall that lead to a reduction in the amount of autolysis [420]. Methicillin resistance
also involves changes to the cell wall [421]. It is not known whether loss of agr precedes
these changes to the cell wall or whether alterations to the cell wall disrupt agr function
[422]. Although in the case of HA-MRSA, it appears that cell wall changes occur prior to
loss of Agr activity [421]. As persistent bacteraemia may be due to increased resistance
to methicillin, vancomycin and tPMPs, this could be one reason why agr dysfunction is
associated with persistence.
1.8 Small colony variants
1.8.1 Discovery of small colony variants
Small colony variants (SCVs) were rst identied in 1910 after pinpoint colonies were
observed on agar plates after a blood culture containing Salmonella typhi was plated after
30 minutes in an autoclave [423]. Originally referred to as dwarf colonies or gonidial `G'
forms, it was thought that SCVs might represent part of a specic life cycle that occurred
during normal bacterial growth [423]. After the identication of SCVs in S. typhi,
SCVs were reported in numerous bacterial species, including S. aureus, Pseudomonas
aeruginosa, Burkholderia pseudomallei, E. coli, Bacillus, Neisseria gonorrhoeae, Vibrio
and Shigella, and also fungi [423{429].
Figure 1.8 shows the colony morphology of an S. aureus SCV compared to the WT
phenotype. Although all bacterial species can form small colonies after encountering
various environmental stresses, there are a number of additional characteristics that a
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Figure 1.8: Colony morphology of WT and SCV S. aureus. USA300 WT (left)
and a isogenic SCV (right) grown on tryptic soy agar overnight at 37C for 24 hours.
strain must have to be considered a SCV. The general characteristics for a S. aureus
SCV are listed in Table 1.2. In addition to their small colony size (that is a result of
slow growth), S. aureus SCVs are less pigmented, have an altered metabolic state and
have decreased expression of agr and agr -regulated toxins even after entering stationary
phase, relative to WT bacteria [430{432].
Table 1.2: General SCV characteristics compared to the wildtype
General characteristics of SCVs References
Phenotypic characteristics
Small colonies (1/10th the size of the normal phenotype) [430, 431]
Non-pigmented or weakly pigmented [430, 431]
Non-haemolytic or weakly haemolytic [430, 431]
Thicker cell wall [433]
Aberrant cell division [434, 435]
Metabolism
Inactive or reduced tricarboxylic acid cycle [436, 437]
Slow growth [430, 431]
Upregulation of genes involved in glycolysis and fermentation [438{441]
Resistance characteristics
Increased resistance to aminoglycosides and -lactams [430, 431]
Increased resistance to antimicrobial peptides [442{444]
Gene expression
Increased expression of sigB [432]
Increased expression of adhesins (FnBP, clumping factor) [445]
Continued on the following page
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Table 1.2 { Continued from previous page
General characteristics of SCVs References
Decreased/absent expression of agr [432]
Decreased expression of hla, coa and hld [432]
1.8.2 Types of SCVs
Two main types of SCVs exist, those decient in the ETC and those decient in thymi-
dine biosynthesis [434]. ETC-decient SCVs tend to be decient in the menadione or
haemin biosynthesis pathways, which are required for the synthesis of the electron ac-
ceptors, menaquinone and cytochromes, respectively [437]. Menaquinone is synthesised
by attachment of an isoprenoid lipid to menadione and it acts as the rst electron accep-
tor in the ETC, accepting electrons from NADPH/FADH2 generated in the TCA cycle
(Figure 1.9) [446]. Electrons are then transferred to the haem prosthetic groups of cy-
tochromes before being transferred to oxygen, the terminal electron acceptor. Electron
transfer results in the generation of an electrochemical gradient by generating protons
that accumulate outside the cell membrane. Protons are able to ow down the electro-
chemical gradient through the membrane via the F0F1 ATPase, which generates energy
that bacteria simultaneously use to generate ATP. Therefore, ETC-decient SCVs are
unable to utilise the ETC to generate energy [431, 437]. It also means that SCVs that
are decient in the menadionine or haemin-biosynthesis pathway are auxotrophic for
menadionine or haemin, respectively [437]. Therefore, supplementation of the culture
medium with menadione restores a menadione-auxotrophic SCV and supplementation
with haem restores a haemin-auxotrophic SCV to the WT phenotype [434]. Less com-
mon ETC-SCVs have also been reported, such as those defective in unsaturated fatty
acid biosynthesis or the F0F1 ATPase [424, 447]. In both these SCVs, the ETC is shut
down, resulting in the characteristic SCV phenotype [437].
Thymidine-decient SCVs (TD-SCVs) also produce the characteristic small colonies
associated with SCVs, although some TD-SCV colonies may also have the appearance of
a `fried egg' with translucent haloes that surround the yellow colony that is typical of S.
aureus [448]. TD-SCVs are defective in thymidine synthesis and so require extracellular
thymidine to survive [448, 449]. In the presence of excessive thymidine, this restores the
WT phenotype in TD-SCVs [448]
SCVs have also been isolated that have a permanently active stringent response or
that have been induced by cold stress [450, 451]. However, these SCVs do not have all
of the typical characteristics described in Table 1.2.
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Figure 1.9: Mutations in the electron transport chain lead to the SCV phenotype.
Mutations have been identied in the menadione, thymidine and haemin biosynthesis pathways
that result in the SCV phenotype. Each of these mutations lead to loss of the ETC chain,
which results in a reduced electron potential, reduced cell wall and protein biosynthesis, reduced
carotenoid biosynthesis and reduced Agr expression. These changes lead to the characteristic
SCV phenotype - increased resistance to certain antibiotics, small colonies, reduced pigmentation
and toxin production. Adapted from Proctor et al. (2006) [434].
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1.8.3 The genetic basis of SCVs
The SCV phenotype is often unstable, with reversion back to the WT phenotype seen
after 2{3 subcultures in enriched media due to the much faster growing phenotype of
WT bacteria [423, 452]. It has been observed that S. aureus can easily phenotype switch
between the WT and SCV phenotype in order to adapt to the environment [453, 454].
Based on this phenomenon, it was thought that the SCV phenotype could be controlled
via a regulatory mechanism [455]. However, it is now known that most SCVs are the
result of mutations within the genome (Figure 1.9) [455]. Many of these mutations
are the result of point mutations and so the SCV can readily switch back to the WT
phenotype if this mutant allele is mutated back to the original nucleotide or as a result of
compensatory mutations [448, 455{457]. Mutations that involve deletions are associated
with a more stable SCV phenotype as it is more dicult to revert to the original sequence
[448, 458].
For the haemin-auxotrophic SCVs, mutations have been described that include a
113 bp deletion of hemH resulting in a truncated protein of 22 amino acids and a
mutation within hemA that leads to a frameshift in the sequence and truncation of the
HemA protein by 54 amino acids. Mutations described that result in the menadione
auxotrophic SCV include deletions and point mutations that result in a frameshift or
missense mutation that aect the function of menB. Point mutations within menC, menE
and menF have also been described [456]. Targeted gene deletions have been made in
the hemB and the menD genes and both of these deletions result in bacteria with a
stable SCV phenotype [459, 460]. In the TD-SCVs, mutations are apparently always
found within the thyA gene, which encodes thymidylate synthase [448, 457, 461]. ThyA
is required for the conversion of uracil to thymidine and so mutations within thyA lead
to a thymidine-auxotrophic SCV [437].
Cui et al. (2012) have also described an additional mechanism that enables phenotype
switching in strain Mu50
 [462]. In this work, it was discovered that the Mu50
 strain
could switch between the WT and SCV phenotype via a large-scale rearrangement of the
genome [462]. This rearrangement occurred at two inverted repeat regions at positions
876,218-879,855 and 2,139,563-2,153,200 of the genome [462]. The rearrangement led
to down-regulation of thiamine synthesis and oxidative phosphorylation, both of which
could generate the SCV phenotype by shutting down the ETC [462].
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1.8.4 Metabolism in SCVs
Mutations within the haemin and menadionine biosynthesis pathway prevent the forma-
tion of electron acceptors that are essential components of the ETC [446]. Shutdown of
the ETC leads to shutdown of the TCA cycle as the NAD+ and FAD+ pool cannot be
fully regenerated. This means SCVs have to utilise substrate-level phosphorylation to
obtain energy and so metabolism within SCVs closely resembles that of WT S. aureus
under anaerobic conditions [437]. To obtain energy, SCVs employ glycolysis and fermen-
tation [438, 439, 441, 463, 464]. SCVs also make use of the arginine deiminase pathway
to generate ATP and a by-product of this is the release of ammonia, which may enable
SCVs to resist acid stress [465]. As fermentation results in the generation of lactic acid,
resistance to acid stress could be important in vitro but it may also be benecial for
survival on skin or within the phagosome of host immune cells [466, 467]. Loss of the
TCA cycle means that SCVs are also unable to utilise sugars such as mannitol, xylose,
sucrose, lactose, glycerol and maltose [438]. The menadione-auxotrophic SCVs are even
more restricted in their carbon sources than haemin-auxotrophic SCVs as menadione is
required for enzymes such as malate quniol oxidoreductase and quinone oxidoreductase
and therefore, menadione-auxotrophic SCVs cannot metabolise D-mannitol, dextrin and
maltotriose [463]. The TD-SCVs are also defective in the TCA cycle, although less is
known about the physiology of these SCVs [436, 464].
The altered metabolic prole of SCVs explains several of its phenotypes. For exam-
ple, slow growth of SCVs occurs because they cannot generate as much ATP through
fermentation and glycolysis as WT bacteria can via aerobic respiration [434]. In addi-
tion, loss of the TCA cycle prevents the generation of carbohydrates and amino acids
that are required for growth and synthesis of phosphatidyl glycerol, a major component
of cell wall teichoic acid [437]. The loss of pigment in SCVs can also be attributed to
loss of the ETC as carotenoid biosynthesis makes use of the P450 system that requires
electrons to function.
1.8.5 Gene expression in SCVs
SCVs display dierential gene expression compared to the WT phenotype [438, 439].
One of the major causes of this is the down-regulation of agr, which leads to repression
of toxins such as hla and hld and other agr -regulated virulence factors such as coa and
up-regulation of adhesins such as fnbA and spa [432, 439, 445, 457, 468]. Although
ClfA is not regulated by agr, SCVs also have increased levels of ClfA [432, 445, 469].
Upregulation of ClfA was also independent of SarA, which is reported to be up-regulated
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in SCVs in some studies but not others [449, 457, 469, 470]. The reason why agr is down-
regulated in SCVs may be because SCVs do not reach a high enough density to generate
sucient AIP to activate the agr system [449]. This is based on evidence that shows
that the agr system can be activated in SCVs after the addition of extracellular AIP
[449, 471]. However, it has also been shown that some SCVs increase expression of the
degradosome and it has been suggested that this could decrease levels of RNAIII and
prevent agr activation [472]. Levels of the stress regulator SigB are also increased in
SCVs and this negatively regulates agr expression [468, 470, 473{475].
1.8.6 SCVs show increased resistance to antimicrobials
Although SCVs have a membrane potential similar to the WT (-120 to -140 mV) when
glucose is available, this potential drops to -60 mV as soon as glucose is utilised [476].
This drop in electrical potential prevents the uptake of molecules that require a large
electrochemical gradient, providing SCVs with resistance to aminoglycosides such as
gentamicin and AMPs such as protamine, lactoferrin B and tPMPs [443, 444, 477{479].
The slow growth of SCVs also renders them more resistant to antibiotics that target
cell wall synthesis such as the -lactams [478{480]. As the SCV phenotype is benecial
for survival against certain antibiotics and AMPs, exposure to these antimicrobials can
select for SCVs [119, 481, 482].
Interestingly, despite loss of the TCA cycle, TD-SCVs are still sensitive to amino-
glycosides [483]. The TD-SCV phenotype does provide resistance to the antibiotic SXT
[484]. SXT inhibits dihydropteroate synthase and dihydrofolate reductase in S. aureus,
which are involved in production of tetrahydrofolic acid, a co-factor utilised by ThyA to
synthesise thymidine [461].
1.8.7 SCVs are associated with persistent infections
SCVs have been isolated from a variety of infections, including those of the blood,
bones, airways and soft tissue [435]. However, the slow growth of SCVs means that they
are often not detected and even when they are detected, they are often misidentied
as coagulase-negative staphylococci as they require at least 18 h before they become
catalase or coagulase positive [465]. Due to their altered metabolism, SCVs cannot be
isolated on selective agar such as MSA and since SCVs are often isolated as a mixed
population, they can easily be overgrown by the WT or revert to WT on culture medium
[438, 463, 485]. To detect SCVs, clinicians have recommended the use of chromogenic
agar and CBA [465]. The use of 16S sequencing and PCR to screen for nuc and coa can
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also facilitate the identication of S. aureus SCVs [465, 486].
SCVs have decreased virulence in most infection models, eliciting a reduced cytokine
response compared to WT S. aureus, although there are two notable exceptions [454,
485, 487, 488]. In a model of rabbit endocarditis, a hemB SCV was just as virulent
as WT S aureus in the spleen and kidneys and a hemB SCV was more virulent than
the WT in a model of mouse arthritis [460, 489]. It is thought that the WT phenotype
was restored during infection of the spleen and kidneys as these organs are known to be
replete with haemin [460]. Whilst the increased virulence in the mouse arthritis model
was explained by the 20-fold increase in the production of proteases in the SCV [489].
It is likely that protease production only contributes to virulence in this model however,
as this nding has not been replicated in other models. Although SCVs tend to have
reduced virulence, they are often associated with persistent infections, with one case
study showing SCV persistence in a patient for over 54 years [431, 490, 491].
Once S. aureus enters bone, it is able to destroy the tissue via the release of cytolytic
toxins, leading to osteomyelitis [492]. Osteomyelitis can be extremely dicult to treat
due to the poor penetration of antibiotics into bone [493]. In many cases, patients are
treated using gentamicin-impregnated beads that are inserted into the bone cavity after
debridement [493]. These beads slowly release gentamicin into the cavity, building up
to concentrations that exceed the MICs of most organisms. Unfortunately, gentamicin
selects for the SCV phenotype and in 29% of osteomyelitis cases, SCVs are detected
[494].
SCVs are also associated with device-related infections and have been isolated from
patients with pacemakers [495, 496]. Some of these infections may be due to the increased
ability of SCVs to form biolms due to their increased production of adhesins such as
ClfA and FnBPs [139, 445]. Increased production of PIA has also been shown in a
menD SCV, which also promotes biolm formation [497]. Biolm production may also
be stimulated by the increased expression of SigB in SCVs [473]. The ability of SCVs
to adhere to bronectin-coated surfaces is also associated with increased resistance to
antibiotics and on top of the resistance that SCVs already have against aminoglycosides,
this mechanism could enable them to persist in host tissues [480].
TD-SCVs are associated with infection of the cystic brosis (CF) lung and can be
selected for upon treatment with SXT [484, 490, 498]. Bacteria isolated from the CF lung
are often hypermutators and the increased frequency of mutations could also lead to the
increased generation of SCVs in this environment [499]. Of the S. aureus strains isolated
from the CF lung, 50% are SCVs [490]. Due to the large amount of pus and necrotic
tissue within the CF lung, TD-SCVs are easily able to acquire extracellular thymidine
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through the production of DNase that degrades the DNA released from dead host cells
[457]. Thymidine can then be taken up via the NupC transporter. During CF infections,
S. aureus is often co-isolated along with the main CF coloniser, P. aeruginosa [500].
Production of 4-hydroxy-2- heptylquinoline-N-oxide (HQNO) by P. aeruginosa inhibits
the ETC of S. aureus, resulting in bacteria that resemble menadione-auxotrophic SCVs
[501]. These HQNO-treated S. aureus are also more resistant to gentamicin and may
contribute to the persistence of S. aureus in the lung.
Persistence of SCVs has also been associated with their increased ability to survive
inside host cells, with the intracellular environment able to select for the SCV phenotype
[482, 502]. The increased expression of FnBP in SCVs enables their increased uptake
and it has been shown that SCVs can persist within the lysosome for up to ve days
[381, 445, 453, 503]. Part of this may be due to their increased expression of the arginine
deiminase pathway that may protect SCVs from the acidic pH found in the lysosome
[466, 467]. SCVs also trigger decreased production of hypoxia-inducible factor, which
normally signals to the host of an intracellular organism [504]. In addition, the decreased
production of cytolysins due to reduced agr would enable SCVs to survive within the
host cell without triggering host cell death [453]
1.8.8 SCVs are associated with persistent bacteraemia
SCVs have been shown to be associated with persistent bacteraemia [447, 456, 495, 496,
505{509]. Although there is evidence that SCVs are more resistant to the tPMPs that
contribute to killing of S. aureus in the bloodstream, it is not fully understood why
SCVs are associated with persistent bacteraemia [444]. As agr mutants are linked to
persistent SAB, it may be that the decreased agr expression found in SCVs could be the
reason why SCVs also survive in the bloodstream.
1.9 Aim of the project
To understand the role of agr and the SCV phenotype in persistent S. aureus blood-
stream infections.
1.10 Hypothesis
That loss of Agr expression promotes survival of S. aureus in the human bloodstream.
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2 Materials and methods
2.1 Chemicals and reagents
Chemicals were purchased from Sigma-Aldrich, unless otherwise stated. Molecular biol-
ogy reagents including those for PCR and restriction digests were purchased from New
England Biolabs (NEB), unless otherwise stated.
2.2 Bacterial strains and plasmids
Bacterial strains and plasmids used in this study are listed in Table 2.1 and 2.2,
respectively.
2.3 Bacterial growth conditions
S. aureus was routinely grown on Tryptic soy agar (TSA; BD) or CBA (Sigma-Aldrich)
plates made with 5% debrinated sheep blood (E&O Laboratories Limited). Plates were
grown statically at 37C for 12-18 h unless otherwise stated. Stationary-phase bacterial
cultures (referred to as overnight cultures during this thesis) were grown for approxi-
mately 16-18 h at 180 rpm in a 37C incubator unless otherwise stated. For S. aureus,
bacteria were routinely grown in Tryptic soy broth (TSB; BD) with 5 ml of culture
grown in a 30 ml universal. For E. coli, 5 ml of Lysogeny Broth (LB; Fisher Scientic)
in a 50 ml polypropylene tube was inoculated with a single colony from LB agar plates
(LB broth and 1.2% w/v Oxoid Technical Agar [Thermo Scientic]). Antibiotic was
added when necessary at the following concentrations - kanamycin (Km; 50 g ml 1),
ampicillin (Amp; 100 g ml 1), chloramphenicol (Cm; 10 g ml 1), tetracycline (Tet; 5
g ml 1), anhydrotetracycline (AHT; 1 g ml 1), erythromycin (Erm; 10 g ml 1) and
gentamicin (Gm; 2 g ml 1). To inhibit the Agr system of USA300 LAC, AIP3 (Peptide
Protein Research Ltd) was added (10 M) to cultures to be grown overnight. To sup-
plement the SCVs, haemin (0.5 g ml 1) was added to TSB for the haemin-auxotrophic
SCV and menadione (1 g g ml 1) was added to TSB for the menadione-auxotrophic
SCV.
Glycerol stocks were made using a 1:1 ratio of 30% glycerol and overnight culture.
Stocks were stored at { 80C.
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Table 2.1: Bacterial strains used in the study
Strain Description Source
Staphylococcus aureus
SH1000 rsbU + derivative of the laboratory strain 8325-4 [510]
SH1001 SH1000 agr [510]
SH1000 hemB ::Tn SH1000 with a bursa aurealis transposon insertion in hemB This work
SH1000 katA::Tn SH1000 with a Tn917 transposon insertion in katA [351]
SH1000 katA::Tn ahpC::tet SH1000 katA::Tn with a TetR cassette interrupting ahpC [511]
SCV1072 Menadione auxotrophic small colony variant derived in vitro A. Edwards
SCV1072 katA::Tn ahpC::tet SCV1072 katA::Tn ahpC ::tet A. Edwards
USA300 LAC CA-MRSA strain derived from a Los Angeles County (LAC) prison [512]
USA300 LAC geh::pCL55 empty pCL55 integrated into USA300 LAC This work
USA300 LAC geh::pCL55 P3-GFP pCL55 P3-GFP integrated into USA300 LAC This work
USA300 LAC geh::pCL55 pfur -GFP pCL55 pfur -GFP integrated into USA300 LAC This work
USA300 LAC geh::pCL55 pkatA-GFP pCL55 pkatA-GFP integrated into USA300 LAC This work
USA300 LAC geh::pCL55 pperR-GFP pCL55 pperR-GFP integrated into USA300 LAC This work
USA300 JE2 USA300 LAC cured of prophages and plasmids. Sensitive to Erm [513]
USA300 agrA::Tn USA300 JE2 with a bursa aurealis transposon insertion in agrA [513]
USA300 hemB ::Tn USA300 JE2 with a bursa aurealis transposon insertion in hemB [513]
USA300 katA::Tn USA300 JE2 with a bursa aurealis transposon insertion in katA [513]
USA300 perR::Tn USA300 JE2 with a bursa aurealis transposon insertion in perR [513]
USA300 fur ::Tn USA300 JE2 with a bursa aurealis transposon insertion in fur [513]
USA300 rexB ::Tn USA300 JE2 with a bursa aurealis transposon insertion in rexB [513]
USA300 sodA::Tn USA300 JE2 with a bursa aurealis transposon insertion in sodA [513]
USA300 sodM ::Tn USA300 JE2 with a bursa aurealis transposon insertion in sodM [513]
USA300 srrB ::Tn USA300 JE2 with a bursa aurealis transposon insertion in srrB [513]
USA300 ahpC ::Tn USA300 JE2 with a bursa aurealis transposon insertion in ahpC [513]
USA300 mrgA::Tn USA300 JE2 with a bursa aurealis transposon insertion in mrgA [513]
USA300 bcp::Tn USA300 JE2 with a bursa aurealis transposon insertion in bcp [513]
USA300 mntA::Tn USA300 JE2 with a bursa aurealis transposon insertion in mntA [513]
USA300 mntB ::Tn USA300 JE2 with a bursa aurealis transposon insertion in mntB [513]
Continued on the following page
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Table 2.1 { Continued from previous page
Strain Description Source
USA300 mntC ::Tn USA300 JE2 with a bursa aurealis transposon insertion in mntC [513]
USA300 hemB USA300 LAC with the hemB gene deleted This work
USA300 hemB geh::pCL55 empty pCL55 integrated into USA300 hemB This work
USA300 hemB geh::pCL55 hemB USA300 hemB complemented with pCL55 hemB This work
USA300 hemB geh::pCL55 P3-GFP pCL55 P3-GFP integrated into USA300 hemB This work
USA300 hemB geh::pCL55 pfur -GFP pCL55 pfur -GFP integrated into USA300 hemB This work
USA300 hemB geh::pCL55 pkatA-GFP pCL55 pkatA-GFP integrated into USA300 hemB This work
USA300 hemB geh::pCL55 pperR-GFP pCL55 pperR-GFP integrated into USA300 hemB This work
USA300 menD USA300 LAC with the menD gene deleted This work
USA300 menD geh::pCL55 empty pCL55 integrated into USA300 menD This work
USA300 menD geh::pCL55 menD USA300 menD complemented with pCL55 menD This work
USA300 menD geh::pCL55 P3-GFP pCL55 P3-GFP integrated into USA300 menD This work
USA300 menD geh::pCL55 pfur -GFP pCL55 pfur -GFP integrated into USA300 menD This work
USA300 menD geh::pCL55 pkatA-GFP pCL55 pkatA-GFP integrated into USA300 menD This work
USA300 menD geh::pCL55 pperR-GFP pCL55 pperR-GFP integrated into USA300 menD This work
USA300 agrA USA300 LAC with the agrA gene deleted This work
USA300 agrA geh::pCL55 empty pCL55 integrated into USA300 agrA This work
USA300 agrA geh::pCL55 P3-GFP pCL55 P3-GFP integrated into USA300 agrA This work
USA300 agrC USA300 LAC with the agrC gene deleted This work
USA300 agrC geh::pCL55 empty pCL55 integrated into USA300 agrC This work
USA300 agrC geh::pCL55 P3-GFP pCL55 P3-GFP integrated into USA300 agrC This work
USA300 agrC + pCN34 USA300 agrC containing pCN34 as a plasmid control This work
USA300 agrC + pCN34 geh::pCL55 empty pCL55 integrated into USA300 agrC + pCN34 This work
USA300 agrC + pCN34 geh::pCL55 P3-GFP pCL55 P3-GFP integrated into USA300 agrC + pCN34 This work
USA300 agrC + agrC WT USA300 agrC containing pCN34 + agrC WT This work
USA300 agrC + agrC WT geh::pCL55 empty pCL55 integrated into USA300 agrC + agrC WT This work
USA300 agrC + agrC WT geh::pCL55 P3-GFP pCL55 P3-GFP integrated into USA300 agrC + agrC WT This work
USA300 agrC + agrC Q305H USA300 agrC containing pCN34 + agrC Q305H This work
USA300 agrC + agrC Q305H geh::pCL55 empty pCL55 integrated into USA300 agrC + agrC Q305H This work
USA300 agrC + agrC Q305H geh::pCL55 P3-GFP pCL55 P3-GFP integrated into USA300 agrC + agrC Q305H This work
USA300 agrC + agrC R238H USA300 agrC containing pCN34 + agrC R238H This work
Continued on the following page
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Strain Description Source
USA300 agrC + agrC R238H geh::pCL55 empty pCL55 integrated into USA300 agrC + agrC R238H This work
USA300 agrC + agrC R238H geh::pCL55 P3-GFP pCL55 P3-GFP integrated into USA300 agrC + agrC R238H This work
USA300 agrC + agrC M234L USA300 agrC containing pCN34 + agrC M234L This work
USA300 agrC + agrC M234L geh::pCL55 empty pCL55 integrated into USA300 agrC + agrC M234L This work
USA300 agrC + agrC M234L geh::pCL55 P3-GFP pCL55 P3-GFP integrated into USA300 agrC + agrC M234L This work
USA300 RNAIII USA300 LAC with the hld gene deleted This work
USA300 RNAIII geh::pCL55 empty pCL55 integrated into USA300 RNAIII This work
USA300 RNAIII geh::pCL55 P3-GFP pCL55 P3-GFP integrated into USA300 RNAIII This work
Escherichia coli K-12
DH10B dcm+dam+hsdRMS endA1 recA1 [514]
DC10B dcm derivative of DH10B [514]
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Table 2.2: Plasmids
Plasmids Description Source
pJET High copy sub-cloning vector. AmpR in E. coli. Thermo Fisher
Scientic
pIMAY Low copy cloning vector used in the mutagenesis of
S. aureus. AmpR in E. coli, CmR in S. aureus.
[514]
pCL55 Low copy plasmid that integrates into the geh lipase
locus of the S. aureus genome. AmpR in E. coli,
CmR in S. aureus.
[515]
pCL55 P3-GFP pCL55 containing P3-GFP [359]
pCL55 pfur -GFP pCL55 containing pfur -GFP This work
pCL55 pkatA-GFP pCL55 containing pkatA-GFP This work
pCL55 pperR-GFP pCL55 containing pperR-GFP This work
pCN34 Low copy shuttle vector. AmpR in E. coli and KanR
in S. aureus.
[516]
pCN34 + agrC WT pCN34 containing the agrC WT gene. [359]
pCN34 + agrC M234L pCN34 containing the constitutively active agrC
variant M234L.
[359]
pCN34 + agrC Q305H pCN34 containing the constitutively active agrC
variant Q305H.
[359]
pCN34 + agrC R238H pCN34 containing the constitutively active agrC
variant R238H.
[359]
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2.4 Molecular biology
Where S. aureus DNA or RNA was required, bacteria were treated with lysostaphin,
which is an endopeptidase that targets the pentaglycine bridge of peptidoglycan and
leads to lysis of the bacterium [517]. Stationary-phase cultures (usually 1 ml unless
otherwise stated) were pelleted (17,000 x g, 3 min) and lysed by re-suspension in lysis
buer (10 g ml 1 lysostaphin and 90 l PBS). Lysostaphin-treated cells were incubated
for one hour at 37C and debris pelleted out by centrifugation at 17,000 x g for 10 min.
2.4.1 Extraction of genomic bacterial DNA
Genomic DNA was extracted by using the Wizard Genomic DNA Purication kit (Prom-
ega) following the instructions provided. DNA was eluted in rehydration solution and
left at 4C overnight to enable the DNA to go into solution. The concentration of the
DNA was assessed by using a NanoDrop-2000 spectrophotometer (Thermo Scientic).
2.4.2 Extraction of bacterial RNA and reverse transcription
Bacterial RNA was extracted using the RNeasy kit (Qiagen) following protocols 4 and
7 with RNA eluted in sterile RNA-free water. RNA concentration was assessed using a
NanoDrop-2000 spectrophotometer (Thermo Scientic).
RNA was reverse-transcribed into complementary DNA (cDNA) using M-MuLV re-
verse transcriptase (Thermo Scientic) with the addition of DNase (New England Bio-
labs) and Oligo(dT)15 primers (Thermo Scientic), following the instructions provided
by Thermo Scientic. cDNA concentration was measured using a NanoDrop-2000 spec-
trophotometer (Thermo Scientic).
2.4.3 Extraction of plasmid DNA
Where high-copy number plasmids were used, the QIAprep Miniprep kit (Qiagen) was
used to extract plasmid DNA using 3{5 ml of a stationary-phase culture. For low-copy
number plasmids, 100 ml of a stationary-phase culture was grown in 500 ml asks and
the QIAquick Midiprep kit (Qiagen) was used to extract for plasmid DNA. Plasmid
extracted by the Midiprep kit was left overnight at 4C in elution buer before use, to
allow the DNA to go into solution. Plasmid DNA concentration was checked using a
NanoDrop-2000 spectrophotometer (Thermo Scientic).
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2.4.4 Polymerase chain reaction
PCR primers were obtained from Sigma-Aldrich and the primers used are shown in Table
2.3. PCRs were carried out using NEB Phusion polymerase following the instructions
provided. The template is shown in Table 2.4 and the cycling conditions in Table 2.5.
PCR reactions were carried out in 0.2 ml tubes (Greiner) in a PTC-200 Peltier Thermal
Cycler (MJ Research).
Colony PCRs were used to eciently screen colonies after cloning. For S. aureus
PCRs, a single colony was re-suspended in 10 l of molecular biology grade water and
microwaved on full power for 3 min in a 800W microwave. For E. coli PCRs, a single
colony was re-suspended in 100 l of molecular grade water and heated to 100C for
10 minutes. The microwave- and heat-treated cells were pelleted (17,000 x g, 3 min)
and 1 l or 5 l was used per PCR reaction for S. aureus and E. coli colony PCRs,
respectively. No DNA controls were also run to check for contamination.
PCR products were puried using the QIAquick PCR Purication kit (Qiagen),
following the instructions provided.
2.4.5 Quantitative real-time polymerase chain reaction
Primers utilised for quantitative real-time polymerase chain reaction (qPCR) were also
obtained from Sigma-Aldrich and are shown in Table 2.3. These primers were designed
to produce a DNA product of approximately 200 bp, with a preference to products
produced at the 3' end of the gene.
qPCR reactions were set up on ice in 0.1 ml strip tubes (Qiagen) using the template
shown in Table 2.6. The samples were then amplied using the Rotor-Gene 3000
(Corbett Research) following the cycle template shown in Table 2.7 and alongside
control samples containing no DNA. Levels of mRNA of the target gene were quantied
by the comparative Ct method (2
 Ct), with normalisation to levels of 16S mRNA.
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Table 2.3: Primers used during the project
Primers Sequence 5' to 3' 
hemB
hemB -A AAGGTACCAAGTTCGTCGGCAGTACGTT
hemB -B TTCATTGTGGTATACACCTGGCAATGACT
hemB -C GTATACCACAATGAAACGTGCAGGTGCT
hemB -D AAAGAGCTCCACCAGGAGAATCCGGCAAT
hemB -Out TCGAGTGAATTGGCGAGACC
hemB -Rev GGCGGTACGACACCCATATTAC
hemB -1AF CCTTTCGTCTTCAACGTATATTCATTGACCC
hemB -1BR GTCTATCAAATTTCATGTTCAATTCCTCCTAGG
hemB -2AF GGAGGAATTGAACATGAAATTTGATAGACATAG
hemB -2BR TACCGAGCTCGAATTCACCTTAATTATCTAAATAGC
hemB -VecA AGATAATTAAGGTGAATTCGAGCTCGGTACC
hemB -VecB AATGAATATACGTTGAAGACGAAAGGGCCTC
menD
menD-A AAGGTACCACGTTCACAAGATGAGGACGA
menD-B ATGTGGCACGCCGTACGCATATAACTCA
menD-C TACGGCGTGCCACATTGTTATCTGAAACTTCG
menD-D AAAGAGCTCCATCAACAAGACGGCGTTCC
menD-Out TGTGGACGAGCAAATTGGGG
menD-Rev TGCGTACTTCAGGGCGATTT
menD-1AF CCCTTTCGTCTTCAATGAATACAAAACCTCTTTAAATC
menD-1BR CTTTATGATTTCCCATATAAAAGCGATCTCCTGCC
menD-2AF GGAGATCGCTTTTATATGGGAAATCATAAAGCAG
menD-2BR ACCGAGCTCGAATTCTTATAATGTGTCATGAATCATTT
menD-VecA CATGACACATTATAAGAATTCGAGCTCGGTAC
menD-VecB AGAGGTTTTGTATTCATTGAAGACGAAAGGG
agrA
agrA-A AAGGTACCGCGCAAGTTCCGTCATGATT
agrA-B AACTGACTTGTTTTGGATCGTCTTCGCA
agrA-C CAAAACAAGTCAGTTAACGGCGTATTCA
agrA-D AAAGAGCTCGGGGCAGGGGATGCATTTAT
agrA-Out TCGGATGAAGCTAAAGTAATAAGGC
agrA-Rev ATACGAAGGGAGCAGATGGTG
RNAIII
RNAIII -A AAGGTACCCGCACAGGAATGGGCTTCT
RNAIII -B ACCATACTCAACTATTTTCCATCACATCTCTGT
RNAIII -C ATAGTTGAGTATGGTCGTGAGCCCCTC
RNAIII -D AAAGAGCTCGCAATGGCCTATGTCACGTC
RNAIII -Out AGCTGCGATGTTACCAATGT
RNAIII -Rev TCCTGCTCGTAGTGGTGCTA
agrC
agrC -A AAGGTACCGCCCATTCCTGTGCGACTTA
agrC -B CTTCACCAGGACGCGCTATCAAACATT
agrC -C CGCGTCCTGGTGAAGGTCGTGGTTTAGGT
agrC -D AAAGAGCTCACCGATGCATAGCAGTGTTCT
agrC -Out GACAGTGAGGAGAGTGGTGT
agrC -Rev TGCGCCATAGGATTGTAGAGTG
Continued on the following page
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Table 2.3 { Continued from previous page
Primers Sequence 5' to 3' 
fur
Promoter Fwd TCGTCTTCAAGAATTGCTTGCATTTTATTGAG
Promoter Rev CTCCTTTACTCATCCCTACTAATAATTAAAATC
pCL55 Fwd ATTATTAGTAGGGATGAGTAAAGGAGAAGA
pCL55 Rev CAATAAAATGCAAGCAATTCTTGAAGACGAAAG
qPCR Fwd GAAGGCGCAAAACATTTCCA
qPCR Rev CCTTTAGCTTGGCACGTTTCAC
katA
Promoter Fwd CGTCTTCAAGAATTCAATTGTAATTTTGATGGG
Promoter Rev CTTCTCCTTTACTCATAGTCATCCCTCCACA
pCL55 Fwd TGTGGAGGGATGACTATGAGTAAAGGAGAAGAA
pCL55 Rev CATCAAAATTACAATTGAATTCTTGAAGACGAA
qPCR Fwd CCCAACTGATGGATACGGCTAT
qPCR Rev TCTGGGTCAGCTTTGTAACA
perR
Promoter Fwd TCGTCTTCAAGAATTCTATTGACACGCG
Promoter Rev TCTTCTCCTTTACTCATCTATATCACCATCTTTCTTAT
pCL55 Fwd AGATGGTGATATAGATGAGTAAAGGAGAAGA
pCL55 Rev CGCGTGTCAATAGAATTCTTGAAGACGAA
qPCR Fwd CTCATCAAGTCGATTCGACT
qPCR Rev GTGTTACGTCAAAGTCAGTC
16S qPCR Fwd GTCTGCAACTCGACTACATG
16S qPCR Rev TCCGATACGGCTACCTTGTT
GFP reporter check Rev CGCTTGACGACTTGTTGTTTAG
IM151 TACATGTCAAGAATAAACTGCCAAAGC
IM152 AATACCTGTGACGGAAGATCACTTCG
pJET1.2 Out CGACTCACTATAGGGAGAGCGGC
pJET1.2 Rev AAGAACATCGATTTTCCATGGCAG
Geh Fwd GTTGTTTTTGTACATGGATTTTTAG
Geh Rev CTTGCTTTCAATTGTGTTCC
pCL55 Rev GCGCATAGGTGAGTTATTAGC
pCN34 Fwd ATCTACACGACGGGGAGTCA
pCN34 Rev CCGCTTACCGGATACCTGTC
 Underlined text highlights overhangs required for the Seamless Cloning/Gibson Assembly
reaction, whilst bold text highlights restriction sites (KpnI: GGTACC or SacI:GAGCTC)
added for cloning purposes.
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Table 2.4: PCR reaction template.
Component 25 l reaction Final concentration
Deionised water 15 l
5X Phusion HF buer 5 l 1
10 mM dNTPs 0.5 l 200 M
Primers 1.25 l 0.2 M
50 mM magnesium chloride 0.75 l 1.5 mM
Template DNA 1 l 10{20 g l 1
Phusion DNA Polymerase 0.25 l 0.02 U l 1
Table 2.5: PCR cycle template.
Reaction stage Reaction conditions Number of cycles
Initial denaturation 98C, 30s1 1
Denaturation 98C, 10s 302
Annealing 50  60C, 20s 302
Extension 72C, 15{30s per Kb 302
Final extension 72C, 5 min 1
Hold 4C, 1 1
1 For E. coli colony PCRs, extension time was increased to 10 min.
2 Increased to 35 cycles for E. coli colony PCRs.
Table 2.6: qPCR reaction template.
Component Volume (l) Concentration
Deionised water 10 l
SYBR Green Jumpstart Taq Readymix 13 l 1.25 units Taq
Primers 1 l 10 M
Template cDNA 1 l 10{100 ng
Table 2.7: qPCR cycle template.
Reaction stage Reaction conditions Number of cycles
Initial denaturation 95C, 10s 1
Continued on the following page
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Table 2.7 { Continued from previous page
Reaction stage Reaction conditions Number of cycles
Annealing 50  55C, 30s 50
Extension 68C, 15s 50
2.4.6 Agarose gel electrophoresis
DNA was typically analysed using 1% (w/v) agarose gels made up with Tris-Borate
EDTA (TBE) buer (0.89M Tris-borate, 0.02 M EDTA, pH 8.0), with 4 l of SYBR Safe
DNA gel stain (Invitrogen) added per 50 ml gel. Gels were run in TBE for approximately
45 minutes at 90 V unless the DNA to be analysed was less than 100 bp, in which case
gels were run for 20 minutes. Samples were loaded with 6 NEB Loading Dye and
analysed against either a 1 Kb or 100 bp DNA ladder, depending on the product size.
Gels were visualised using the UV transilluminator AlphaImager (Alpha Innotech)
or the SafeImager (Invitrogen) when gel extraction was to be carried out. For gel ex-
traction, the DNA band of interest was excised using a fresh scalpel and puried using
the QIAquick Gel Extraction kit (Qiagen), following the manufacturer's instructions.
2.4.7 Restriction digests
Digestions were carried out in a waterbath following the instructions provided with
the enzymes (Table 2.8). For double digests, buer compatibility was checked using
the NEB Enzyme Checker. Where complete plasmid digestion was required, overnight
digests (16-18 h) were carried out if no star activity was indicated. Digests were puried
using the QIAquick PCR purication kit or loaded directly on a gel with Loading Dye
if analysis was required.
Table 2.8: Restriction digest template.
Component Concentration
Restriction Enzyme 10 units
DNA 1 g
10 NEB Buer 1
Water Up to 50 l
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2.4.8 Ligations
DNA ligations were carried out overnight (16-18 h) at 16C using 1 unit of T4 DNA
ligase as per the manufacturer's instructions (Table 2.9). DNA was ligated at a ratio of
1:3 vector to insert, with the ligated DNA used directly in subsequent transformations.
Table 2.9: Ligation template.
Component Concentration
10 T4 DNA Ligase Buer 1
Vector DNA (4 kb) 50 ng (0.020 pmol)
Insert DNA (1 kb) 37.5 ng (0.060 pmol)
T4 DNA Ligase 1 unit
Nuclease-free water Up to 20 l
2.4.9 Preparation of chemically competent E. coli
A stationary-phase culture (2 ml) was used to inoculate 100 ml of pre-warmed LB in a
500 ml ask. Bacteria were grown until an OD600 of 0.3{0.5. Cells were pelleted (1100
x g, 15 minutes, 4C) and re-suspended in 30 ml of ice-cold calcium chloride (50 mM)
by gentle shaking. Cells were incubated on ice for 20 minutes and then pelleted (1100
x g, 15 minutes). Finally, cells were re-suspended in 4 ml of ice-cold 100 mM calcium
chloride with 15% glycerol. The cells were aliquoted (100 l) using a 1 ml pipette tip
before being ash frozen in liquid nitrogen to prevent ice crystals forming and damaging
the cells. Competent cells were stored at {80C until required.
2.4.10 Transformation of chemically competent E. coli
Competent cells were defrosted on ice and DNA was added (approximately 50 ng in
a volume of 5 l or less) or water as a control. The cells were incubated on ice for 30
minutes and then heat-shocked in a waterbath (42C, 90 seconds). Cells were transferred
to ice for 2 minutes and 900 l of LB was added. The transformed bacteria were then
allowed to recover in a shaking incubator for one hour at 37C to give the bacteria time
to switch on antibiotic resistance genes supplied by the plasmid. Bacteria were then
plated (100 l) onto antibiotic-containing plates. Plates were incubated for up to 24
hours to select for transformants, but no longer where ampicillin was used, to avoid the
emergence of satellite colonies.
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2.4.11 Preparation of electrocompetent S. aureus
A stationary-phase culture was diluted 1:100 into a ask and grown to an OD600 of 0.5{
0.6. Cells were pelleted (1100 x g, 15 minutes, 4C). Pelleted cells were washed twice
in an equal volume of sterile 0.5 M sucrose, then washed once in half the volume of 0.5
M sucrose. Cells were pelleted a nal time and resuspended in 1:100 of 0.5 M sucrose.
These cells were aliquoted into 100 l aliquots and frozen at {80C.
2.4.12 Transformation of electrocompetent S. aureus
Plasmid DNA to be used for transformation was acquired at a high concentration (300{
800 ng l 1) and 20 l dialysed against deionised water for 20-30 minutes using 13 mm,
0.025 m lters (Millipore). A water only control was dialysed simultaneously.
Dialysed plasmid DNA or the water only control (15 l) was added to an aliquot of
defrosted electrocompetent cells. Cells were electroporated in electroporation cuvettes
(VWR) at 100 
, 2.5 kV, 25 F with a desired time constant of 2.1{2.5. Immediately
after electroporation, TSB with 0.5 M sucrose (900 l) was added to the cells before
incubation for 1 hour (37C, 180 rpm). The cells were then pelleted (17,000 x g) and
resuspended in 100 l of TSB before plating all of the bacteria onto selective antibiotic
plates. Agar plates were incubated for up to 72 h.
2.4.13 DNA sequencing
Samples for DNA sequencing were typically prepared from PCR products, although
occasionally whole plasmids were sequenced. Samples were sent with 3.2 picomole of
primer (forward or reverse) and 200{600 ng of DNA (with a total volume of 10 l) to
the MRC Clinical Sciences Centre Genomics Core Laboratory. Sequencing was carried
out using Sanger Dideoxy sequencing using the ABI3730xl sequencer. Sequence analysis
was performed using ChromosLite and by comparing sequences to a known sequence
using ClustalW (EMBO).
2.5 Construction of USA300 mutants
Flanking regions (approximately 500 bp) of the gene of interest were amplied by PCR
using primers A and B and primers C and D (see Table 2.3). For primers B and C,
overhangs were incorporated to enable joining of amplicons AB and CD. Restriction
digest sites for KpnI and SacI, were incorporated at the 5' terminus of primers A and
D (with the addition of 2{3 additional nucleotides to facilitate ecient digestion), re-
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spectively. Amplicons AB and CD were joined using the recombinase in the Geneart
Seamless Cloning and Genetic Assembly Kit (ThermoFisher Scientic) as per the man-
ufacturer's instructions. Following recombination, ABCD was amplied by PCR using
primers A and D. The PCR product was analysed on an agarose gel and the appropriate
band was gel extracted using the QIAquick Gel Extraction Kit (as described in Section
2.4.6).
Puried fragment ABCD was ligated into blunt-ended vector pJET and transformed
into chemically-competent E. coli DC10B. Colony PCRs were performed to ensure the
appropriate fragment had been cloned (using primers pJET1.2 Out and pJET1.2 Rev)
and PCR products sequenced. Following sequence conrmation, restriction digests of
pJET containing fragment ABCD and plasmid pIMAY were carried out using KpnI and
SacI. KpnI and SacI digested pIMAY was then ligated with similarly digested ABCD and
the plasmid was transformed into E. coli DC10B. Colony PCRs were again performed
(using primers IM151 and IM152) and PCR products were sent for sequencing to ensure
no additional mutations had been acquired.
pIMAY containing fragment ABCD was then recovered by Midiprep and transformed
into electrocompetent S. aureus USA300. Transformants were grown for up to 72 h at
28C on CBA with Cm10. Several transformants were selected and re-grown onto fresh
CBA plates with Cm10. These plates were incubated for 16-18 h at 37C to select for
integration as temperatures over 30C are not permissive of rolling circle replication of
pIMAY. Integration was conrmed by colony PCRs using primer A and Rev and primer
B and Out. Colonies that contained the integrated plasmid were cultured overnight
in TSB (180 rpm, 37C) and then plated onto CBA containing AHT. The plates were
incubated at 28C for 24{48 h to select for loss of the plasmid via AHT-induced anti-
secY expression. To select for the hemB and menD mutants, a loop of bacteria
from the AHT plates were restreaked onto TSA plates with Gm. Colonies with the SCV
phenotype were screened by colony PCR using primers Out and Rev, which anked the
deletion site. For the agr mutants, 50{100 colonies were patched onto CBA containing
AHT and CBA containing Cm10. Colonies that had grown in the presence of AHT,
but not the Cm10 plates, and which had lost haemolytic activity, were screened by
colony PCR using primers Out and Rev. All mutants were conrmed by PCR and DNA
sequencing.
To construct the double hemB agr mutants, the three agr mutants (agrA, agrC
and RNAIII ) were made electrocompetent and transformed with pIMAY containing
hemB ABCD. The same mutant construction protocol was followed as above, with each
of the mutants selected for on TSA Gm plates. The mutants were conrmed by colony
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PCR using primers Out and Rev for both mutations and these PCR products were
sequenced.
2.6 Phage transduction
The SH1000 hemB ::Tn mutant was constructed by phage transduction. The donor
bacteria, JE2 hemB ::Tn, was grown overnight in TSB with Erm. Stationary-phase
bacteria (200 l) were added to 25 ml of TSB containing 250 l 1M MgSO4 and 250 l
1M CaCl2. The bacteria were grown for 1 h (37
C, 180 rpm) alongside a blank (TSB with
MgSO4 and CaCl2 only). 11 (100 l) was then added and the bacteria were incubated
(37C, 180 rpm) until complete lysis was observed (at least 4 hours).
After complete lysis, the phage lysate was centrifuged (17,000 x g, 3 min) and stored
at 4C (phage lysate A). The above steps were repeated but instead of fresh lysate, 1 ml
of phage lysate A was added. Bacteria were incubated (37C, 180 rpm) until complete
lysis. The phage lysate was then centrifuged (17,000 x g, 3 min) and lter sterilised
using a 22 M lter (VWR). The phage lysate (phage lysate B) was stored at 4C until
use.
Recipient cells (SH1000 WT) were grown overnight in 20 ml LK Broth (1% w/v
tryptone, 0.5% w/v yeast extract, 0.7% potassium chloride). The culture was centrifuged
(4000 x g, 15 min), the supernatant was removed and the bacterial pellet was resuspended
in 1 ml LK Broth. To 500 l LK broth containing 10 mM CaCl2, 250 l of SH1000 was
added and 250 l of phage lysate B. The bacteria and phage were mixed and incubated
at 37C statically for 25 min alongside a no phage control. Both samples were then
incubated with shaking (180 rpm, 37C) for 15 min. Ice cold 0.02 M sodium citrate (500
l) was then added and the samples were centrifuged (10,000 x g, 10 min). The pellets
were resuspended in 500 l 0.02 M sodium citrate and kept on ice for 2 h. Finally, 100
l of the samples were plated neat onto LKA plates containing 0.05% v/v citrate and
Erm. The plates were grown for up to 48 h and colonies were re-streaked at least 3
times onto TSA containing 0.05% v/v citrate to cure the phage. The resulting SH1000
hemB ::Tn isolate had the characteristic SCV colony morphology and was conrmed by
colony PCR and sequencing.
2.7 Complementation of USA300 mutants
The USA300 agrC mutant was complemented using pCN34 containing either the WT
agrC gene or a constitutively active version of agrC (see Table 2.2). The agrC mutant
was made electrocompetent as described in Section 2.4.11 and then transformed with
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pCN34 containing one of the agrC variants or pCN34 alone as a control. Transformants
were plated onto CBA plates with Km50 and incubated at 37C overnight. Haemolysis
was restored in strains containing a copy of agrC. Colony PCR was performed on all
strains, including the plasmid control, using pCN34 Fwd and Rev to conrm the presence
of the plasmid.
The USA300 hemB and menD genes were complemented by transforming the
electrocompetent cells with plasmid pCL55 containing either a copy of the hemB or
menD gene. These plasmids were constructed by amplifying the promoter region of
each gene (using primers 1AF and 1BR), the gene of interest (using primers 2AF and
2BR) and plasmid pCL55 (using primers VecA and VecB). Each of the primers contained
overhangs to enable the plasmid to be constructed using the Gibson Assembly kit (NEB).
Following Gibson assembly, the plasmid was immediately transformed into S. aureus
(alongside a pCL55 only plasmid control) and transformants were selected for by plating
onto TSA with Cm10. The WT phenotype was restored in complemented strains and
colony PCR was performed on all strains using primers 1AF and 2BR. This PCR product
was also sequenced to ensure no additional mutations had been acquired.
2.8 Construction of reporter constructs
The fur, perR and katA promoters were amplied using the primers Promoter fwd and
Promoter Rev (Table 2.3). The pCL55 P3-GFP plasmid was amplied using pCL55
Fwd and pCL55 Rev to include the gfp gene but lacking the P3 promoter sequence.
As all the primers contained overhangs, each of the promoters could then be joined to
the corresponding plasmid backbone using the Gibson Assembly kit (NEB). Following
the manufacturer's instructions, the plasmid was then transformed into E. coli DC10B.
Transformants were selected on LB Amp plates and the reporter plasmids were screened
by colony PCR using Promoter Fwd and GFP reporter check Rev. The reporters were
then conrmed by sequencing to ensure the sequence was still intact. Each of the re-
porters were then transformed into electrocompetent USA300 WT, hemB and menD
and plated onto TSA agar plates with Cm10. Transformants were grown overnight at
37C and screened by colony PCR using the Geh Fwd and Geh Rev primers. Once
again, the PCR products were sequenced.
2.9 P3-GFP reporter assay and growth curves
Strains were transformed with the pCL55 plasmid containing the Agr-P3 promoter fused
to GFP, which was constructed by James et al (2013) [359]. Strains containing the P3
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reporter constructs were grown on TSA plates containing Cm10 and these plates were
then used to grow overnight cultures. To restore Agr activity in AIP3-treated bacteria,
the stationary-phase cultures were washed three times with TSB and grown with 10 M
AIP1 (Peptide Protein Research Ltd).
Stationary-phase cultures (grown without antibiotic) were diluted 1:5 into fresh TSB
and 200 l was added to a 96 well at-bottom plate with black walls suitable for uores-
ence measurements (Greiner). The same batch of TSB was used for each set of repeats
and samples were added in triplicate and grown alongside a TSB blank.
Samples were grown in a POLARstar multiwell plate reader (BMG Labtech) with
shaking (500 rpm, 37C). Growth readings (OD600) and the relative uorescence unit
(RFU) readings (OD485) were taken simultaneously every 30 minutes for 17 h. Measure-
ments were subtracted from blank readings and OD600 or RFU plotted versus time. To
account for growth dierences between strains, OD485 measurements were divided by
OD600 readings.
2.10 Haemolysis assay
Stationary-phase cultures (2 ml) were pelleted (17,000 x g, 3 min) and the supernatant
was transferred to fresh 2 ml tubes. Serial 1:2 dilutions of the supernatant was made
in fresh TSB up to the 1:32 dilution. The neat or diluted supernatant (400 l) was
mixed with 2% debrinated sheep (E&O Laboratories Limited) or human blood (freshly
donated) in PBS at a 1:1 ratio. 1% SDS was used as a positive control and TSB only as
a negative control.
The supernatant and blood mixture was incubated in a static incubator (37C). After
1 h, the mixture was pelleted (500 x g, 10 minutes) and the supernatant transferred to
a fresh 96 well plate. The samples were then read at 485 nm in a plate reader and
haemolysis was determined as a percentage of the WT haemolysis at the neat dilution.
2.11 SCV reversion assay
SCVs were grown overnight with Gm and then plated (107 CFU) onto TSA plates.
Plates were then incubated for up to 48 hours at 37C to detect spontaneous reversion
to the WT colony phenotype.
2.12 Gentamicin susceptibility testing
Stationary phase cultures (107 CFU) were spread onto TSA and allowed to air dry.
Gentamicin discs (10 mg dry gentamicin; Scientic Laboratory Supplies) were placed in
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the centre of the agar plate before incubation at 37C for 16h. The radius of the zone of
inhibition was measured at multiple points and the average was used to determine the
sensitivity of each strain.
2.13 Catalase activity assay
Overnight cultures (1 ml) were washed three times with PBS and 107 CFU were added
to 100 M H2O2 in PBS (1 ml). Bacteria were incubated in the H2O2 in the dark in a
37C water bath. At time zero and every 15 minutes (up to an hour), 200 l of sample
was pelleted (17,000 x g, 3 min) and 20 l added to a 96 well plate. Catalase activity was
measured indirectly by measuring the concentration of H2O2 overtime, using the Pierce
Quantitative Peroxide Assay (Aqueous Compatible) kit (Thermo Fisher). Reagents A
and B (at a ratio of 1:100, 200 l total volume) were added to each sample immediately,
following the manufacturer's instructions. The assay was then incubated for 20{30 min
and the samples were read at 595 nm in a plate reader. The H2O2 concentration was
measured by using a standard curve, made by reading the optical densities of samples
with known concentrations of H2O2.
2.14 Bacterial survival assays
2.14.1 Blood survival assay
Stationary-phase cultures were washed three times in PBS and adjusted to 106 CFU
ml 1 in PBS. Bacteria (10 l, 104 CFU) were added to a 96 well plate and incubated
with 90 l of freshly donated blood (collected in EDTA-treated tubes; BD) or PBS (for
the time zero timepoint) where required. Blood was treated 15 min prior to incubation
with bacteria with DPI (50 M), DMSO (7.5 l ml 1) or bovine catalase (50 g ml 1)
as needed. Plates were then sealed with paralm and incubated in the shaking incubator
(37C, 180 rpm). At each timepoint (2, 4 and 6 hours post-incubation), the blood was
serially diluted 10-fold in PBS and the neat, 10 1, 10 2 and 10 3 dilutions (10 l) were
plated onto CBA. Plates were incubated for 48 hours at 37C and CFUs were counted.
Survival was calculated as a percentage of the number of bacteria in the inoculum.
2.14.2 Hydrogen peroxide survival assay
Overnight cultures were washed three times in PBS and adjusted to 106 CFU ml 1 in
PBS. Bacteria (10 l, 104 CFU) were added to a 96 well plate and 90l of freshly diluted
H2O2 (15, 20 or 30 mM in PBS) or PBS (for the time zero timepoint) was added. Plates
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were incubated in the static incubator (37C) in the dark. After 1 hour, the bacteria were
serially diluted 10-fold in PBS and the neat, 10 1, 10 2 and 10 3 dilutions (10 l) were
plated on CBA (which contains catalase that prevents any further peroxide killing after
plating). Plates were incubated for up to 48 hours at 37C and CFUs were enumerated.
Survival is shown as a percentage of the number of bacteria in the inoculum.
2.14.3 Neutrophil survival assay
106 neutrophils (HL-60s or freshly-isolated human PMNs) were added to 90 l Hanks'
Balanced Salt Solution (HBSS) with calcium and magnesium (Thermo Fisher Scientic)
and 10% human plasma. Stationary-phase bacteria were washed twice in PBS and 105
CFU were added to the neutrophils and HBSS (MOI 1:10) to a nal volume of 200 l.
The bacterial and neutrophil suspension was then incubated at 37C with tumbling. At
each timepoint (30, 60, 120 and 180 min), 100 l of the suspension was transferred to
a 96 well plate and serially diluted in PBS to the 10 3 dilution. Each of the dilutions
(including neat) were then plated onto CBA . Plates were incubated for 48 hours at 37C
before counting. Survival was calculated as a percentage of the bacteria in the starting
inoculum (T0).
2.15 Eukaryotic cell preparation
2.15.1 Culture of HL-60 cells
HL-60s (ATCC CCL-240) were grown in Iscove's Modied Dulbecco's Medium (Sigma-
Aldrich) with the addition of fetal bovine serum to a nal concentration of 20%. Cells
were grown in T-75 asks (Corning) at 37C, 5% CO2 and medium was replenished
every 2{3 days to maintain cell density between 1 105 and 1 106 cells ml 1. HL-60s
were dierentiated into neutrophils by supplementation of the medium with 1% DMSO
for 5 days prior to use in the neutrophil killing assay. Cell morphology was assessed by
microscopy to ensure that the majority ( 95%) of cells had dierentiated.
2.15.2 Isolation of polymorphonuclear leukocytes
Blood (20 ml) freshly collected in EDTA-treated tubes was layered over 20 ml room-
temperature Polymorph prep (Alere Limited). Cells were separated by centrifuga-
tion (500 x g, 45{60 minutes, brake o) until a clear separation of blood, peripheral
blood mononuclear cells (PBMCs) and polymorphonuclear leukocytes (PMNs) was seen.
Plasma was taken from the top layer and stored at room temperature, the PBMCs were
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discarded and the PMNs were transferred to a fresh 50 ml polypropylene tube. Up to
50 ml of HBSS without calcium or magnesium (Thermo Fisher Scientic) was added to
the PMNs and cells were pelleted (400 x g, 10 minutes, brake o). The supernatant
was removed and the PMNs were resuspended in 5 ml of red blood cell lysing buer
(eBioscience) before incubation at 37C for 5 minutes. Up to 50 ml of HBSS (without
calcium or magnesium) was added to the PMNs and cells were pelleted again (400 x g,
10 minutes, brake o). The PMNs were resuspended in 2 ml of HBSS without calcium
or magnesium. PMNs were then counted using a haemocytometer and adjusted to 1 
107 cells ml 1.
2.16 Flow cytometry
2.16.1 Fluorescent labelling of S. aureus
Stationary-phase bacteria (1 ml) were pelleted (17,000  g, 3 min) and washed twice
with PBS. The pellet was resuspended in 200 l of 1.5 mM uorescein isothiocyanate
(FITC) dissolved in freshly prepared carbonate buer (0.05 M sodium carbonate and
0.1 M sodium chloride). Bacteria were then incubated for 60 min (room-temperature,
tumbling) in the dark. FITC-labelled bacteria were then washed three times in carbonate
buer and adjusted to 1  106 CFU ml 1 in PBS.
2.16.2 Preparation of blood samples for cell analysis
FITC-labelled bacteria (10 l, 1  104 CFU) were added to 96-well plates prior to the
addition of 90 l of freshly isolated blood, as described for the whole blood killing assay.
At each of the timepoints (0, 2, 4 and 6 h), the blood/bacteria mixture (100 l) was
added to 900 l 1 red blood cell lysis solution (eBioscience) and incubated at room
temperature in the dark for 10 min. Samples were then centrifuged (500  g, 10 min),
the pellet washed once in PBS (1 ml) before a nal centrifugation (500  g, 10 min) and
resuspension in 100 l PBS or 1% paraformaldehyde (PFA; Aymetrix) if no further
staining was required. Where samples were to be analysed for host cell death, samples
were incubated in PBS containing the Zombie Violet live-dead dye (Biolegend) at a
1:500, 1:1000 or 1:2000 dilution as required for 15 min in the dark. Free primary amine
groups were quenched using 1.4 ml 1% bovine serum albumin (BSA) and samples were
centrifuged (500  g, 10 min) before resuspension in 100 l 1% PFA. Positive controls
were made by heat-killing host cells (100C, 10 min) prior to Zombie staining. Samples
were xed overnight (12-16 h) at 4C.
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2.16.3 Analysis of FITC-labelled bacteria incubated in whole blood
Samples were analysed on a Fortessa ow cytometer (BD) and at least 10,000 events were
captured (except for the bacteria only samples where at least 1000 events were captured).
Green (FITC-bacteria) and violet (Zombie-labelled host cells) uorescence were detected
at 488/530 (30) nm and 404/450 nm, respectively. Based on preliminary analyses and
using the methodology of Surewaard et al. (2013), free bacteria (i.e. bacteria not
phagocytosed) were identied as events with a side scatter of  50K [364]. Whilst,
host cells were identied as events with a side scatter of > 50K. Samples were analysed
alongside controls - bacteria without FITC labelling, host cells with or without Zombie
stain, uninfected host cells and heat-killed host cells - as appropriate. Data were analysed
using FlowJo software (Version 10) and compensation was not necessary as the spectra
of the uorescent signals did not overlap.
To conrm that free bacteria were pelleted along with the host cells during ow cy-
tometry preparation, the number of bacteria in the lysate and the pellet were quantied.
Blood (100 l) was spiked with 105 CFU of bacteria. The spiked blood was immediately
added to 900 l of red blood cell lysis solution (eBioscience) and incubated at room
temperature for 10 min. The lysed blood was then centrifuged (500  g, 10 min) and
the lysate (100 l) was transferred to a fresh 96 well plate. Serial dilutions (1:10) were
made up to the 10 3 dilution and 10 l of each of the dilutions (including neat) was
plated onto CBA plates. The remaining lysate was resuspended and 100 l of the pellet
and lysate suspension was transferred to a fresh 96 well plate. Serial dilutions (1:10)
were again made up to the 10 3 dilution and 10 l of each of the dilutions (including
neat) was plated onto CBA plates. The plates were incubated at 37C for 16-18 h and
the CFU enumerated.
2.17 Microscopy
2.17.1 Preparation and visualisation of blood smears
Blood (10 l) was spotted onto microscope slides (VWR) and spread using a plastic
stick to create a thin lm. The blood smear was allowed to air dry before being stained
using Hemacolor Rapid Staining kit (Merck Millipore) according to the manufacturer's
instructions. Slides were sealed with a coverslip and visualised on a Wideeld micro-
scope (Zeiss Axiovert 200) using a 100 1.4 oil phase 3 objective and brighteld Kohler
illumination. Fluorescence was captured using the GFP channel of the microscope and
seven separate elds were captured simultaneously to assess the percentage of bacteria
labelled with FITC. Bacteria were counted from microscopy images using ImageJ.
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2.17.2 Preparation and visualisation of freshly isolated human neutrophils
A suspension of isolated neutrophils (approximately 1  102 { 103 cells ml 1) was
spotted onto microscope slides and spread using a plastic stick to create a thin lm.
The suspension was allowed to air dry and the slide was stained using Hemacolor Rapid
Staining kit (Merck Millipore). Slides were visualised on an ECLIPSE TS100/100-F
microscope (Nikon) using a 40 objective. Images were taken using the Nikon Coolpix
990.
2.18 Inductively coupled plasma mass spectrometry
Bacteria were grown for 16-18 h (5 ml of WT and 50 ml of SCV) and centrifuged (1100 x
g, 15 minutes, 4C). The bacteria were then resuspended in 1 ml of PBS containing 100
g ml 1 lysostaphin and a 1:1000 dilution of DNase (Qiagen) before static incubation
(37C for 2{3 h). Bacterial lysates were then heat-killed at 80C for 10 min and then
stored at {80C until analysis.
Bacterial lysates were analysed on an ICP-MS 7900 (Agilent Technologies) alongside
lysate buer, TSB, standards and quality control material containing known concen-
trations of iron, manganese, copper and zinc (ClinChek, RECIPE) made up in water
as instructed by the manufacturer. Prior to running the samples, the machine was
calibrated using a custom standard (PlasmaCAL, SPC Sciences) serially diluted 1:2 in
carrier/wash solution (1% v/v Trimethylamine hydroxide from 25% w/w stock [Elec-
tronics Grade, Alfa Aesar], 2.5% v/v Butan-1-ol [SuperPurity, ROMIL] and 0.05 g L 1
EDTA [Alfa Aesar]) and a blank. The bacterial lysates were then analysed both undi-
luted and after a 1:10 dilution in water. The standards, QC material and samples were
diluted 1:50 in sample diluent containing a germanium internal standard (carrier/wash
solution and 75 g L 1 Germanium [Specure, Alfa Aesar]). The ICP-MS was used in
helium mode and germanium was used as the internal standard. Values obtained for
each strain were corrected for total CFU counts and converted to nmol L 1 units.
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3 Construction and characterisation of S. aureus mutants
3.1 Introduction
In 1884, Robert Koch published a set of criteria for determining whether a particular
organism was the causative agent of a disease [518]. Over a century later, Koch's postu-
lates were adapted by Stanley Falkow to enable molecular microbiologists to determine
whether a particular gene contributes to the pathogenicity of a micro-organism [519].
These were named Molecular Koch's postulates (shown in Figure 3.1).
Following these principles, one way to understand the role of Agr during bloodstream
infections would be to construct mutations within agr and test how these mutants survive
in blood. Constructing mutants in a single well-characterised strain, rather than using
available mutants in dierent backgrounds, enables direct comparison of the mutants
to the isogenic WT strain and allows us to be condent whether a particular mutation
aects staphylococcal survival. These results can then be conrmed by complementing
the mutant strain by reintroduction of the gene at a second locus to ensure that spon-
taneous mutations or polar eects of the targeted mutation have not confounded the
ndings.
Figure 3.1: Stanley Falkow's Molecular Koch's postulates. A list of criteria used
to determine whether a gene is important for the virulence of an organism. Adapted from
Falkow (2004).
Constructing mutants within S. aureus is technically dicult when compared to the
mutagenesis of E. coli. This is due to the presence of numerous restriction systems that
are present within S. aureus that target and selectively degrade exogenous DNA [520].
There are three identied restriction systems present in S. aureus - type I, II, and IV
[520]. The Type I system consists of a HsdS1HsdM2HsdR2 endonuclease complex that
recognises and cleaves unmethylated DNA. The Type II system involves a restriction
endonuclease such as Sau3A, which cuts at a short, specic recognition site (4{8 bp).
However, the main barrier that prevents ecient transformation of DNA from E. coli
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into S. aureus is the type IV restriction system, SauUSI, which reduces the transfor-
mation frequency by 104-fold [521, 522]. SauUSI is an endonuclease that recognises
the methylation or hemi-methylation of cytosines [522]. Once recognised, SauUSI will
cleave 2{18 bp from the methylation site in a process requiring the presence of ATP
and divalent cations. Since E. coli methylates cytosine residues via the Dam and Dcm
methylases, any DNA shuttled through E. coli will be degraded by most strains of S.
aureus if it is transformed directly [523{525].
One way to construct mutants in S. aureus is to use readily transformable strains
such as RN4220. RN4220 was derived from NCTC8325-4 (RN0450) by subjecting 8325-4
to nitrosoguanidine mutagenesis to select for a mutant that would eectively take up
foreign DNA [520, 526, 527]. Sequencing of RN4220 has revealed a mutation within the
type I restriction system, in hsdR, although a nonsense mutation within the SauUSI
restriction system has also been identied and is now thought to be the main reason
why this strain readily accepts DNA from E. coli [520, 521]. Mutagenesis can then be
carried out by allelic replacement using the plasmid pKOR1, which was constructed by
Bae and Schneewind (2006) [528]. Unfortunately, this method has a number of problems
associated with it. Firstly, due to the substantial manipulation that these strains have
undergone, they have acquired secondary mutations that aect key phenotypic proper-
ties. For example, strain 8325-4 has acquired mutations in rsbU and tcaR, which are
activators of SigB and Spa, respectively [526]. Strain RN4220 is defective in Agr ex-
pression [418, 526]. Secondly, the use of pKOR1 is awed as the temperature shift to
43C used to select for homologous recombination is thought to select for sae mutations
[514, 528].
Another method typically used to construct mutants is by transposon mutagenesis
using phage transduction. Phage transduction is ecient and can be carried out in
multiple strains by choosing the correct phage. Strain 8325-4, mentioned earlier, was
generated by UV treating strain NCTC8325 to cure it of three phages and therefore,
this strain is heavily used in studies where phage transduction is required [526, 527]. A
number of transposon libraries have been constructed in S. aureus that are available for
use [513, 529]. This includes the Network on Antimicrobial Resistance in Staphylococcus
aureus (NARSA) transposon library, which utilised the bursa aurealis transposon to
generate 1952 mutants in the CA-MRSA strain JE2 [513]. Whilst transposon libraries
can be a convenient way to screen for genes of interest, insertions of transposons can
often have polar eects and these are particularly problematic when the gene of interest
is located within an operon. Transposon mutagenesis is also limited to strains which are
sensitive to the antibiotic used to select for insertion of the transposon. For example,
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the NARSA transposon library makes use of an erythromycin cassette meaning strains
such as USA300 LAC that are already resistant to erythromycin, are not amenable to
this approach. There are additional antibiotic resistance cassettes, however their use can
prohibit subsequent complementation.
A recent method published by Monk et al. (2012) solves many of the problems
listed above for constructing mutants in S. aureus and enables the transformation and
mutagenesis of most S. aureus strains [514]. In this method, DNA is shuttled through
an E. coli mutant called DC10B that lacks the dcm gene, which encodes the cytosine
methyltransferase. Therefore, S. aureus is unable to recognise E. coli DNA as foreign
and so it does not degrade it. The mutagenesis process is then carried out via allelic
exchange and mutagenesis is similar to pKOR1, although a temperature shift at 28C
is utilised instead. This method results in a markerless deletion, enabling the deletion
of genes located in operons, whilst minimising the likelihood of polar eects. It was
therefore determined that this method would be the best approach to construct mutants
in S. aureus.
This chapter will outline the process of constructing stable Agr and SCV mutants
within S. aureus using the method described by Monk et al. (2012). The mutants were
subsequently characterised using a range of assays and this chapter will discuss why the
mutants generated were suitable for studying the role of Agr and the SCV phenotype in
persistent bacteraemia.
Aim: To construct mutants that inactivate Agr or confer the SCV phe-
notype within S. aureus and to characterise these mutants with respect to
previously described phenotypes.
3.2 Construction of mutants
Mutants were constructed in S. aureus USA300 LAC, which is the predominant strain
found within the United States of America [512]. USA300 is a CA-MRSA strain that is
responsible for more than a third of bloodstream infections and has undergone relatively
little manipulation within the laboratory with no curing of plasmids [530, 531]. Therefore
USA300 was deemed to be an appropriate model strain to use in order to study the
persistence of S. aureus in blood.
To understand the role of Agr during S. aureus bacteraemia, mutations were con-
structed in the agr operon (Figure 3.2A). Knockouts of the agrA and agrC genes were
made as these are where the majority of mutations are found in agr mutants isolated
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from bacteraemia patients [385, 404, 405, 407, 412, 418, 532]. A RNAIII mutant was
also constructed by knocking out the gene encoding delta toxin (hld) to determine how
dierent components of the Agr system function during infection.
Figure 3.2: Genes selected for mutagenesis in the construction of agr mutants
and stable SCVs in S. aureus. Mutations within agr were created by deleting either
the agrA, agrC or the hld gene (highlighted in red) from the Agr operon (A). Stable
SCVs were constructed by deleting either the hemB (highlighted in green) or the menD
(highlighted in blue) gene from the hem and men operons, respectively (B). Not to scale.
To understand the biology of SCVs during bacteraemia, stable SCVs were con-
structed by deleting genes involved in the ETC (Figure 3.2B). Based on the muta-
tions commonly found in clinically-derived and published SCVs, knockouts were made
in the hemB and menD genes [422, 438, 439, 455, 456, 459, 533, 534]. The hemB
gene encodes 5-aminolevulinic acid dehydratase and is involved in haem biosynthesis
and the menD gene encodes a 2-succinyl-6-hydroxy-2, 4-cyclohexadiene-1-carboxylic
acid synthase/2-oxoglutarate decarboxylase and is involved in menaquinone biosynthe-
sis. These two biosynthetic pathways are essential for the production of electron trans-
porters that function in the ETC. Knocking out the haem biosynthesis pathway results
in a haemin-auxotrophic SCV, whilst the disruption of menadione biosynthesis results
in a menadione-auxotrophic SCV. Consequently, the WT phenotype can be restored in
the SCVs by supplementing the culture medium with haemin or menadione, respectively
[431, 447, 482].
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As all of the target genes are located within operons, it was important to use the
mutagenesis approach developed by Monk et al. (2012) as the process results in a scarless
mutant, reducing the likelihood of polar eects on other genes within the operon.
3.3 The mutagenesis strategy
To construct mutants, approximately 500 bp anking the gene of interest was amplied
using primer pairs A and B, and C and D, as shown in Figure 3.3, using hemB as an
example. Restriction sites were incorporated into these primers, resulting in fragment
AB containing a 5' KpnI site and fragment CD containing a 3' SacI site. Overhangs were
incorporated into each fragment so that the 3' end of fragment AB and the 5' end of
fragment CD were complimentary. Fragments AB and CD could then joined by Geneart
Seamless Cloning (see section 2.5 in the Materials & Methods) and cloned into pIMAY
using corresponding restriction sites.
Plasmid pIMAY containing fragment ABCD was transformed into E. coli strain
DC10B, which lacks the cytosine methyltransferase gene. E. coli transformants were
identied by growth on ampicillin-containing LB agar. These transformants were then
cultured in LB broth and miniprepped for plasmid pIMAY containing fragment ABCD.
To determine that the insert was correct, restriction digests were carried out and the
plasmid was sequenced. Constructs with the correct sequence were then transformed
into the S. aureus USA300 strain by electroporation. Transformants were selected for
by growth at 28C for up to 72 hours on LB agar plates containing chloramphenicol,
with this temperature enabling replication of pIMAY. Colonies that grew at 28C were
then sub-cloned onto fresh plates containing chloramphenicol before incubation at 37C.
Homologous recombination of fragment ABCD into the S. aureus genome (resulting in
integration of the entire plasmid) was selected for by growth at 37C, since this tem-
perature is not permissive for rolling-circle replication of the plasmid. Consequently,
transformants will only grow if plasmid integration has occurred. Integration of the
plasmid into the chromosome was then conrmed by PCR with either primer pair Out
Fwd and D, or primer pair A and Out Rev (data not shown; see Figure 3.3 for an-
nealing sites). Where no integration has occurred, PCR products were identical but
where integration had occurred, a smaller PCR product was produced for the primers
that amplify across the location of integration and this can occur either via AB or CD
integration (an example of an AB integration of pIMAY is shown in Figure 3.3) [514].
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Figure 3.3: Mutagenesis strategy for construction of S. aureus mutants. Flanking
regions of the gene of interest were amplied with KpnI and SacI restriction digest sites and
recombined using Geneart Seamless Cloning (fragment ABCD) before being cloned into corre-
sponding restriction sites that had been cut in plasmid pIMAY. pIMAY ABCD was passaged
through E. coli DC10B and transformed into S. aureus. Homologous recombination between the
anking regions of the gene of interest and the corresponding regions in the plasmid results in
integration of the plasmid. AHT-induction of anti-secY selects for loss of the plasmid resulting
in a reversion to the WT or loss of the gene of interest. Construction of the hemB mutant via
AB recombination is shown as an example but each mutant was constructed using the same
principle. For the SCVs, an additional selection on Gm plates was used to enrich for mutants.
Figure adapted from Monk et al. (2012).
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Deletion of the gene of interest was then achieved by selecting for loss of the plasmid
using anhydrotetracycline (AHT), which induced expression of a small antisense RNA
(anti-secY ) that blocked translation of the transporter SecY. As the SecY transporter
is important for secretion, blocking its production results in slow growth in strains that
retain the integrated plasmid [514]. Therefore, normal-sized colonies were selected as
these were likely to have lost the plasmid. Mutants were then screened for by replica
plating onto agar plates containing AHT or chloramphenicol (Figure 3.4). Strains that
had lost the plasmid grew normally on AHT and were sensitive to chloramphenicol. Loss
of the plasmid occurred at a low frequency, with just over 10% of the colonies screened
losing resistance to chloramphenicol. In the case of the SCVs (the hemB and menD
mutants), mutants were selected for by plating onto Gm agar plates with small colonies
selected for further screening. For the agr mutants, replica plating was carried out on
CBA containing AHT and mutants were screened for by lack of haemolysis (for the
agrA and agrC mutants) or reduced haemolysis (for the RNAIII mutant).
Figure 3.4: Replica plating to screen for potential mutants. Mutants of S.
aureus were screened for by replica plating onto AHT and Cm10 plates to select for loss
of plasmid pIMAY. An example of a screen for the hemB SCV is shown and black circles
highlight which colonies were selected for screening based on chloramphenicol sensitivity.
Finally, mutations were conrmed by PCR with primers Out Fwd and Out Rev. In
the mutants, this PCR resulted in a smaller amplicon (where the gene of interest has
been lost) than the same PCR undertaken with WT DNA. For each of the mutants
constructed, the results of these PCRs are shown in Figure 3.5. Sequencing of these
PCR products was also undertaken to conrm the mutation and check that the anking
DNA (approximately 100 bp either side) had not been mutated.
To assess the role of Agr in the SCVs, double mutants were constructed in the hemB
background. This was done by transforming the agrA, agrC and RNAIII mutants
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Figure 3.5: Gel electrophoresis images conrming the construction of single
deletion mutants in S. aureus. DNA isolated from either USA300 WT or the mu-
tants (hemB, menD, agrA, agrC, RNAIII ) was amplied by PCR using primers
anking the deleted gene. PCR products were analysed on a 1% agarose gel next to a 1
kb DNA ladder, to conrm the loss of DNA in the mutants.
with plasmid pIMAY hemB ABCD and by repeating the mutagenesis strategy outlined
above. The hemB SCV was again selected for by plating integrants onto Gm plates.
Construction of the double mutants was conrmed by PCR to check for loss of the
hemB gene as well as for the appropriate gene that had already been deleted from the
Agr system (Figure 3.6). Sequencing was used to conrm the deletion of hemB and
the additional mutation within the Agr system.
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Figure 3.6: Gel electrophoresis images conrming the construction of Agr
mutations in the S. aureus hemB SCV. DNA isolated from either USA300 WT or
the double mutants (hemBagrA, hemBagrC or hemBRNAIII ) was amplied
by PCR using primers anking the deleted genes of interest. PCR products were analysed
on a 1% agarose gel next to a 1 kb DNA ladder and conrm the loss of DNA in the
mutants.
3.4 Complementation of mutants
The agrC mutant was complemented using plasmid pCN34 containing a copy of the
agrC gene under its native promoter (P2), which was constructed by James et al. (2013)
[359]. The agrC mutant was also complemented with constructs containing constitu-
tively active AgrC gene variants (M234L, R238H, Q305H) as well as pCN34 alone to
act as a plasmid only control [359]. Complementation was conrmed by restoration of
haemolysis (visualised after growth on CBA and measured by the haemolysis assay; see
section 3.8) and resistance to kanamycin. Successful transformation of the agrC mu-
tant with the pCN34 only control was conrmed by PCR with primers amplifying the
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pUC19 ori region and resistance to kanamycin (data not shown).
Complementation of the hemB and menD SCVs was achieved by cloning each gene
into the integrative vector pCL55 under the control of its native promoter. As both genes
are located in operons, the genes and their respective promoters were amplied separately
and joined together using Gibson assembly (details are provided in the Material and
Methods, section 2.7). For hemB, the promoter sequence was previously identied by
Kafala and Sasarman (1997) and therefore this sequence was amplied [535]. For menD,
the 331 bases before menF were amplied (the rst gene in the men operon). The
hemB and menD genes were amplied based on annotations of the FPR3757 S. aureus
genome on NCBI. Restoration of the WT phenotype (normal growth and pigmentation)
and resistance to chloramphenicol was used to initially screen for complemented strains.
Conrmation of complementation was conrmed along with strains containing empty
pCL55 (as plasmid only controls), using PCR and DNA sequencing (data not shown).
3.5 Phenotypic characterisation of mutants
Once the construction of the mutants had been conrmed by DNA sequencing, they were
characterised in a range of assays to test whether they had the expected phenotype, as
described previously in the literature.
Since each of the mutants constructed had a distinct phenotype - either as an agr
mutant (for the agrA, agrC, RNAIII mutants) or as an SCV (for the hemB and
menD mutants), the strains were initially characterised by their appearance on solid
media. Strains were grown on TSA and CBA plates and incubated for 16 hours, or for
48 hours in the case of the SCVs (Figures 3.7 and 3.8).
When the WT was grown on TSA, it grew normally and produced a yellow pigment
(Figure 3.7). When the WT was grown on CBA, a large zone of haemolysis was seen
around colonies due to the production of Agr-regulated haemolytic toxins such as Hla,
Hld and the PSMs [149, 210, 536]. In comparison, both the agrA and agrC mutants
grew like WT on TSA, but lacked haemolysis on CBA, which was expected due to the
lack of haemolysins produced by agr mutants [537]. In the case of the RNAIII mutant,
growth was normal on TSA and whilst haemolysis was drastically reduced on CBA, there
was a very small zone of clearing noted. This is because not all of the haemolytic toxins
produced by S. aureus are regulated through RNAIII, with the PSMs controlled via
AgrA [91]. Haemolysis of the agrC mutant was restored by complementation with
pCN34 containing either the WT agrC gene or a constitutively active copy (M234L,
R238H, Q305H). However, no haemolysis was seen with the plasmid only control.
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Figure 3.7: Phenotypic characterisation of the WT and agr mutants grown
on agar plates. Strains were grown on TSA (left) or CBA (right) for 18h to determine
their phenotype. Close-up images are shown to aid visualisation and highlight haemolysis
in the WT, RNAIII and complemented agrC mutants, which can be seen on CBA
as halos of pale red around bacterial colonies. Scale bars in the bottom right of each
image represent one centimetre.
Both the hemB and menD mutants displayed the typical slow growth associated
with the SCV phenotype when grown on TSA plates (Figure 3.8) [433, 447, 459]. Of
note, the two SCVs displayed a dierent phenotype when grown on CBA. For the hemB
SCV, colonies grew at a similar rate to the WT and were haemolytic. This increased
growth on CBA but not TSA was also noticeable in the hemB SCV containing mutations
within agrA, agrC and RNAIII, with haemolytic activity mimicking the results of the
Agr mutants shown in Figure 3.7. As the hemB SCV is a haem-auxotroph, it is likely
that the free haem within the CBA plates (due to degradation of the sheep blood and lysis
of the red blood cells) was able to chemically complement the phenotype. Restoration of
the WT growth prole and haemolysis enables the liberation of more haem that further
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promotes growth.
Figure 3.8: Phenotypic characterisation of the SCVs grown on agar plates.
Strains were grown on TSA (left) or CBA (right) for 18h to check their phenotype. A
close-up image is shown to highlight the SCV colonies and the haemolysis of the hemB
SCV, which can be seen as halos of pale red around the bacterial colonies. TSA plates
were photographed against a black background to aid visualisation and scale bars shown
in the bottom right of each image represent one centimetre.
For the menD SCV, growth was similar on both TSA and CBA plates as the defect
in menadione biosynthesis cannot be restored by the acquisition of exogenous haem.
Despite no restoration of growth, some haemolysis was seen around the menD colonies.
Therefore, in both SCVs, the Agr system remains intact and appears to retain a low
level of activity.
Pigmentation is reduced in SCVs as the ETC is required for STX production [538].
Therefore, pigmentation in the two SCV mutants was visualised in bacterial pellets of
16 hour cultures grown with or without haemin (for the hemB SCVs) or menadione (for
the menD SCV). When the SCVs were grown without supplementation, they exhibited
a typical small pellet with a reduction in the amount of pigmentation compared to the
WT pellet (Figure 3.9). Both the size and pigmentation of the pellet was restored to
WT levels when the SCV was grown with the appropriate supplement. The presence of
a second mutation within the Agr system in the hemB SCV did not aect pigmentation.
Reduced pigmentation for the SCVs could be due to there being fewer cells overall,
however increasing the number of SCVs to WT levels did not increase pigmentation
[422].
Both the hemB and menD SCVs were complemented by the presence of pCL55
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Figure 3.9: Staphyloxanthin pigmentation in the WT and SCVs. 16 hour
cultures of USA300 WT and the SCVs (grown in the absence/presence of haemin for
the hemB SCV or menadione for the menD SCV) were pelleted. Images of the pellets for
each of the strains is shown to highlight the loss of pigmentation in the SCVs. Close-up
images are shown for each of the strains below the original to highlight pigmentation.
containing a copy of the hemB or menD gene under its native promoter, respectively
(Figure 3.10). Growth of the complemented strains on TSA (Figure 3.10A) was
similar to the WT whilst the plasmid only control grew with a SCV phenotype. Pig-
mentation was also increased in the complemented strains to levels similar to the WT
but was not altered in the plasmid only controls (Figure 3.10B).
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3.6 Growth proles of mutants
Growth of the mutants was measured by taking optical density (OD) readings (at 600
nm) of freshly diluted overnight cultures, every 30 minutes for 17 hours using a microplate
reader.
As can be seen in Figure 3.11A, the USA300 WT strain produced a typical growth
curve with an exponential phase between 1-4 hours. As the bacteria entered stationary
phase, these OD600 readings reached a stable maximum of approximately 2.0. Whilst
growth rate was similar for the agr mutants, bacterial density was lower between 4-16
hours with the Agr mutants steadily accumulating biomass. Nevertheless, nal density
readings were similar to the WT with no signicant dierences between the strains.
The growth of the agrC mutant was complemented by the introduction of the pCN34
plasmid containing agrC, whilst the plasmid only control had a similar growth prole
to the agrC mutant (Figure 3.11B). The strains complemented with constitutive
copies of agrC produced similar growth curves to the WT strain, although it took
approximately 1{2 hours longer for the constitutively active mutants to reach stationary
phase.
For the SCVs, the growth measurements conrmed the results from the plate-based
phenotypic assay. Compared to the WT, which reached an OD600 reading of 2.0, both
the hemB and menD SCVs reached a much lower maximum OD600 of approximately 1.5
(Figure 3.11C,E). For the hemB SCVs, there was a small degree of variation in this
nal OD600 reading depending on whether the strain had a second mutation in the Agr
system with signicant dierences between the various hemB strains at their nal OD
reading (Figure 3.11C). Bacterial density of the hemBagrC and hemBRNAIII
strains was similar but lower than the hemB strain, whilst the hemBagrA strain
had a slightly higher density compared to hemB. This suggests that mutations within
dierent components of the Agr system aect growth of the hemB SCV dierently.
By supplementing the hemB cultures with haemin and the menD cultures with
menadione, growth of the SCVs was partially restored (Figure 3.11C,E). This conrms
that the reduced growth of the mutants is due to the mutations within the haemin and
menadione biosynthetic pathways, respectively, rather than the acquisition of additional
mutations during genetic manipulation. Although the supplements promoted growth,
they can also be toxic and this likely explains why the supplemented strains did not
grow exactly like the WT. When the SCVs were complemented genetically, growth was
fully restored. By contrast, SCVs transformed with the empty plasmid grew like the
SCVs without the plasmid, with no restoration of growth seen (Figure 3.11D,F).
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Figure 3.10: Phenotypic characterisation of the complemented SCV strains. The phe-
notype of the hemB and menD SCVs containing either the empty plasmid or pCL55 containing
the appropriate coding sequence were compared to the SCVs without plasmid by examination of
colony morphology on TSA after 18 hours (A) and pigmentation of bacterial pellets generated
from 16 hour cultures (B). Scale bars in (A) represent one centimetre.
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Figure 3.11: Growth proles of USA300 WT, agr mutants and SCVs. Growth of
USA300 WT and the mutants was assessed by taking OD600 readings every 30 minutes for 17
hours. Growth is shown for the WT and agr mutants (A), the complemented agrC strain (B),
the hemB SCVs with or without haemin supplementation (C), and genetic complementation (D),
the menD SCV with or without menadione supplementation (E), and genetic complementation
(F). Graphs represent the mean of at least four experiments and error bars were omitted for
clarication but were within 10% of the mean.
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3.7 Agr activity of wildtype S. aureus and mutants
To conrm loss of Agr activity in the agr mutants, Agr reporter constructs (P3-GFP
reporters) obtained from James et al (2013) were utilised [359]. In these constructs,
promoter P3 from the Agr operon is located upstream of the gfp gene. Therefore,
readings of GFP can be used to assess P3 activity and can be measured alongside growth
using a plate reader [359]. The Agr activity (as measured by relative uorescence units
or RFU) for the mutants is shown (Figure 3.12). Figure 3.13 shows the same data
divided by OD600 values taken simultaneously, to account for growth dierences between
strains.
Over 17 hours of growth, Agr activity was detected in the WT strain as the bacte-
ria switched to the exponential growth phase - after approximately 2 hours of growth
(Figure 3.12A and 3.13A). Agr activity increased as growth continued but plateaued
as the bacteria entered stationary phase. In contrast, no Agr signal was detected at any
timepoint from the agrA and agrC mutants. For the RNAIII mutant, Agr activity
was similar to the WT strain. This is because P3 activity is driven by AgrBDCA and is
unaected by RNAIII expression. These data conrm therefore, that agrBDCA is intact
in the RNAIII mutant.
Whilst Agr activity is often reported as being non-existent in SCVs (on the basis of
haemolysis on CBA), this is the rst time that Agr activity has been quantied within
SCVs over an entire growth curve [431, 444, 490, 502]. Over the 17 hour timecourse,
very little Agr activity was detected in either of the SCVs (Figure 3.12C,D), even
after correcting for the lower growth of the SCVs (Figure 3.13C,D). In the case of
the hemB SCV, no Agr activity was detected and these results mimic the data for the
Agr mutants, with no further decrease in Agr activity noticeable in the hemBagrA
or hemBagrC SCV. However, in the menD SCV, a slight increase in Agr activity
was seen over time, although this activity was dramatically reduced compared to the
WT. Agr activity in the SCVs was partially restored by chemical complementation.
Unfortunately, the genetically complemented strains could not be tested as both the P3-
GFP reporters and the plasmid used to complement the SCVs are derived from pCL55,
which integrates into the same geh locus. No other plasmid could be used to complement
the SCVs due to the resistance prole of USA300 and the limited number of plasmids
available for S. aureus.
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Figure 3.12: Agr activity of USA300 WT, agr mutants and SCVs as measured by
GFP uorescence using P3-GFP reporter assays. Agr activity of USA300 WT and the
mutants was assessed by taking RFU readings every 30 minutes for 17 hours. Agr activity
(RFU) is shown for the WT and Agr mutants (A), the complemented agrC strain (B), the
hemB SCVs with and without haemin supplementation (C) and the menD SCV with or without
menadione supplementation (D). Graphs represent the mean of at least four experiments and
error bars were omitted for clarication but were within 10% of the mean.
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Figure 3.13: Agr activity of USA300 WT, agr mutants and SCVs measured by
GFP uorescence and corrected for growth dierences by OD600 measurements.
Agr activity of USA300 WT and the mutants (as seen in Figure 3.12) was corrected for growth
by dividing the RFU readings with the OD600 readings seen in Figure 3.13 [359]. Agr activity
(RFU) readings over OD600 is shown for the WT and Agr mutants (A), the complemented agrC
strain (B), the hemB SCVs with and without haemin supplementation (C) and the menD SCV
with or without menadione supplementation (D). Graphs represent the mean of at least four
experiments and error bars were omitted for clarication but were within 10% of the mean.
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3.8 Haemolytic activity of WT and mutants correlates with Agr ac-
tivity
To conrm the P3-GFP reporter results and determine whether cytolytic toxin produc-
tion corresponded with the levels of Agr activity, the ability of the WT and the mutants
to lyse erythrocytes was tested. Since staphylococcal toxins are species-specic, it was
necessary to determine haemolysis in more than one species to ensure that toxin pro-
duction was abrogated in the agr mutants [179, 180]. Therefore, haemolysis assays were
performed with human blood and sheep blood [539].
The haemolytic activity of each of the strains was determined by incubating blood
with supernatant from 16 hour cultures (neat or serially diluted in TSB) for one hour
at a 1:1 ratio with 2% blood. Intact red blood cells were pelleted by centrifugation and
an OD450 reading was taken of the supernatant. The haemolysis data for the sheep and
human blood is shown in Figure 3.14 and Figure 3.15, respectively.
In both sheep and human blood, the WT supernatant was able to completely lyse all
of the red blood cells even when diluted 1:8. The supernatant from the agrA and agrC
strains was 89{99-fold less haemolytic in human blood and 18{19-fold less haemolytic
in sheep blood compared to the WT supernatant. This corresponds well with their
phenotypes on CBA and P3-GFP activity (Figures 3.7 and 3.13A). Haemolysis was
restored in the complemented agrC mutant strains with similar levels of haemolysis
seen for the strain complemented with the WT agrC gene and those with constitutively
active agrC. By contrast, no haemolysis was observed for the agrC strain bearing the
empty plasmid. Culture supernatant from the RNAIII mutant was weakly haemolytic
in sheep blood, correlating with the phenotype on CBA, suggesting that the PSMs are
the main toxins responsible for this haemolysis.
For the hemB SCV, haemolysis was similar to the agrA and agrC mutants, with
only 7% haemolysis of sheep blood and 2% haemolysis of human blood after incubation
with undiluted supernatant (Figure 3.14 and 3.15). This was expected as no Agr ac-
tivity was detected in the P3-GFP reporter assay. For the menD SCV, there was 23{26%
haemolysis with the undiluted supernatant. Although this dierence was insignicant
when compared to the haemolysis caused by the undiluted supernatant from the agr
mutants, it could be explained by the small amount of Agr activity that was detected
in the P3-GFP reporter assays. Whilst these results could be explained by the lower
density of the SCVs compared to the WT, when density was increased to WT levels, no
change in haemolysis was observed [471]. Toxin production could be restored in both
SCVs by chemical complementation, with haemolysis levels similar to the WT for both
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sheep and human blood. Supernatant from the genetically complemented strains lysed
red blood cells to the same extent as the WT in both sheep and human blood. This
assay conrms that the mutants have the expected phenotype, which correlates with the
P3-GFP reporter results.
Figure 3.14: Haemolysis of sheep blood by USA300 WT, agr mutants and
SCVs. Percentage haemolysis of sheep blood by the culture supernatants from 16 hour
cultures of the agr mutants (A) and the SCVs (B) were adjusted and compared to
USA300 WT (with the neat dilution set to 100%). Supernatant was mixed with 2%
blood in PBS at a 1:1 ratio at dierent dilutions from neat to 1/32. Results shown are
at least three assays with error bars representing SEM. Signicance was measured using
the Student's T-test, with haemolysis of the undiluted supernatant from the mutants
compared to the WT (* P  0.05; ** P  0.01; *** P  0.001).
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Figure 3.15: Haemolysis of human blood by USA300 WT, agr mutants and
SCVs. Percentage haemolysis of human blood by the culture supernatants from 16
hour cultures of the agr mutants (A) and the SCVs (B) were adjusted and compared
to USA300 WT (with the neat dilution set to 100%). Supernatant was mixed with 2%
blood in PBS at a 1:1 ratio at dierent dilutions from neat to 1/32. Results shown are
the average of at least three assays with error bars representing the SEM. Signicance
was measured using the Student's T-test, with haemolysis of the undiluted supernatant
from the mutants compared to the WT (* P  0.05; ** P  0.01; *** P  0.001).
3.9 Reversion rate of the SCVs
Constructing stable knockouts in the hemB and menD genes was necessary due to the
unstable nature of clinically-isolated SCVs, which often arise due to point mutations that
may be easily repaired or compensated for during subculture [129, 437, 454{456, 540].
Therefore, the stability of the hemB and menD SCVs was assessed by growing the
strains overnight in gentamicin before plating 107 CFU onto TSA plates. The plates
were incubated at 37C for 48 hours to detect reversion to the WT [534]. Neither SCV
produced colonies with the WT phenotype, conrming that both SCVs were stable (data
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not shown).
3.10 Resistance of SCVs to gentamicin
Due to the reduced membrane potential in SCVs (as a result of a non-functional ETC),
SCVs are resistant to gentamicin [431, 434, 437]. This is because gentamicin requires an
electrochemical gradient to cross the membrane [541, 542]. Therefore, to further charac-
terise the SCVs, susceptibility to gentamicin was determined by zone of inhibition assays.
Stationary phase cultures (107 CFU per plate) were spread onto TSA and gentamicin
discs were placed in the centre of the agar plate before incubation overnight. The size
of the zone where growth of the bacteria was inhibited was then used to determine how
sensitive each strain was. The larger the zone of inhibition, the greater the sensitivity
to the antibiotic.
As expected, when compared to the hemB and menD SCVs, the zone of inhibition
caused by gentamicin was much larger for the WT, meaning that the WT was more
sensitive to gentamicin (Figure 3.16A). This dierence was even more evident when the
WT and either of the SCVs were grown opposite each other on the same plate (Figure
3.16B), with much smaller zones observed for the SCVs. These zones of clearing were
measured and are shown in Figure 3.16C. For the WT, growth could only occur 20
mm away from the gentamicin disc. In comparison, both the hemB and menD SCVs
could grow 12 mm from the disc. Resistance to gentamicin was increased in genetically
complemented SCVs, with zones of inhibition matching the WT. By contrast, the empty
plasmid control strains were just as resistant as the SCVs without the plasmid.
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Figure 3.16: Resistance of the hemB and menD SCVs to gentamicin. Sensitivity to
gentamicin was assessed by plating bacteria onto TSA and measuring growth inhibition after
incubation of the plates for 24 hours at 37C after placement of a Gm-containing paper disc in
the centre of each plate. Zones of inhibiton are shown for the WT and the SCVs when grown
separately (A) or opposite each other (B) on TSA plates and measurements of the zones of
inhibition (in mm) are shown in (C). Results shown are the average of at least three assays with
error bars representing the SEM. Asterisks show signicance level as measured by the Student's
T-test, with strains compared to the WT (* P  0.05; ** P  0.01; *** P  0.001).
108
3.11 Discussion
In this chapter, mutations that inactivate the Agr system or confer the SCV phenotype
were successfully generated using a new approach developed by Monk et al (2012) [514].
These mutations were conrmed by both PCR and DNA sequencing. To check that no
additional mutations had occurred during the mutagenesis process that could aect the
phenotype of the mutants, a range of assays were used to characterise the strains.
For the Agr mutants, growth was similar to the WT and Agr activity was completely
abolished, which corresponded to a lack of toxin production, with the strains unable to
lyse erythrocytes. In the RNAIII mutant, a low level of haemolysis was still detected
despite the fact that RNAIII was not present to activate expression of toxins such as
Hla. This is likely due to the action of the -PSMs, which are directly regulated by
AgrA and are able to lyse erythrocytes [91, 210]. These results conrm that the Agr
mutants functioned as expected based on previous publications and that these strains
were good models to assess the role of Agr during bacteraemia [60, 61, 537].
Based on several previous publications, the two SCVs (hemB and menD) had all
the expected phenotypes, with slow growth, reduced toxin production, low Agr activity,
decreased pigmentation and increased resistance to gentamicin [431, 442, 447, 459, 476,
478, 479]. Many studies that have focused on SCVs have examined clinical SCVs, which
can be problematic as these are often from undened backgrounds and the SCVs are
unstable and revert readily to the WT upon subculture [452, 474]. This is because the
mutations involved in the SCV phenotype are often point mutations, although in one
case a ip-op inversion involving half of the chromosome has been described [455, 456,
461, 462, 534]. In both situations however, S. aureus is able to switch easily back to
the WT phenotype by inverting the chromosome in the case of the ip-op inversion
or by repair of the original mutation or via the acquisition of compensatory mutations
[499, 534]. In order to overcome this problem, stable SCVs have been constructed by
using transposons or antibiotic resistance cassettes to interrupt genes involved in the
ETC [445, 459, 485]. Since these genes are often located within operons, polar eects
can occur as the insertion of an antibiotic cassette may aect the reading frame of
the operon. Unfortunately, in the majority of these studies, the strains were not fully
characterised and complementation was not done so it is not known if downstream
eects may have been partially responsible for some of the phenotypes reported. In one
published hemB mutant, there is evidence to suggest up-regulation of both hemB and
hemL (the gene just downstream of hemB) due to the promoter of an erythromycin
cassette [441]. Therefore, to avoid these o-target eects, stable SCVs were constructed
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by making markerless deletions in the well-dened strain USA300 LAC.
Growth of the two SCVs (hemB and menD) was drastically reduced compared to
the WT, as expected. However, there was very little dierence in growth of the hemB
SCV compared to the menD SCV. Previous studies have shown that regardless of the
auxotrophy of the SCV, there is a down-regulation of genes linked to the TCA cycle
and an up-regulation of genes associated with fermentation and glycolysis [438, 439,
441, 463, 464, 543]. In this way, SCVs grow similarly to WT bacteria under anaerobic
conditions. Loss of the TCA cycle leads to the accumulation of NADH that is recycled
via fermentation and results in the build up of lactate [438]. This increase in lactate leads
to an acidic pH and SCVs respond by up-regulation of arginine deiminase, which can
help generate ATP as well as being involved in acid resistance. Overall, ATP production
is reduced compared to the WT however and this leads to the slow growth of SCVs and
restricts them from metabolising carboxylic acids and amino acids to the same extent
as the WT [438]. The menD SCV is even more defective in its ability to utilise carbon
sources, with it unable to metabolise D-mannitol, dextrin and maltotriose. This is due
to a number of enzymes requiring menadione for their function, including the malate
quinol oxidoreductase (Mqo2) and the quinone oxidoreductase. Loss of Mqo2 results in
the menD mutant lacking the fumurate reductase pathway, which the hemB SCV can
still use. Whilst the menD SCV is aected in menaquinone production due to mutations
within the biosynthesis pathway, haemin biosynthesis is also reduced [544, 545]. Yet
despite these dierences, the menD SCV grew just as well as the hemB SCV when
growth was measured in a 96-well plate and this is likely due to using a rich growth
medium (TSB). Within the host, growth dierences and survival would likely be more
pronounced depending on the site of infection and nutrient availability. In a model of
rabbit endocarditis, survival of a hemB SCV was similar to the WT in the kidneys
and the spleen and this is likely to be due to the amount of haem that is available in
these organs that enables the hemB SCV to be chemically complemented [460]. This
highlights the importance of testing the survival of more than one type of SCV within
blood in order to obtain a comprehensive understanding as to how SCVs function during
bacteraemia.
This is the rst study to fully characterise isogenic SCVs and to quantify the level of
Agr activity within SCVs over a growth curve. Despite there being some haemolysis on
CBA, Agr activity was drastically reduced in both SCVs. Although some previous pub-
lications have described SCVs to have zero Agr activity, low levels of Agr activity was
detected in both of the SCVs under our experimental conditions [432, 445]. Detection
of low-level Agr activity was possible due to the sensitivity of using GFP reporters and
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activity corresponded well to one previous study that used yellow uorescent protein
to measure Agr activity in SCVs [485]. Whilst the hemB SCV was chemically comple-
mented by the haem in the CBA and thus appeared haemolytic, very little Agr activity
was detected using the P3-GFP reporter assay. In comparison, the menD SCV appeared
to be only slightly haemolytic on CBA and this corresponded to reduced Agr activity
in the P3-GFP reporter assay. Although Agr activity was slightly higher in the menD
SCV compared to the hemB SCV, it was signicantly reduced compared to the WT.
Both of the SCVs still had an intact Agr operon, however, as activity was restored after
chemical complementation. This restoration was only partial in the hemB SCV and is
likely a combination of haem being toxic to the bacterial cell and because haem is known
to repress Agr activity [395, 396, 546].
The reason why Agr activity is reduced in SCVs is not fully understood, although
the nal cell density of the SCV is likely too low to generate enough AIP to activate
the Agr system. Indeed, when SCVs are supplemented with AIP from a strain of the
same agr type, levels of Agr activity increase [439, 449, 471]. Additionally, levels of
the stress-induced sigma factor SigB are reported to be higher in SCVs and it is known
that SigB acts as a repressor of Agr activity [432, 475, 510]. When SigB was mutated
in a clinically-derived SCV, increased levels of hla and RNAIII were seen [470]. This
suggests that reduced cell density is only part of the reason why SCVs have reduced
Agr activity. There is also evidence that many of the virulence factors in S. aureus
are regulated by the metabolic state of the organism [547]. For example, CodY is a
repressor of RNAIII and responds to levels of carbon and nitrogen by sensing branched-
chain amino acids and guanosine-triphosphate (GTP). Considering that the SCVs have
such an altered metabolic state, with the TCA cycle switched o and a reliance on
fermentative growth, it is likely that other factors that regulate virulence in response to
metabolism are involved.
Overall, the work described in this chapter has shown that the strains constructed
are good model organisms to evaluate the importance of Agr and the SCV phenotype
during S. aureus bloodstream infections.
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4 Survival of S. aureus in whole human blood
4.1 Introduction
The importance of Agr for virulence has been demonstrated in a wide range of dier-
ent in vivo animal infection models [62{69]. However, paradoxically, despite the im-
portance of Agr in controlling numerous leukocidins that enable S. aureus to escape
neutrophil killing, agr mutants are often isolated from patients with persistent bacter-
aemia [386, 403]. SCVs are also isolated from patients with persistent bacteraemia and
it is hypothesised therefore that low Agr activity promotes S. aureus survival in blood
[447, 456, 472, 495, 496, 506, 507, 509]. Whilst these clinical studies provide some insight
into the role of Agr in the bloodstream, they only show an association. Therefore, this
chapter will describe experiments undertaken to understand the role of Agr and the SCV
phenotype in the survival of S. aureus in the bloodstream, utilising mutants that were
constructed in Chapter 3.
Animal models have been widely used to assess the survival of S. aureus in the
bloodstream [144, 548{551]. However, S. aureus has adapted to the human host and
thus many strategies that enable it to evade and kill neutrophils do not function in other
animals. For example, S. aureus produces toxins (PVL and LukAB), iron sequestration
molecules (Isd) and enzymes (Phospholipase C) that are all specically adapted to hu-
man cells and tissues [179, 194, 548, 552]. Both the PVL and LukAB toxins are able
to lyse human neutrophils but are incapable of lysing murine or macaque neutrophils
[179, 194]. This also means that the immune systems in animals have not adapted to
combat S. aureus infection in the same way as humans and molecules recognised by the
human immune system may not be recognised in the same way in animals. Further-
more, neutrophils from mice are dierent to humans, for example, defensins are absent
in murine neutrophils and they have reduced levels of MPO [362].
Another problem with using animal models is that dissecting how much of the killing
of S. aureus is directly due to killing in the bloodstream is much more dicult as it
is impossible to control the infection from spreading to other parts of the body and
causing secondary infections [384]. It is well-described that S. aureus can adhere to and
invade the endothelium, enabling the bacteria to hide from immune cells and survive
[120, 384, 540]. This attachment to vessels within the host also makes it dicult to
liberate all of the bacteria from the animal and so colony forming unit (CFU) counts
may not be a reliable measure of survival.
One way around the problem of animal models is to make use of neutrophils isolated
from human blood [278, 343, 364]. This is a rather labour-intensive process that involves
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applying blood to a isoosmotic density gradient, lysing the red blood cells, washing and
nally adjusting the cells to a desired density. During this process it is easy to activate the
neutrophils, leading to accelerated apoptosis and unreliable results regarding the ability
of neutrophils to kill S. aureus [553]. This system also lacks many of the components
that have important roles in recognising and killing S. aureus in the bloodstream. For
example, platelets are known to interact with neutrophils and enhance bacterial killing,
whilst the coagulation cascade is an important process that S. aureus may utilise to
evade phagocytosis [290, 320, 554].
A model system that provides an ecient and reproducible way to assess the survival
of multiple strains in the bloodstream is the ex vivo whole human blood model. In this
model, bacteria are incubated with freshly donated human blood and bacterial survival
determined by plating for CFU. Previous groups have used this method and shown that
there is a time-dependent killing of S. aureus and that CFU counts is a reliable method
to measure survival [317, 343, 548, 555, 556]. This system also includes components such
as platelets that are absent in neutrophil assays but are known to have important roles
in bacterial killing. Therefore, to assess the importance of Agr and the SCV phenotype
in the bloodstream, the ex vivo whole human blood model was used. This chapter will
describe how the mutants characterised in Chapter 3 survive in whole human blood and
start to investigate the molecular basis for this survival.
Aim: To assess how agr mutants and strains with mutations that confer
the SCV phenotype survive within an ex vivo whole human blood model in
order to determine the molecular basis for persistence of S. aureus in the
bloodstream.
4.2 S. aureus survival in human blood varies depending on the donor
In many published experiments where bacterial survival is measured, extremely high
inoculums (108{109 CFU) are used but this does not accurately represent the situation
within the host [330, 331, 555]. In bloodstream infections in particular, there are very few
bacteria (1{30 CFU) present in one millilitre of blood [557]. Therefore, a low inoculum of
104 CFU was chosen for the ex vivo whole blood survival assay, which was a compromise
between creating a realistic model system and having sucient levels of bacteria to
enable enumeration. The methodology of Liu et al. (2005) was closely followed to assess
whether the whole blood model would be acceptable to study the survival of S. aureus
in the bloodstream [343]. Briey, USA300 WT was incubated in a microplate with 90
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l of freshly donated, EDTA-treated human blood obtained from healthy donors. After
the addition of bacteria to the blood, the microplate was incubated (180 rpm, 37C) for
up to 6 hours as this was deemed long enough to observe killing of WT bacteria and
publications have suggested that neutrophils lose viability after this point [558]. At 2,
4 and 6 hours post-incubation, the blood was serially diluted and bacterial survival was
measured by plating the undiluted or serially diluted blood onto CBA. Plating on CBA
was helpful for two reasons - so that we could measure the emergence of agr mutants
and also because CBA contains exogenous catalase and so prevents any further killing
of bacteria by ROS generated by immune cells [559]. Survival at each time point was
then measured as a percentage of the inoculum at the start of the assay.
Figure 4.1: S. aureus survival in human blood varies depending on the blood
donor but follows the same trend. Survival of S. aureus USA300 WT after incuba-
tion in human blood was measured by plating for CFUs 2, 4 and 6 hours post-inoculation.
The graph shows survival as a percentage of the inoculum at time zero after incubation
in blood derived from ve dierent healthy donors. Results shown are the mean of at
least two assays done in duplicate with error bars that represent SEM.
Over six hours, there was a signicant decrease in S. aureus CFU, with less than
10% of the inoculum viable by the end of the assay (Figure 4.1). There was variation
depending on the blood donor, which is expected since the immune response to S. aureus
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and the presence of reactive IgG will vary between individuals. For example, in some
donors, previous S. aureus infections may enable their immune cells to recognise the
bacteria faster and thus kill more eciently. The immune system is also aected by
other variables such as age and lifestyle habits such as whether the donor smokes or
drinks alcohol, which could aect their ability to kill S. aureus. However, despite the
variation, the general trend was the same, with a signicant level of killing (10{100-fold
by 6 hours) of S. aureus in blood from all of the donors. This experiment conrmed
that the whole blood model was a good system to study the survival of S. aureus in the
bloodstream as it provided a sucient dynamic range to detect dierences in the survival
of mutants. In addition, based on this experiment, it was decided that the survival of
mutants should be tested using blood from multiple donors.
4.3 Loss of Agr is detrimental to the survival of S. aureus in human
blood
To test the role of Agr in S. aureus bloodstream infections, the agr mutants (agrA,
agrC and RNAIII ) discussed in Chapter 3, were incubated in human blood and
survival was compared with the isogenic parental strain USA300 WT. For both the
agrA and agrC mutants, where the complete Agr system is ablated, survival was
signicantly decreased compared to the WT (Figure 4.2A). In the agrA mutant, sur-
vival was signicantly lower than the WT from 2 hours (P=0.00142) and in the agrC
mutant from 4 hours on (P=0.0271). In the RNAIII mutant, there was an intermedi-
ate phenotype with survival levels falling between the agrC and agrA mutants and the
WT. This reduction in survival was only signicantly dierent from the WT at 2 hours
(P=0.0266). As mentioned in Chapter 3, the RNAIII mutant still has intact AgrA and
thus can still lyse erythrocytes and neutrophils through the action of the PSMs. This
result suggests that these contribute to the survival of S. aureus but that a complete
Agr system is required for maximal survival of S. aureus in human blood.
To determine whether Agr-mediated survival of S. aureus was restricted to USA300,
the importance of Agr was also tested in SH1000, a methicillin-sensitive strain of S.
aureus. Over the six hours, there was time-dependent killing of SH1000 WT, resembling
that seen for USA300 WT (Figure 4.2B). However, SH1000 survival was signicantly
higher than USA300 (11.1% compared to 2.6%) by the six hour timepoint (P=0.007).
This may be due to SH1000 being more pigmented than USA300 (data not shown), with
the STX pigment able to act as an antioxidant that can protect S. aureus from neutrophil
killing [343]. Despite this increased survival, a mutant with a disrupted agr operon from
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Figure 4.2: Loss of Agr is detrimental to S. aureus survival in human blood.
Survival of S. aureus after inoculation into human blood was measured by plating for
CFUs after 2, 4 and 6 hours incubation. The graphs show survival as a percentage of the
inoculum at time zero after incubation of (A) USA300 or isogenic agr mutants (agrA,
agrC and RNAIII ) or (B) SH1000 and agr mutant SH1001 in blood. Results shown
represent the mean of at least four assays done in duplicate using blood from at least
three dierent donors, with error bars representing SEM.
the same background (SH1001) was signicantly more susceptible to immune killing than
the WT from 2 hours on (P=0.001). This highlights that Agr is important for survival
in human blood regardless of whether the strain is MSSA or MRSA.
The importance of Agr in the whole blood survival assay was conrmed by measur-
ing survival of the genetically-complemented USA300 agrC strain. The presence of
plasmid pCN34 containing a copy of the agrC gene in agrC, restored survival back to
USA300 WT levels (Figure 4.3). Whilst a plasmid only control strain was as susceptible
to immune-mediated killing as the agrC mutant without plasmid.
It has been reported that Agr is inactivated in the bloodstream due to sequestration
of AIP by host lipids and so any action of agr is thought to only occur after uptake
by polymorphonuclear leukocytes (PMNs) [359{361, 364, 399]. To determine whether
forcing Agr on beneted S. aureus in the bloodstream, the survival of agrC mutants
harbouring point mutations in agrC, resulting in agrC being constitutively active, were
tested [359]. Regardless of the point mutation (Q305H, M234L, R238H), these mutants
survived at similar levels to S. aureus expressing the WT gene (Figure 4.3). Therefore,
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Figure 4.3: Complementation of the agrC mutant restores survival in
blood, although constitutive agrC mutants do not show enhanced survival
compared to the control. Survival of S. aureus after incubation in human blood was
measured by plating for CFUs after 2, 4 and 6 hours incubation. The graph shows this
survival as a percentage of the inoculum at time zero after incubation of blood with the
USA300 agrC mutant harbouring either empty plasmid pCN34 or pCN34 containing
either the WT agrC gene or an agrC variant (Q305H, R238H, M234L) that is constitu-
tively active. Results shown are the mean of at least ve assays done in duplicate using
blood from at least three dierent donors, with error bars representing SEM.
if Agr is inactive in the blood, forcing it on does not promote survival. This suggests that
Agr contributes to survival after phagocytic uptake, perhaps because the relevant toxins
are only able to function once the bacteria is internalised. Previous publications have
shown that the PSMs are non-functional in serum due to sequestration by low density
lipoproteins, and so their expression may only be benecial to S. aureus survival after
uptake into phagocytes [364, 399].
4.4 Agr must be expressed to prevent killing in blood
Previous work with neutrophils failed to detect an increase in Agr activity after S. aureus
uptake [328, 333]. However, it has also been shown that an intact Agr operon promotes
S. aureus survival in the neutrophil [334]. Therefore, to test whether agr expression was
necessary for S. aureus survival or if an intact agr operon was all that was required, Agr
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activity was inhibited in USA300 by incubating overnight cultures in the presence of an
inhibitory AIP. AIP3 was chosen as USA300 belongs to the agr type I group and Agr
activity can be inhibited using either AIP2 or AIP3 [82, 97, 560].
To check that AIP3 was functioning as expected, the Agr activity of the USA300
WT strain containing the P3-GFP reporter construct was measured using a microplate
reader. Stationary phase WT and agrC cultures treated with or without AIP3 were
sub-cultured into fresh TSB and GFP activity and growth (by OD600) was measured in
a microplate reader over 17 hours. Whilst the Agr activity of the untreated WT strain
increased as the bacteria went into exponential phase, the WT strain treated with AIP3
showed no activity, with no dierence in GFP compared to the agrC mutant (Figure
4.4A). This means that the AIP3 competitively inhibited Agr activity and that the
peptide continued to block Agr activity even after subculture. This inhibitory activity
also remained even if the bacteria were washed three times in PBS before subculturing
into fresh TSB (Figure 4.4B). To ensure that this aect was not due to the peptide
selecting for agr mutants, the stationary phase cultures treated with or without AIP3
were washed as before and subcultured into fresh TSB containing AIP1, which is pro-
duced by USA300. Adding AIP1 restored Agr activity of the AIP3-treated WT strain
to the same level as the untreated WT strain. This suggests that the inhibitory AIP
must remain bound to the AgrC molecule and that despite new AgrC synthesis, Agr
activation can only occur when AIP1 is present in molar excess to allow displacement of
the inhibitor.
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Figure 4.4: The Agr inhibitory action of AIP3 on USA300 can only be relieved upon
exposure to AIP1. Agr activity was measured in USA300 and agrC P3-GFP strains in a
microplate reader. Bacteria were incubated until stationary phase with or without the inhibitory
AIP3. Bacteria were subcultured unwashed (A), washed (B) or washed with the addition of AIP1
into the nal culture medium (C). Agr activity is shown as P3-GFP RFU/OD600 and is shown
over 17 h. Graphs represent the mean of at least three experiments done in triplicate. Error
bars displaying SEM were omitted for clarity but were within 10% of the mean.
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The stable and long-lasting inhibition of Agr by AIP3 enabled us to assess whether an
intact agr operon was sucient for survival of S. aureus in blood. USA300 WT treated
with AIP3 had signicantly reduced survival after six hours incubation in human blood
compared to WT that had been grown without AIP3 (Figure 4.5). AIP3-treated WT
bacterial survival was similar to the survival of the agrC mutant. Treating the agrC
mutant with AIP3 had no eect on survival. This result suggests that having an intact
agr system is not sucient for survival and that it must be expressed at least at a low
level to promote survival.
Figure 4.5: Agr activity is required for survival of the WT. Stationary phase
USA300 WT or the agrC mutant were grown with or without inhibitory AIP3 before
incubation in whole human blood. Survival after 6 hours of incubation is shown as a
percentage of the inoculum. Results shown are the mean of at least three assays done in
duplicate using blood from at least two dierent donors and error bars represent SEM.
Asterisks show signicance level as measured by Student's T-test (* P  0.05).
4.5 SCVs survive in human blood despite reduced Agr activity
As shown in Chapter 3, both the hemB and the menD SCVs have signicantly reduced
Agr activity relative to the WT. Therefore, based on the data shown above, showing
that agr is important for the survival of USA300 and SH1000 WT in blood, it was
hypothesised that SCVs would be similarly susceptible to immune killing. However,
surprisingly, both of the SCVs survived at much higher levels than USA300 WT over
6 hours, with virtually no killing of either mutant (Figure 4.6A). This dierence in
survival was signicant from 2 hours (P=0.03 for hemB and P=0.002 for menD). The
enhanced survival of the SCV phenotype was also observed for the SH1000 MSSA strain
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(Figure 4.6B), with a hemB ::Tn mutant surviving signicantly better than the WT
over 6 hours (P=0.0008 at 2 hours). Therefore, despite the greatly reduced Agr activity
of the SCVs, they were able to avoid the killing that was seen with the agr mutants,
suggesting that the strains can survive via a mechanism distinct from that seen for the
WT and independent of agr.
Figure 4.6: SCVs survive better than the WT in blood despite reduced Agr
activity. Survival of S. aureus after incubation in human blood for up to 6 hours
is shown. Survival was measured as a percentage of the inoculum at time zero after
incubation of blood with either (A) WT USA300 and the SCVs (hemB and menD) or
(B) WT SH1000 and a hemB ::Tn mutant. Results shown are the mean of at least three
assays done in duplicate using blood from at least two dierent donors, with error bars
that represent SEM.
To ensure the SCVs had not acquired additional mutations during construction that
might promote survival in blood, the mutants were chemically complemented with either
haem or menadione for the hemB and menD SCVs, respectively. Chemical complemen-
tation of the hemB SCV with haemin led to increased killing of the SCV, with levels
similar to the WT at each of the timepoints (Figure 4.7). Whilst complementation of
the menD SCV was partially complemented with menadione, with survival by 6 hours
not signicantly dierent from the WT. This means that the survival of the SCVs in
blood is due to the hemB or menD mutations and not due to the acquisition of other
mutations during manipulation of the SCVs.
Survival of the SCVs was also reduced to WT levels by genetic complementation
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Figure 4.7: Chemical complementation of the SCVs reduces survival to WT
levels in blood. Survival of S. aureus after incubation in human blood was measured
up to 6 hours post-incubation. The graphs show this survival as a percentage of the
inoculum at time zero after incubation of blood with either (A) USA300 WT and the
hemB SCV with or without supplementation with haemin or (B) USA300 and the menD
SCV with or without supplementation with menadione. Results shown are the mean of
at least three assays done in duplicate using blood from at least two dierent donors,
with error bars representing SEM.
(Figure 4.8). Transformation of the hemB or menD mutant with plasmids containing
a copy of the WT hemB or menD gene, led to increased killing of the mutants, with
survival similar to the WT at each of the timepoints. Whilst survival of the plasmid
only control strains was just as high as for the SCVs lacking plasmid. This result, along
with the chemical complementation data, further conrms that the SCV survival is due
to the mutations constructed in the haem and menaquinone biosynthesis pathways and
is not the result of additional mutations such as those that may promote resistance to
oxidative stress.
Although Agr activity is reduced in both the hemB and menD mutants, the agr
system is still intact in both SCVs as activity can be restored in the strains by chemical
or genetic complementation (see Chapter 3). To fully determine whether the very low
levels of Agr activity seen in the SCVs could still be important for survival of the
SCVs, agr mutations (agrA, agrC and RNAIII ) were constructed in the hemB
SCV. When these double mutants were assessed for survival in blood (Figure 4.9),
122
Figure 4.8: Genetic complementation of the SCVs reduces survival to WT
levels in blood. The graph shows survival of as a percentage of the inoculum at
time zero of (A) USA300 WT and the hemB SCV with either empty pCL55 or pCL55
containing hemB or (B) USA300 and the menD SCV with either empty pCL55 or pCL55
containing menD after incubation in blood for up to 6 hours. Results shown are the
mean of at least three assays done in duplicate using blood from at least two dierent
donors, with error bars representing SEM.
there were no signicant dierences compared to the single hemB mutant at any of the
timepoints. This means that Agr plays no role in SCV survival in blood, at least for the
hemB SCV, and that another mechanism must be involved.
4.6 A menD SCV protects the WT from killing in blood
Bacteria isolated from patients often exist as mixed populations and clinical SCVs are
often detected alongside bacteria with the WT phenotype [431, 459, 465, 485, 490].
Previous work has shown that mixed populations can be useful as a bet-hedging strategy
so that, depending on the conditions that the bacteria are exposed to, there is a higher
likelihood that some bacteria will survive [561, 562]. For example, in the case of the
SCVs, slow growth and a lack of virulence factors such as toxins can be a disadvantage
when compared to the WT. However, if the population are exposed to the antibiotic
gentamicin, the SCVs are more resistant and have a survival advantage compared to the
WT [452]. Therefore, having a mixed population prevents the entire population from
being eradicated if the environment suddenly changes.
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Figure 4.9: Deletion of agr in a hemB SCV does not aect its survival in
blood. The graph shows survival as a percentage of the inoculum at time zero after
incubation of blood with USA300 WT and the hemB SCV with additional mutations in
agrA, agrC and RNAIII. Results shown are the mean of at least three assays done in
duplicate using blood from at least two dierent donors, with error bars that represent
SEM.
To mimic the situation inside the host, blood was incubated with a mixed population
of the WT and either the hemB or menD SCV (at a 1:1 ratio, 104 CFU in total). As
usual, bacterial survival of the mixed population was measured by plating the blood
(neat or serially diluted) onto CBA at 2, 4 and 6 hours. The blood was also plated
onto CBA plates containing gentamicin to determine the relative survival of the menD
SCV, as only the SCV would grow on the antibiotic plates. The relative WT survival
could then be determined by subtracting the CFU values obtained on the gentamicin
plates from the total values obtained from the CBA plates without gentamicin. As the
CBA plates could chemically complement the hemB SCV and thus potentially reduce it's
resistance to gentamicin, relative survival of the WT and the hemB SCV was determined
by rst plating the mixed population onto CBA plates without antibiotic. Next, fty
colonies were subcultured onto TSA plates to determine whether the strain was WT or
SCV on the basis of phenotype. The ratio of WT:SCV survival could then be used to
enumerate the relative survival of the WT and hemB SCV in the mixed population.
As shown in Figure 4.10A, when the hemB SCV was incubated with the WT strain
in blood, there was no signicant dierence in the survival of either strain compared
to when each strain was separately incubated with blood (Figure 4.6A). When the
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WT was incubated with the menD strain however, there was a signicant increase in
the survival of the WT, with a signicant dierence seen from 2 hours onwards when
compared to survival of the WT strain incubated alone with blood (P=0.0008; Figure
4.10B). The survival of the menD SCV was the same as assays where the menD SCV
had been incubated with blood alone (Figure 4.6A). This suggests that the menD SCV
is able to protect the WT from killing.
Figure 4.10: The menD SCV but not the hemB SCV protects the WT from
killing in blood. Survival of S. aureus after incubation in human blood was measured
by plating for CFUs 2, 4 and 6 hours post-incubation. USA300 WT and either the hemB
SCV (A) or menD SCV (B) were mixed at a 1:1 ratio and the graphs show respective
survival for each of the strains as a percentage of their inoculum at time zero. This was
determined for (A) by subculturing up to 50 colonies from each of the nal timepoints
onto TSA with gentamicin to determine the ratio of hemB SCVs to WT bacteria that
had survived. For (B), blood containing the WT and menD mixture was plated onto
CBA with or without gentamicin to determine the respective survival of the WT and
menD SCV. Results shown are the mean of at least four assays done in duplicate using
blood from at least three dierent donors, with error bars that represent SEM.
From this experiment it was also noted that there was no increase in the number
of SCVs during the assay, meaning there was no detectable switching from the WT to
SCV. Whilst the SCV phenotype is clearly benecial for survival in the blood assay, it is
possible that the low inoculum used in the assay means that any switching to the SCV
phenotype is below the limits of detection. Killing of the WT may also be so rapid that
any switching between phenotypes is not possible.
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4.7 SCV survival in human blood is not due to evasion of phagocytosis
It was hypothesised that the SCVs may survive in whole blood by evading phagocytosis
and therefore avoiding killing by neutrophils. S. aureus has evolved many ways to
avoid uptake by neutrophils, some of which involve the expression of surface proteins
that enable the bacterium to coat itself in host proteins and avoid the immune system
[261, 563]. Since SCVs have a much higher expression of surface proteins than the WT,
this was a plausible explanation for how they survived in blood [439, 445].
To measure the uptake of SCVs and compare this to the WT and agr mutants,
ow cytometry was chosen as this method generates quantitative data with less bias
than alternative methods such as microscopy. In addition, since there are 10-fold more
neutrophils than bacteria, this method enabled us to look at a large number of cells.
In ow cytometry, samples are passed through a machine such that single cells can be
detected by a laser. As the single cell passes across the path of the laser, the light
is refracted to create forward (FSC) and side-scatter (SSC), which is measured by the
machine. These paramaters enable estimates of cell size (FSC) and cell complexity (SSC)
such that cell types can be categorised based on the scatter plots. To accurately detect
a particular cell type within a sample, uorescence can be used.
Since bacteria are extremely small and not very complex, they generate very low
slopes on FSC and SSC plots with values  50 K units. However, if bacteria are taken
up by host cells such as neutrophils, the FSC and SSC would be the same as host cells
without bacteria and it would be impossible to accurately state whether the bacteria
were within the cell. This problem can be overcome by labelling the bacteria with a
uorescent marker.
Bacteria were labelled with uorescein isothiocyanate (FITC), which has been used
successfully in the past to label S. aureus [442, 454]. FITC conjugates to uncharged
amines on the bacterial cell surface that are found on bacterial proteins and lysine
residues [564]. Therefore, only bacteria that are FITC-positive at the start of the assay
can be detected, however, as no replication was seen by any strain in the blood survival
assays, this was not considered to be a concern.
One way that ow cytometry could produce a biased and inaccurate result, would
be if the labelling was not equal between strains. Bacteria were labelled with FITC (as
described in section 2.16.1 in the Material & Methods) and then coated onto microscope
slides and visualised by wideeld microscopy. Images were captured simultaneously
using brighteld Kohler illumination and uorescence captured using the GFP channel.
A comparison of each of these images for each of the strains is shown in Figure 4.11A
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(brighteld - left, uorescence - right). The FITC signal was strong for all of the strains.
The number of FITC-positive bacteria in each frame (approximately 100) were scored as
a percentage of the total bacteria seen in the brighteld image. This was done for seven
separate frames and the results averaged to give the percentage bacteria labelled with
FITC (Figure 4.11B). Overall, the majority of the bacteria (96-100%) were stained
with FITC and there were no signicant dierences between the strains.
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Figure 4.11: USA300 WT, the hemB and menD SCVs and the agrC mutant are
labelled equally with FITC. Each of the strains were labelled with FITC and microscopy
was used to visualise them. Wideeld (left) and uorescent (right) microscopy images of the
bacteria were taken simultaneously (A). Seven frames with approximately 100 bacteria were
scored and graph (B) shows the percentage of bacteria that were positive for FITC. Error bars
represent SEM.
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As FITC conjugates to surface proteins, it was important to check that labelling
with FITC had no eect on the survival of the strains in the blood survival assays
as phagocytosis often relies on the immune cells recognising antigens on the bacterial
cell surface [261]. Bacteria were labelled with or without FITC as usual, washed three
times in PBS and 104 CFU were incubated in blood as with for all previous assays.
Unusually, during these assays, survival for both the WT and agrC ) mutant was much
higher at the 6 hour timepoint than seen previously (10-fold and 57-fold respectively)
and the reason for this is unknown. However, by six hours signicantly greater killing
of the agr mutant was seen compared to the WT (P=0.0217). There were also no
signicant dierences in survival between bacteria labelled with FITC and unlabelled
bacteria (Figure 4.12). Therefore, FITC did not aect phagocytosis as it did not alter
survival of any of the strains. This validates the use of FITC as a marker to measure
uptake of the strains into host cells.
Figure 4.12: Survival of the strains in blood was not aected by FITC la-
belling. The graph shows survival at 6h as a percentage of the inoculum at time zero
for USA300 WT, the hemB and menD SCVs and the agr mutant with FITC labelling
(green bars) or without FITC (grey bars). The graph represents at least three experi-
ments done in duplicate with at least two dierent donors blood. Error bars represent
SEM.
To measure uptake of the strains within blood, the FITC-labelled bacteria were
incubated with blood following the same standard procedure as for the blood killing
assay (Figure 4.13). At each of the timepoints (2, 4, 6 hours), the red blood cells
were lysed and the remaining host cells in the blood were washed in PBS to remove
any of the debris and red blood cell lysis solution before xing the cells with 1% PFA,
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which has been shown to not aect phagocytosis measurements by ow cytometry [565].
Fixing was necessary to prevent any further uptake of the bacteria or killing and also
due to regulations regarding use of the ow cytometer. Due to the low centrifugal speeds
used in the wash steps to avoid damage to the host cells, it was necessary to check that
unphagocytosed bacteria were not being lost. To investigate this, blood was incubated
with 107 CFU and immediately mixed with red blood cell lysis solution. After complete
red blood cell lysis, the cells were pelleted (500 x g, 10 min) and the supernatant was
plated onto CBA neat or serially diluted (up to 1000-fold) in PBS. The pellet was then
resuspended and this mixture was then plated onto CBA neat or serially-diluted (up to
1000-fold) in PBS. After enumeration of the CFU in the pellet and supernatant fractions,
it was found that almost all of the bacteria was located with the pellet (Figure 4.14)
meaning that the wash step did not result in substantial loss of any free bacteria, which
could lead to an overestimation of the number of bacteria phagocytosed.
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Figure 4.13: Preparation of blood and bacteria for ow cytometry Freshly donated
human blood was incubated with bacteria labelled with FITC for up to 6 h. At 2, 4 or 6 h
the erythrocytes were lysed using red blood cell lysis solution (5 min, room temperature) before
pelleting the remaining host cells by centrifugation (500 x g, 10 min) and washing once in PBS
before pelleting again. When host cell death was measured, a portion of the host cells were
killed (100C, 10 min), whilst the rest were kept at room temperature. The host cells were
stained with Zombie Violet (a live/dead dye) as necessary for 15 min in the dark. Host cells
and bacteria were then xed with 1% PFA for 16-18 h before analysis on a ow cytometer.
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After 16{18 h xation in the dark, the samples were analysed on a ow cytometer
and 20,000 events were captured. By using bacteria only and host cell only controls,
the ow cytometer was used to determine whether the bacteria were associated with
the host cells. When the FITC-labelled bacteria only were analysed, cells were detected
with a low SSC (SSC-A  50K units) and 99.2 % of them FITC-positive i.e. they
were captured by the 488-530 (30) detector (Figure 4.15A). Whilst the host only cells
had a broad side scatter from 0 to 250K units (due to the dierent cell types found
in blood) and the majority were not detectable by the 488-530 (30) detector (99.9%,
Figure 4.15B). Using these controls, the ow cytometer plots could be easily gated
into two populations, cells that were FITC-positive and cells that were FITC-negative.
Since the host cells were unlabelled, any FITC-positive cells with a higher SSC-A than
50K units represented host cells that had taken up bacteria. Phagocytosis could then be
determined by measuring the number of FITC-positive cells with a SSC-A  50K units
as a percentage of the total number of FITC-positive cells detected (Figure 4.15D{
F). Whilst some cells were detected as FITC-positive in the host cell only controls, the
number of events were low ( 20{30) compared to the host cells incubated with bacteria
( 300).
Following this gating strategy to measure phagocytosis, it was found that by two
hours there was a high degree of phagocytosis for all of the strains tested (Figure 4.16),
which ts well with the ndings of previous publications [328, 330]. The number of
bacteria phagocytosed slightly decreased by 4 and 6 hours post-incubation, which could
relate to some bacteria escaping from the host cells, but this decrease was statistically
insignicant and the percentage phagocytosed remained high. There were no signicant
dierences between the strains at any of the timepoints, meaning there must be an
alternative reason for the enhanced SCV survival in blood.
4.8 SCVs survive just as well as the WT against neutrophil killing
Neutrophils are the main defence in S. aureus bloodstream infections [261]. Therefore
it was decided to examine the resistance of each strain to these cells, to understand
whether other blood components were contributing to enhanced SCV survival.
Initially, due to the short-lived nature of neutrophils, experiments were conducted
with HL-60 cells, a neutrophil-like cell line [566, 567]. HL-60s can be cultured in large
quantitites and then dierentiated into granulocytes by the addition of dimethyl sulfoxide
(DMSO). Addition of DMSO resulted in the cells becoming rounded and these grew in
suspension, rather than as an attached monolayer, similar to isolated neutrophils (data
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Figure 4.14: Most bacteria are associated with the host cell pellet after red
blood cell lysis. To ensure that free bacteria were not lost during the red blood cell
lysis and wash steps, host cells were pelleted after red blood cell lysis of blood incubated
with bacteria and both the lysate and the pellet resuspended in lysate were plated. The
graph shows the percentage of bacteria recovered from the supernatant (yellow bars) and
the pellet (blue bars). The graph represents at least three experiments done in duplicate
and error bars are represented as SEM.
not shown). However, when 105 CFU of each strain were incubated (37C, tumbling)
with 106 HL-60 cells and 10% normal human serum, there was no killing of any of the
strains even up to 3 hours post-incubation (data not shown). This suggests that uptake
of the strains by the HL-60s was poor and by doing a lysostaphin-protection assay, this
conrmed that less than 2% of the inoculum were being phagocytosed (data not shown).
Since neutrophils in the host are highly competent for phagocytosis, this cell line did not
appear to accurately represent the situtation in blood. Previous work has also previously
shown defective superoxide production in HL-60 cells, with S.aureus only being killed
after six days incubation [568]. Therefore, killing of bacteria by neutrophils isolated from
fresh human blood was tested as follows.
Neutrophils were isolated from freshly-donated EDTA-treated human blood using
Polymorphprep, which is a dense gradient consisting of metrizoate and a polysaccharide
that enables the separation of erythroyctes, PMNs and mononuclear cells from blood
[569]. As neutrophils are the most common cell type in blood (approximately 106 cells
ml 1) after erythrocytes, 30 ml of blood was used to isolate approximately 2 ml of
neutrophils at a nal concentration of 107 cells ml 1 [553, 570]. After separation of
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Figure 4.15: Gating strategy to assess phagocytosis of S. aureus by host
cells in human blood. FITC-positive cells were gated on the basis of FITC-labelled
bacteria detected by the 488-530 (30) laser (A) and the prole of unlabelled host cells
(B). Phagocytosis could be determined by a shift in the FITC-positive cells to a SSC
 50K (C). Free and phagocytosed FITC-bacteria could then be gated on by gating on
cells in the FITC-positive gate that had a SSC of  50K or  50K, respectively. Most
of the FITC-bacteria only cells were in the free bacteria gate (D), whilst very few events
were seen for the host cells only as no FITC-labelled bacteria were present, suggesting
autouorescent cells (E). A signicant proportion of the FITC-labelled bacteria were
phagocytosed after incubation with host cells (F). One representative ow cytometry
experiment is shown.
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Figure 4.16: Phagocytosis of USA300 WT, the hemB and menD SCVs and
the agrC mutant is equal in blood. Percentage phagocytosis was determined by
measuring the percentage of bacteria gated as phagocytosed using ow cytometry (see
Figure 4.15). The graph represents the mean from at least three experiments done in
duplicate and error bars represent the SEM.
the PMN layer, any contaminating red blood cells were lysed using red blood cell lysis
solution. The PMNs were resuspended in HBSS without calcium and magnesium to
prevent cell activation and adjusted to 107 cells ml 1. The morphology of the PMNs
was checked by staining with Hemacolor (Pappenheim staining) and compared to blood
smears previously obtained. As shown in Figure 4.17A, PMNs are evident in the
blood smears amongst the red blood cells as cells with a violet-stained lobed nucleus
with a light violet cytoplasm (white arrows). When PMNs isolated from human blood
were stained with the same Hemacolor stain, they also retain the distinct violet colour
(Figure 4.17B). The latter images were taken one day after isolation, however no
evidence of cell death or activation was seen when cells were checked before use (data
not shown).
After isolation, PMNs (106 cells) were added to 900 l of HBSS with calcium and
magnesium and 0.1% gelatin and 100 l of plasma isolated from the donor during the
initial Polymorphprep separation. Bacteria were added (105 CFU) and the bacteria and
neutrophil suspension was incubated with tumbling at 37C. At 30, 60, 120 and 180
minutes post-incubation, 50 l of the suspension was taken and serially diluted up to
1000-fold in PBS and plated onto CBA to measure survival. The results of the neutrophil
survival assay are shown in Figure 4.18 and over the 3 hours, there was a signicant
degree of killing for all of the strains. Whilst there was no obvious dierence between the
WT and the SCV strains (with the SCVs surviving at either the same level or slightly
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Figure 4.17: Wideeld microscopy of neutrophils within a bloodsmear and
isolated from blood. Human blood was smeared onto microscope slides and stained
using Hemacolor before imaging using wideeld microscopy. Neutrophils (white arrows)
are seen with a dark violet lobed nucleus with a pale violet cytoplasm, surrounded by
red blood cells (A). Neutrophils were also isolated from human blood using Polymor-
phprep and were smeared onto a microscope slide and stained with Hemacolor (B).
Representative images from two isolation procedures are shown.
higher), there was a trend towards higher killing of the agrC mutant. Unfortunately,
no statistical analyses could be carried out with this experiment as only two replicates
are shown. This is due to technical issues that arose in subsequent neutrophil killing
experiments, with the neutrophils producing large quantities of NETs after 2 hours of
incubation with bacteria. It was deemed that CFU-plating would not be an accurate
way of determining survival of the bacteria when this occured. For the two replicates
obtained, there was also a high degree of variation between technical replicates and also
across biological replicates. It is unknown why this occurred but it could be that the
PMNs were activated to dierent extents during the isolation, which could greatly aect
phagocytosis of the bacteria and bacterial killing. However, this experiment further
validates the use of a whole blood model system as reproducibility was extremely high
compared to the neutrophil survival assays.
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Figure 4.18: Neutrophils isolated from human blood killed S. aureus but
results were variable. Neutrophils were isolated from human blood using Polymorph-
prep and 106 PMNs were incubated with 105 CFU of bacteria with 10% plasma. Bacteria
were incubated with PMNs for up to three hours and survival is shown as a percentage
of the CFU at each of the timepoints and the CFU in the inoculum at time zero. The
graph shows the mean of two experiments done in duplicate and error bars represent
SEM.
4.9 SCV survival in human blood is not due to elevated neutrophil
death
S. aureus avoids killing by neutrophils via the expression of numerous toxins that are
able to kill the neutrophil from within [364, 399] Many of these toxins are under the
control of Agr, although some of the leukotoxins (such as Hlg) appear to be expressed
in the bloodstream independently of Agr [328]. Therefore, the agr mutants may be
more susceptible to killing in the blood due to an inability to produce toxins and cause
neutrophil death. Whilst the SCVs also have reduced Agr activity, their increased sur-
vival may be due to increased expression of other genes that enable the SCVs to kill
neutrophils, for example, Hlg.
Flow cytometry was used to measure the degree of neutrophil death caused by the
dierent strains. Killing of neutrophils was measured through the use of a live/dead,
membrane-impermeable uorescent dye called Zombie Violet, which was used prior to
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xation. Zombie Violet functions by reacting with primary amine groups that are located
on proteins [571]. When live cells are stained, Zombie Violet can only react with a small
number of proteins located on the cell surface. However, dead cells that have lysed will
be permeable to the dye and due to the high number of proteins within the cytoplasm, a
bright uorescent signal will be detected. Before xation, which leads to permeabilisation
of the cells, Zombie dye that has not reacted can be quenched using 1% BSA.
As live/dead dyes react dierently with dierent cell types, it was necessary to rst
optimise the conditions so that Zombie Violet could be used to accurately measure
neutrophil death. Leukocytes were puried from blood by lysis of the red blood cells
using red blood cell lysis solution and the remaining host cells were resuspended in PBS
(Figure 4.13). A portion of these cells were then killed by heating them to 100C
for 10 minutes as a positive control. These heat-killed cells were stained alongside
the live host cells using Zombie Violet (at a 1/500, 1/1000 or 1/2000 dilution). A
portion of the untreated and heat-treated host cells were not stained to quantify any
background uorescence. As can be seen in Figure 4.19, there were very little Zombie
Violet positive cells detected when the cells were live and unstained. Slightly higher
background uorescence was seen for the unstained, heat-treated cells and this control
was used to help gate out background uorescence. When the heat-treated cells were
stained with Zombie Violet, most of the cells were detected as Zombie Violet positive
when the 1/500 dilution was used (97%). However, the 1/500 dilution also led to a lack
of specicity since 13% of the live cells also stained positive for Zombie Violet. As the
Zombie Violet was diluted, this non-specic binding was reduced but so was detection
of the dead cells. Therefore, as a compromise, the 1/1000 dilution was chosen.
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Figure 4.19: Optimisation of the live/dead Zombie Violet staining protocol. Use of the Zombie Violet live/dead
dye was optimised by comparing the number of Zombie Violet positive cells after incubation of the dye with heat-killed
(bottom) or untreated (top) host cells isolated from blood and after red blood cell lysis treatment. Host cells were unstained
(to assess background uorescence) or after dilution of the Zombie Violet 1/500, 1/1000 or 1/2000. Using the unstained
control, Zombie violet positive cells were gated. The 1/1000 dilution was the optimal condition as less non-specic staining
was seen for the live cells but staining of the dead cells was still observed. One representative set of ow cytometry plots is
shown in each panel.
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To measure killing of host cells in the blood by the dierent strains, bacteria were
labelled with FITC and incubated with blood as in the previous ow cytometry experi-
ment (see Figure 4.13). At time zero and after 2, 4 and 6 hours post-incubation, the
red blood cells were lysed and the remaining cells were washed in PBS before staining
with Zombie Violet (1/1000 dilution, 15 minutes in the dark). At each timepoint, blood
not incubated with bacteria was also treated with red blood cell lysis solution and the
remaining cells were either heat-killed or kept at room temperature and then stained
with Zombie Violet as controls. Unstained cells not heat-killed were also prepared as a
negative control. After Zombie Violet staining, all of the cells were washed with 1% BSA
to quench any free dye remaining, before xation with 1% PFA. After 16{18 h xation,
the samples were analysed using a ow cytometer. To measure killing by the strains,
FITC-positive bacteria with a SSC-A higher than 50K units were gated to rst select
for bacteria associated with host cells (see Figure 4.20D). The percentage of Zombie
Violet positive cells in this gate (Figure 4.20E) were then used to measure the degree
of host cell killing by each of the strains. As there was no spectral overlap between FITC
and Zombie Violet, compensation was not necessary (data not shown).
The ow cytometry plots, from one representative experiment, showing the number
of Zombie Violet positive cells associated with FITC-bacteria after incubation with each
of the bacterial strains (WT, hemB, menD and agrC ) are shown in Figure 4.21.
This gure demonstrates that there is very little host cell death at time zero but this
increases after 2 hours incubation with the bacteria (corresponding well with the high
level of phagocytosis at this timepoint). Over the 6 hours, there was a slight increase in
the degree of host cell death, regardless of which strain the blood was incubated with,
as can be seen in Figure 4.22. Cell death was the same regardless of which strain was
incubated with blood. Whilst this may be surprising considering the reported role of
Agr in producing toxins that contribute to host cell death, this could be due to the low
inoculum used in the assay. Although not shown, as no FITC-positive cells could be
gated on, the host cells that were not incubated with bacteria had a similar level of cell
death over time. This suggests that most of the host cell death was not due to bacterial
cytotoxicity. It is possible that the host cells being out of their natural environment and
the processing for ow cytometry may have resulted in host cell death. Alternatively,
bacteria may kill host cells and then be taken up by a second cell and so this killing
would not be detected. Nevertheless, these results show that there were no detectable
dierences in the cytotoxicity of the strains and the reason why SCVs survive so well in
blood is not due to an increased ability to kill neutrophils.
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Figure 4.20: Gating strategy to measure the amount of host cell killing by the
strains using Zombie Violet. FITC-labelled bacteria were incubated with blood and
the percentage of dead host cells was determined by ow cytometry by gating on cells
positive for Zombie Violet (detected by the 404/450 laser). Background uorescence was
determined by unstained host cells (A), stained live host cells (B) and stained heat-killed
host cells (C) were used as negative and postive controls, respectively. To measure host
cell killing by the bacteria, FITC-positive cells were gated on with a SSC  50K units
and then Zombie Violet positive cells were gated on to measure the number of dead cells
associated with bacteria.
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Figure 4.21: Flow cytometry plots showing host cell killing by each of the strains
using Zombie Violet. Host cell killing in blood by each of the strains was measured after 0, 2,
4 and 6 hours incubation. Dead cells were determined as cells that were positive for the live/dead
dye Zombie Violet as detected by the 405/450 laser. Events were gated to FITC-positive cells
with a  50K SSC. One representative image is shown for each of the timepoints for each strain.
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Figure 4.22: Host cell killing in blood is the same after incubation with either
USA300 WT or a hemB, menD or agr mutant. The percentage of host cells that
were Zombie Violet positive and associated with FITC-positive bacteria is shown in the
graph, with values representing the mean of at least three experiments done in duplicate
with at least two dierent donors. Error bars represent the SEM.
4.10 Discussion
In this chapter, the role of Agr and the SCV phenotype in bacterial survival during
bloodstream infection was assessed using an ex vivo whole human blood model. It was
found that WT S. aureus was killed in a time-dependent manner in blood and although
variation was seen between donors, the same trend of killing was observed.
Although agr mutants are often isolated from patients with bacteraemia, when the
agrA, agrC and RNAIII mutants were incubated with human blood, enhanced
killing was observed for all of the mutants by 2{4 h post-incubation. This killing was
especially noticeable for the agrC and agrA mutants. Therefore, it is likely that
at least some of the genes positively regulated by Agr that are involved in immune
evasion and host cell killing, are important for survival in the bloodstream. The fact
that the RNAIII mutant survives better than the agrA and agrC mutants but less
well than the WT suggests that genes regulated by AgrA contribute to survival. The
AgrA-regulated PSMs have been shown to contribute to killing of neutrophils and as
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the RNAIII mutant can still activate the expression of these toxins, this could explain
why this intermediate survival phenotype is seen [91]. Clearly, additional factors are
important for maximal survival however and phospholipase C and the leukocidins are
examples of RNAIII-regulated proteins with published roles in the survival of S. aureus
that could be involved [179, 194, 548]. Survival of a MSSA strain, SH1000, was also
dependent on Agr as enhanced killing was seen when the agr operon was deleted.
There are a number of reasons that could explain the discrepancy between the data
described in this chapter showing Agr to be important for survival in blood and the
clinical data, which appears to show selection for agr mutations within the bloodstream
[386, 401, 403, 404, 412]. Firstly, in the ex vivo whole blood model, interactions with
other parts of the body such as the endothelium cannot be assessed. However, in vivo S.
aureus is capable of adhering to and invading the endothelium [120, 384, 540]. Loss of agr
leads to the upregulation of adhesins that may promote attachment and extravasation
[60]. As agr mutants have reduced cytotoxicity due to the downregulation of toxins,
there is some evidence that suggests that loss of agr can enable S. aureus to persist
within the intracellular environment of host cells without causing host damage [376, 572].
Survival within host cells would enable S. aureus to escape the immune system and thus
avoid killing [126, 127, 573]. This intracellular environment could act as a reservoir for
S. aureus, with bacteria able to seed back into the bloodstream and cause bacteraemia
upon lysis of the host cell [574, 575]. However, although loss of Agr may promote survival
in certain cell types, a number of groups have shown that Agr function is necessary to
avoid autophagy and acidication of the phagosome, which non-professional phagocytes
use to kill invading pathogens [576{578].
Selection for agr mutants within bacteraemia patients may also be due to the addi-
tional selection pressure attributed to antibiotic use. HA-MRSA strains tend to contain
the SCCmec type II element, which is associated with decreased toxin expression that
is thought to compensate for the high cost of expressing the antibiotic resistance genes
[579]. When the mecA or SCCmec element is deleted, increased toxicity is seen, meaning
the SCCmec is involved in the regulation of virulence as well as methicillin resistance.
The fudoh gene, identied on SCCmec type I and III elements located near the mecI
gene, may also be involved as it has been shown to negatively regulate toxin expression
[580]. The PSM-mec element located on HA-MRSA SCCmec elements also functions to
repress PSM expression [580]. Alternatively, the use of PBP2'/PBP2a may modify the
cell wall such that AgrC cannot be activated by AIP [421]. In the hospital-setting, se-
lection for high antibiotic resistance and low virulence may be tolerated as transmission
between patients may still be high due to constant contact with healthcare workers car-
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rying S. aureus and patients with compromised immune systems, who are more prone to
infection [579]. CA-MRSA strains tend to acquire SCCmec type IV elements and have
high Agr expression but also lower methicillin resistance, meaning that they are able to
infect healthy individuals in the community but are less t in the hospital compared to
HA-MRSA with the SCCmec type II element [54]. The expression of Agr appears to
have a tness cost within the hospital as evidenced in work by Paulander et al. (2013)
which showed that sub-lethal exposure to certain antibiotics (mupirocin, rifampicin and
ciprooxacin but not vancomycin) induced Agr expression and this induction reduced
tness when compared to an agr mutant [579].
Agr dysfunction has also been associated with an increased MIC to vancomycin, with
decreased Agr expression associated with the VISA phenotype [411, 413, 414, 581, 582].
Resistance to tPMPs is also associated with increased vancomycin resistance and Agr
dysfunction [403, 420, 583]. Since killing by both vancomycin and tPMPs is thought to
occur by triggering autolysis, it is thought that the reduced expression of autolysins in agr
mutants could decrease bacterial sensitivity to these molecules [584, 585]. Whilst there
is a clear association between Agr dysfunction and resistance to tPMPs and vancomycin,
it is still not understood whether Agr dysfunction enables bacteria to adapt and become
more resistant to vancomycin or if adaption to vancomycin leads to a thicker cell wall
and this interferes with Agr activity. Either way, vancomycin treatment is associated
with loss of Agr function. Therefore, in the case of hospital patients with compromised
immune systems, antibiotic-resistant but Agr-defective strains may be more successful
than antibiotic-sensitive and Agr-active isolates.
Loss of Agr can also promote the formation of biolms, which could enable S. aureus
to persist within the hospital on medical devices such as catheters that could act as a
source for recurrent bacteraemia [586, 587]. In a recent study by Ferreira et al. (2013),
loss of Agr was associated with increased biolm formation, with mutants forming denser
and more compact biolms than Agr-functional strains [572]. This may be due to the
increased expression of adhesins such as FnBP, Spa and SasG and the decreased expres-
sion of proteases and surfactants (such as -toxin and the PSMs) that may be important
in the dispersal of biolms [140]. Resistance to oxacillin has been shown to reduce viru-
lence and increase biolm formation, inducing a switch from PIA-dependent biolms to
protein adhesin-dependent biolms by repressing the production of PIA [588]. Whilst
these oxacillin-resistant strains caused decreased mortality in mice and were poor at
surviving in the liver, blood, spleen and kidney, they were able to colonise catheters to
the same extent as oxacillin-sensitive strains and more oxacillin-resistant bacteria were
recovered from the peri-catheter tissue [588]. Once again, this suggests that lower vir-
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ulence is associated with antibiotic resistance but that the increased biolm formation
could enable S. aureus to persist in environments within the hospital where it could seed
back into the bloodstream.
Finally, agr mutants are likely to be overestimated within bacteraemia patients due
to the methodology used to test whether an isolate lacks agr. In the majority of publica-
tions, Agr function is measured by using the CAMP assay which involves plating isolates
on CBA and assessing if the strain is capable of lysing the blood via the action of -
toxin [386, 403, 405, 409, 413]. Unfortunately, although this assay is quick to perform,
it overestimates the number of strains that are agr mutants. Recent techniques that
involving real-time PCR, MALDI-TOF and the vesicle lysis test (VLT), which measures
the ability of a strain to lyse vesicles, are all more sensitive in detecting if a strain is
functional for Agr [415, 589, 590]. Using the VLT assay, only 3% of clinical isolates were
deemed to be Agr-negative compared to 18% when the CAMP assay was used [415]. This
suggests that Agr loss may not be as common in bacteraemia patients as rst thought
and that more accurate methods will need to be used to determine if there is a strong
link between Agr loss and bloodstream infections.
Despite the importance of Agr in the ex vivo human blood model, survival of the
hemB and menD SCVs, which have reduced Agr activity, was much higher than for
WT S. aureus. Very little killing of either mutant was seen over the six hour incubation
period, suggesting that SCVs utilise a very dierent survival mechanism distinct from
Agr and STX. Supporting this, survival of the hemB SCV with additional mutations
in agr (agrA, agrC and RNAIII ) was not signicantly dierent compared with the
survival of the hemB single mutant. It was determined that the increased survival was
not due to dierences in uptake between strains or due to dierences in the cytotoxicity
of the strains. Since most of the bacteria are taken up during the whole blood survival
assays, this suggests that the SCVs are more resistant to microbicides produced after
uptake or that they do not trigger the same pathways after uptake and are therefore
not exposed to the same factors as the WT. In neutrophils, killing of bacteria occurs by
restricting nutrients (for example by sequestering iron and zinc) and attacking the cell
with a combination of enzymes, AMPs and ROS [261, 591]. There have been a number
of publications that show that SCVs are more resistant to certain AMPs [443, 460, 477].
Although, AMPs are likely to contribute to killing, neutrophils are thought to kill S.
aureus mainly through the action of ROS, as individuals defective for the oxidative burst
suer with recurrent staphylococcal infections [257, 258, 261]. However, SCVs have been
reported to have reduced STX and so they may be more sensitive to ROS [343]. In the
neutrophil survival assays described in this chapter, survival of the SCVs was either
146
slightly higher or similar to the WT and only the agr mutant appeared to be more
susceptible to killing. Unfortunately, technical issues and variability meant that these
results are not reliable.
It was interesting that when blood was incubated with a mix of WT and SCV, only
the menD SCV was able to inuence WT survival. Whilst the WT and hemB SCV
survived as they did when incubated alone, presence of the menD SCV increased WT
survival. This suggests that the menD SCV is able to produce a factor that the WT
can use to its benet. Although gene expression in both the hemB and menD SCVs
is similar, with genes involved in the TCA cycle downregulated and genes involved in
anerobic respiration upregulated, additional genes with functions other than carbon or
amino acid metabolism are dierentially regulated. Arginine deiminase can help generate
ATP in S. aureus but it also may be important in protecting S. aureus from acid shock
and this gene is upregulated in menD compared to hemB [439]. Hemoproteins that
require haem as a co-factor will only be functional in the menD SCV and the production
of one of these proteins may contribute to survival of the WT strain [439, 441, 463]. For
example, catalase is a secreted hemoprotein that helps break down H2O2 into oxygen and
water and it could theoretically be used by the WT strain to resist oxidative stress [352].
This would require both increased production of catalase for the menD SCV to increase
survival compared to the same number of WT bacteria and potentially engulfment of the
two strains into an individual phagosome. It is worth noting however that it is unlikely
that the production of catalase fully explains why the SCVs survive as the hemB SCV
survives just as well as the menD SCV in blood despite being unable to produce the
peroxidase.
This chapter has shown the importance of Agr for survival in the bloodstream. How-
ever, it has also shown that S. aureus may survive via an Agr-independent mechanism
via the SCV phenotype. Agr expression results in the production of toxins that enable
S. aureus to lyse the neutrophil and escape the antimicrobial defence molecules that
are released into the phagosome [261]. Therefore, it is hypothesised that loss of Agr is
detrimental in blood as bacteria are unable to produce toxins and so cannot escape neu-
trophil killing (Figure 4.23). SCVs lack Agr expression, and thus toxin expression, but
are able to survive better than even the WT. Since the increased survival of the SCVs
is not due to reduced uptake or increased cytotoxicity, it is hypothesised that SCVs are
somehow able to resist killing by neutrophils (Figure 4.23). The next chapter will aim
to determine the mechanism by which SCVs avoid neutrophil killing.
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Figure 4.23: S. aureus survives killing in the bloodstream by Agr-dependent
and Agr-independent mechanisms. In the bloodstream, S. aureus is engulfed by
neutrophils and tracked to the phagosome. One of the ways that WT S. aureus can
avoid killing by neutrophils is by releasing Agr-regulated toxins that cause neutrophil
lysis (A). Mutants that lack Agr are unable to produce these toxins and lyse neutrophils,
therefore, they are killed by defence molecules (such as ROS, AMPs and nitric oxide)
released into the phagosome (B). SCVs that lack Agr and toxin production are able to
survive better than WT bacteria. As the amount of phagocytosis and cytotoxicity was
equal between the WT and the SCVs, it is hypothesised that SCVs must resist killing
once inside the phagosome (C).
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5 Resistance of SCVs to oxidative stress
5.1 Introduction
In the previous chapter, it was shown that haem- and menadione-auxotrophic SCVs are
signicantly less susceptible to killing in human blood compared to WT S. aureus. This
increased survival was not due to evasion of phagocytosis as the SCVs were internalised
to the same extent as the WT and an agrC mutant. Additionally, SCV survival was
not due to increased cytotoxic activity as neutrophil cell death was identical in blood
incubated with either the WT, the hemB or menD SCVs or an agrC mutant. These
results indicate that the increased survival is due to elevated resistance to immune-
generated microbiocides.
Previous work has shown that SCVs are more resistant to AMPs, as the loss of
the ETC results in a reduced membrane potential that prevents the action of cationic
peptides that require a large membrane potential for their function [443, 444, 477]. As
neutrophils release AMPs into the phagolysosome, it could be that resistance to AMPs
provides SCVs with an advantage over WT S. aureus [248]. However, killing of S.
aureus by neutrophils is primarily dependent on ROS production as inhibition of the
NADPH oxidase, which prevents the generation of ROS, also prevents S. aureus killing
[256, 257, 268]. Therefore, it was hypothesised that SCVs are less susceptible to killing
due to increased resistance to oxidative stress.
As mentioned in the Introduction, S. aureus has evolved a variety of dierent mech-
anisms to resist oxidative stress produced from an external source such as a neutrophil.
These oxidative stress resistance mechanisms also provide protection against endogenous
ROS that is generated within bacteria, following interaction of oxygen with proteins that
donate electrons, resulting in reduction of oxygen to produce O {2 and H2O2 (Figure 5.1)
[592]. In a reaction called the Fenton reaction, this H2O2 can react with ferrous iron,
either free within the cytoplasm or bound in iron-sulfur clusters of proteins, to generate
OH and HO{ [272]. In addition, metals such as copper and cadmium may also react
with H2O2 in a Fenton-like reaction to also generate OH and HO
{ [593]. Exposure of
bacteria to oxidative stress results in the oxidation of proteins and amino acids, result-
ing in protein inactivation and aggregation. Proteins containing cysteine, methionine or
tryptophan are especially susceptible to oxidation and inactivation [592]. ROS can also
cause DNA damage, resulting in mutations that may be lethal to the bacterium [594].
Some of the mechanisms that S. aureus uses to resist the eects of oxidative stress are
shown in Figure 5.2. The production of the STX pigment provides resistance to oxida-
tive stress as the molecule contains multiple conjugated bonds that enable it to quench
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Figure 5.1: Redox reactions that occur within the bacterial cell. Oxygen can
be reduced to superoxide (O {2 ) after interaction with proteins that donate electrons.
O {2 can be dismutated to H2O2 by the action of superoxide dismutases (SOD). In turn,
H2O2 can be broken down into H2O and O2 by the action of catalase. Alternatively,
H2O2 may react with ferrous iron (Fe
2+) to generate hydroxyl radicals (OH ), hydroxide
(HO{) and ferric iron (Fe3+).
singlet oxygen [343]. S. aureus also encodes a number of enzymes that are responsible
for degrading specic ROS species. The superoxide dismutases (Sods), SodA and SodM,
are manganese-dependent enzymes that dismutate O {2 to H2O2. SodA is deemed to be
the major Sod, responding to internal oxidative stress, whilst SodM responds to external
stress [346, 347]. S. aureus is then capable of breaking down H2O2 through the activity
of two enzymes, catalase (KatA) and alkyl hydroperoxide reductase (AhpC), encoded by
katA and ahpCF respectively [351]. KatA protects S. aureus from high concentrations
of H2O2 (over 10 M), whilst AhpC protects against low concentrations of H2O2 (under
10 M) and is active against a broader spectrum of ROS such as organic peroxides and
peroxynitrate [351]. Loss of either one of the enzymes results in increased activity of the
other enzyme, enabling them to partially compensate for each other [351].
Due to its role in the Fenton reaction, metal homeostasis is tightly linked to oxidative
stress resistance. To meet the growth requirements of the bacterium, metal ions must
be kept at a sucient level as a number of metabolic enzymes depend on these for their
function [369, 595]. In addition, proteins in the ETC and catalase require iron in the
form of haem. Intracellular levels of free metal ions must be low enough to avoid the
deleterious redox reactions that occur in the presence of metals such as iron and copper
however. This is achieved in the cytoplasm by storing most of the unused iron in ferritin
(Ftn) or bacterioferritin comigratory protein (Bcp) [596, 597]. MrgA also acts as an
iron chelator to protect S. aureus from ROS [352]. Furthermore, S. aureus harbours
a number of iron transporters that are tightly regulated by the Ferric uptake regulator
(Fur) [598]. Fur acts as a transcriptional repressor; under conditions where iron levels
are high it complexes with iron, enabling binding to a consensus DNA sequence (referred
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Figure 5.2: S. aureus has evolved several dierent mechanisms to resist ox-
idative stress. S. aureus is exposed to both internally- and externally-generated ROS
and this results in damage to proteins and DNA, which can be detrimental for bac-
terial survival. Dierent types of DNA damage can occur after exposure to oxidative
stress, including double-strand breaks, base lesions and base changes. Base lesions are
repaired by MutM, MutY and MutT, double-strand breaks are repaired by RecA and
AddAB/RexAB, mismatched nucleotides are repaired by UvrABC and Mfd; some of
these proteins are shown in the diagram. Proteins are susceptible to oxidation and this
can lead to protein aggregation and misfolding. MsrA and MsrB repair oxidised me-
thionine residues, IscS and ScdA repair iron-sulfur clusters and proteins such as the
Clp family of proteases and chaperones degrade proteins and prevent aggregation. S.
aureus can also degrade dierent types of ROS; SodA and SodM break down O {2 to
H2O2, which can be further broken down to water and oxygen by KatA and AhpC.
Metal ions such as iron can react with oxygen to generate harmful byproducts, therefore
S. aureus has to tightly control levels. This is acheived by regulators that control tran-
scription of metal transporters in response to levels of the corresponding metal. Storage
molecules, chaperones and chelators also prevent high levels of free metal. In addition,
the membrane-bound antioxidant staphyloxanthin protects against singlet oxygen.
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to as the Fur box) located upstream of several genes involved in the acquisition of iron
[598]. In addition, Fur is known to positively regulate KatA, although as Fur usually
acts as a repressor, it is thought that this interaction must be indirect [368]. fur mutants
are more sensitive to oxidative stress, which may be due to down-regulation of KatA,
the inability of S. aureus to regulate iron levels in the cell, or, most likely a combination
of both factors [368].
S. aureus also controls levels of zinc through the Fur homologue, Zur, which regu-
lates the zinc transport operon ZnuABC [352]. Levels of copper are regulated by the
CsoR repressor, which represses the action of the CopA transporters and CopZ copper
chaperone when copper levels are low [352]. Manganese is an important metal that con-
tributes to oxidative stess resistance. Due to its high reducing potential compared to
iron and copper, manganese is often utilised in proteins that may be subject to oxidative
stress [599, 600]. For example, both SodA and SodM are thought to use manganese as
a co-factor [347, 348]. In addition, manganese acts as a natural superoxide dismutase
and so the acquisition of manganese protects S. aureus from some forms of oxidative
stress [600]. The mntABC operon and mntH both encode manganese transporters, with
MntABC acting as the major manganese transporter [350]. Expression of mntABC is
regulated by MntR, which represses mntABC expression 50-fold when manganese is
abundant [350].
Repair of the damage caused by oxidative stress is important for S. aureus survival.
DNA damage, for example, can introduce harmful mutations within the genome that
must be rapidly detected and repaired [594]. Many of the DNA repair pathways identied
in E. coli have homologues in S. aureus. Base lesions are detected by DNA glycosylases;
MutM, MutY and MutT detect damage to purines, adenines and guanines, respectively
[352]. Mismatched nucleotides are identied and repaired by the MutSL proteins, whilst
nucleotide excision repair is carried out by the UvrABC protein complex along with
Mfd. Double-strand breaks are repaired by RecA and the AddAB (otherwise known as
RexAB) complex, which are functionally homologous to the RecABCD system in E. coli
[352]. RecA is also able to induce the SOS-response by cleavage of LexA, which normally
acts to repress genes involved in DNA repair [601]. S. aureus also has dedicated proteins
that function to repair proteins damaged by oxidation. S. aureus possesses two Msr
proteins, MsrA and MsrB, that repair oxidised methionine residues of the respective S
and R forms [352]. Whilst, iron-sulfur clusters are thought to be repaired by the action
of IscS and ScdA [602, 603]. In addition, S. aureus counteracts protein aggregation and
misfolding by expressing chaperones and proteases, such as the Clp family of ATPases
[604]. One of the members of this family is ClpC, which has been implicated in providing
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resistance against oxidative stress [605].
S. aureus has a number of regulators that are responsive to oxidation, such as SarZ
and SrrAB, which enable S. aureus to co-ordinate virulence, metabolism and defences
in response to levels of oxygen [547]. The Peroxide responsive repressor (PerR) is one
such regulator, which is responsible for repressing genes involved in oxidative stress
resistance (Figure 5.3) [606]. PerR is a Fur homologue and acts as a repressor when
iron is limited and manganese levels are high (1{2 M) by binding as a dimer to the
PerR consensus sequence [606]. Under these circumstances, PerR utilises manganese as
a co-factor (PerR-Mn) and is resistant to oxidation due to the high reducing potential of
manganese. PerR has a greater anity for iron however, and therefore, under conditions
of high iron or when iron and manganese are present, PerR will preferentially bind iron
(PerR-Fe) [607]. PerR-Fe is highly sensitive to oxidation and upon oxidation of two
regulatory histidines (43 and 47), PerR undergoes protein modications that results
in loss of its DNA-binding ability [607]. S. aureus PerR-Fe is much more sensitive to
oxidation than PerR-Fe found in Bacillus subtilis or E. coli, with oxidation occurring
when peroxide is as low as 50 nM. Whilst PerR-Fe can act as a repressor under oxygen-
limited conditions, during aerobic growth, PerR-Fe is rapidly oxidised and can no longer
bind DNA. This occurs without the addition of external peroxide and suggests that
PerR-Fe responds mostly to endogenous ROS [607].
Oxidation of PerR leads to the induction of genes that encode MntABC, Fur, Ftn,
TrxB, AhpC, KatA, Bcp, PerR and MrgA [606]. Additional genes with PerR boxes have
also been reported although their functions are not well understood [608]. Many of the
genes regulated by PerR have been mentioned above (katA, ahpCF, mrgA, ftn, bcp, fur
and mntABC ) and provide resistance to oxidative stress. In addition to these, PerR
regulates TrxB, a thioredoxin that along with TrxA and thiol reductants act to create
a reducing environment in the cytoplasm that facilitates the reduction of ROS such as
H2O2 [352]. The thioredoxins also regenerate proteins such as AhpC and the MsrAB by
delivering them electrons, which they require for their activity [609]. MrgA, as well as
being an iron chelator, is involved in supercoiling of the bacterial chromosome, which
can provide protection against the DNA damage caused by oxidative stress by reducing
the amount of surface area available to ROS species [610].
On the basis that SCVs display reduced STX pigment, it could be hypothesised
that SCVs are more susceptible to ROS than WT S. aureus [343]. Transcriptomic
and proteomic studies have also shown reduced katA expression in SCVs and haem-
auxotrophic SCVs in particular are unable to produce functional catalase as haem is an
essential co-factor [543, 611]. In addition, the production of antioxidants is regulated by
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Figure 5.3: The PerR regulator represses oxidative stress resistance genes
under oxygen-limited conditions. PerR is a transcriptional repressor of a number
of genes that are involved in oxidative stress resistance within S. aureus and PerR also
autoregulates the expression of its own gene (A). In the absence of oxidative stress, PerR
binds as a dimer upstream of genes involved in oxidative stress resistance (katA and perR
are shown as examples) to block transcription (B). When S. aureus encounters oxidative
stress, this triggers oxidation of the iron residues within PerR, resulting in loss of its
DNA binding activity and transcription of the PerR regulon (C).
menaquinone in Gram-negative bacteria and this same pathway may be necessary for
optimal resistance to oxidative stress in S. aureus [497]. However, the ability of SCVs
to resist ROS has never been directly tested.
Aims: 1. To assess the importance of ROS in staphylococcal killing within
the ex vivo blood model.
2. To determine whether SCVs are more resistant than the WT to ROS and
to determine whether increased resistance to ROS enables SCV survival in
human blood.
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5.2 Killing of S. aureus in human blood is due to ROS production
Neutrophils are the key host defence against S. aureus infection, producing a ROS
burst that acts as the major killing mechanism [248]. To understand why the SCVs
and agr mutants dier in their susceptibility to host defences, it was rst necessary
to determine the role of ROS-mediated killing in the whole blood model. This was
achieved by using the avoenzyme inhibitor, diphenyleneiodonium (DPI), which blocks
the NADPH oxidase that is responsible for the ROS burst [612]. Blood was treated with
DPI or DMSO (the solvent DPI is dissolved into) as a control, for 30 minutes prior to
the addition of bacteria. After 6 hours incubation, there was a signicant increase in
the survival of WT USA300 and SH1000 in blood treated with DPI, with up to 80% of
the inoculum viable (Figure 5.4A). Only 4{14 % of the bacteria remained viable by
the 6 hour timepoint in blood treated with the DMSO control (Figure 5.4A). This was
also true for mutants lacking Agr function, with much reduced killing of USA300 agrC
and SH1001 agr incubated in DPI-treated blood (Figure 5.4A). This demonstrates
that most of the killing of S. aureus within blood is due to ROS production, as has
been shown previously in neutrophils [268, 329]. The fact that killing could not be fully
prevented may be due to DPI not completely blocking NADPH oxidase activity or other
mechanisms that are not dependent on ROS, such as killing by nitric oxide or AMPs.
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Figure 5.4: Killing of S. aureus in human blood is due to the production of ROS.
Blood was incubated with the NADPH-oxidase inhibitor DPI, or DMSO as a control, 30 min
before incubation with bacteria. Percentage survival, after 6 hours incubation, is shown for (A)
USA300 and SH1000 WT and corresponding agr mutants, USA300 agrC and SH1001 agr,
and (B) USA300 and the SCVs, hemB and menD. Asterisks show signicance as measured by
the Student's T-test (* P  0.05; ** P  0.01; *** P  0.001). The graph represents the mean
of at least four independent experiments repeated in duplicate and error bars represent SEM.
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When the hemB and menD SCVs were incubated in blood treated with DPI, the
dierences in killing compared to the DMSO-control were less profound than was seen
for USA300 WT and the agrC mutant due to their already high survival (Figure
5.4B). For the hemB SCV, treatment with DPI increased survival, with 76% of the
inoculum viable after 6 hours compared to the 37% that survived in the DMSO-treated
blood. In previous blood killing experiments however, survival of the hemB SCV has
been much higher, with 70% of the inoculum viable at 6 hours (Figure 4.6A). This
suggests that DMSO may have a negative impact on survival of the hemB SCV in blood
but that the addition of DPI can still increase survival. For the menD SCV, survival at
6 hours was high regardless of whether blood was treated with DPI or DMSO, with the
results similar to previous experiments (Figure 4.6A). There was signicantly higher
survival of the menD SCV in DMSO-treated blood compared to the DPI-treated blood,
although it is not understood why. Regardless, even though SCV survival was high,
blocking ROS production did not substantially increase survival and did not enable
replication over 6 hours. As ROS production was so important for killing of WT S.
aureus and agr mutants in human blood, we hypothesised that survival of the SCVs was
due to decreased susceptibility to ROS.
5.3 SCVs are more resistant to hydrogen peroxide than WT S. aureus
To test whether SCVs are more resistant to ROS, stationary phase bacteria were exposed
to H2O2, a type of ROS that bacteria are exposed to in the neutrophil phagosome
[259, 269]. Bacteria (104 CFU) were challenged with various concentrations of H2O2
(15 mM, 20 mM or 25 mM) in PBS and survival was measured. After the addition of
H2O2, bacteria were incubated at 37
C in the dark due to the light-sensitivity of H2O2.
Although these concentrations are much higher than the levels of H2O2 predicted within
the phagosome, only one or a few bacteria are usually present in a single phagosome
[259, 332]. To detect dierences in susceptibility to H2O2, higher numbers of bacteria are
necessary however, meaning that bacteria are less susceptible to low H2O2 concentrations
due to the presence of enzymes that quickly break down H2O2. Susceptibility of bacteria
to H2O2 was measured by plating undiluted and serially diluted bacteria onto CBA
plates, which prevented further killing due to catalase present within this medium [559].
Survival was determined by CFU counts and presented as a percentage of the inoculum.
Signicant killing of USA300 WT was seen after subjecting the bacteria to each of
the three dierent concentrations of H2O2 for one hour (Figure 5.5). Only 14% of the
WT inoculum was viable after the bacteria were exposed to 15 mM H2O2 and killing
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was dose-dependent, with less survival seen as the H2O2 concentration was increased to
20 mM and 25 mM. The agrC mutant was just as susceptible to H2O2 as the WT,
with no signicant dierences seen at any of the concentrations. By contrast, survival
of the hemB and menD SCVs was signicantly higher than the WT at each of the
concentrations. No signicant dierence in survival was found between the hemB and
menD SCVs after incubation with any of the concentrations of H2O2.
Figure 5.5: SCVs are more resistant to hydrogen peroxide than WT S. au-
reus. Bacteria (USA300 WT, hemB, menD and agrC ) were incubated for one
hour in the dark with PBS containing either 15, 20 or 25 mM H2O2. Asterisks show
signicance as measured by the Student's T-test (* P  0.05; ** P  0.01; *** P 
0.001) with survival compared to the WT exposed to the same concentration of H2O2.
Survival is shown as a percentage of the inoculum. Data are shown as the mean of at
least four independent experiments repeated in duplicate. Error bars represent SEM.
Restoration of the WT phenotype in the SCVs via introduction of plasmid pCL55,
containing a copy of either the WT hemB or menD gene, into each respective SCV,
resulted in increased susceptibility of both of the SCVs to 15 mM H2O2 (Figure 5.6).
This decreased survival resembled that seen for the WT after exposure to H2O2. When
the hemB and menD SCVs were transformed with plasmid pCL55 only as a control, sur-
vival was unaected when compared to survival of the SCVs without pCL55. Therefore,
the increased resistance of the SCVs to H2O2 is due to the mutations within the haemin
and menadione biosynthesis pathways and not due to the acquisition of spontaneous
mutations that increase resistance to oxidative stress.
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Figure 5.6: Genetic complementation of the SCVs reduces resistance to hy-
drogen peroxide to WT levels. Percentage survival of the inoculum is shown for
USA300 WT, the hemB and menD SCV and corresponding genetically comple-
mented strains (hemB with pCL55 hemB and menD with pCL55 menD) and plasmid
controls (hemB with pCL55 empty and menD with pCL55 empty) after exposure
to 15 mM H2O2. Asterisks show signicance as measured by the Student's T-test (* P
 0.05; ** P  0.01; *** P  0.001) and error bars represent SEM. Graph shows the
mean of three independent experiments repeated in duplicate.
5.4 A mutation in perR confers resistance to oxidative stress in WT
S. aureus but not in the WT treated with HQNO
To determine the molecular basis for SCV resistance to ROS, a targeted genetic screen
was carried out using the NARSA transposon library in an attempt to identify genes
responsible for the phenotype. This library contains 1,920 mutants with each gene
disrupted by the bursa aurealis transposon that confers resistance to erythromycin.
Twelve mutants (perR::Tn, katA::Tn, fur ::Tn, ahpC ::Tn, mrgA::Tn, bcp::Tn, srrB ::Tn,
sodA::Tn, sodM ::Tn, mntA::Tn, mntB ::Tn and mntC ::Tn) were selected on the basis
of previous publications that have reported them to be important in S. aureus resis-
tance to oxidative stress [350{352, 368, 606, 613]. Unfortunately, ftn and trxB, two
PerR-regulated genes implicated in oxidative stress, were not available in this library.
To quickly determine genes important for SCV resistance to oxidative stress, each
transposon mutant was grown for 18 hours with or without HQNO, an inhibitor of the
ETC that confers a menadione-auxotrophic SCV-like phenotype [501]. These mutants
(104 CFU) were then exposed to 15 mM H2O2 for one hour before plating for CFU
on CBA as described in the previous experiments. Survival was then compared to the
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survival of JE2, the isogenic strain for the NARSA transposon library, grown with or
without HQNO.
As can be seen in Figure 5.7, after incubation with HQNO, the WT JE2 strain
was signicantly less susceptible to H2O2, compared to bacteria grown without HQNO,
validating this approach. The perR::Tn mutant grown without HQNO had signicantly
higher survival than the JE2 strain (P < 0:00004), with more than 10-fold more bacteria
viable after treatment with 15 mM H2O2. These data are in agreement with previous
reports and further validates this method [368, 606]. Survival of the perR::Tn mutant
was remarkably similar when grown with or without HQNO, which may suggest that
perR expression is aected within SCVs.
For some of the mutants (ahpC ::Tn, srrB ::Tn, sodA::Tn and sodM ), survival after
growth with or without HQNO corresponded to the survival of the JE2 strain treated
with or without HQNO. This suggests that these genes do not play any role in resistance
to H2O2 in SCVs under the conditions tested.
Figure 5.7: Genetic screen for oxidative stress resistance genes associated
with SCV resistance to H2O2. Bacterial cultures were grown for up to 18 h in the
presence (yellow bars) or absence (green-grey bars) of HQNO. Stationary phase bacteria
were then exposed to 15 mM H2O2 for one hour. Survival is shown as a percentage of the
inoculum as determined by counting CFUs. Asterisks show signicance as measured by
the Student's T-test (* P  0.05; ** P  0.01; *** P  0.001). Data shown is the mean
of at least four independent experiments repeated in triplicate and error bars represent
SEM.
Increased killing was seen for the katA and mntB mutants, regardless of whether the
strains had been treated with or without HQNO, with less than 5% of the bacteria viable
after exposure to 15 mM H2O2. This suggests that these genes are highly important for
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both the WT and SCV in providing resistance against H2O2.
Resistance to H2O2 was reduced for some strains only when they had been grown in
the presence of HQNO. This was the case for fur ::Tn, bcp::Tn, mntA::Tn and mntC ::Tn,
which were signicantly more susceptible (P < 0:05 for fur ::Tn, P < 0:008 for bcp::Tn,
P < 0:0005 for mntA::Tn and P < 0:001 for mntC ::Tn) than the JE2 strain grown with
HQNO. Therefore, it may be that these genes are important in providing resistance to
H2O2 in the SCV background. These genes may also contribute to resistance in the WT
background, although survival of these mutants grown without HQNO did not dier
signicantly from JE2 grown without HQNO.
Some of the mutants had increased survival against H2O2 only when the cultures
had been grown without HQNO. Survival was slightly higher in two mutants, mrgA
and mntA, with loss of these genes leading to survival being 1.8-fold and 4.4-fold higher
respectively than the untreated JE2 strain. It is interesting that the mntA, mntB and
mntC strains showed dierences in survival despite belonging to the same operon. One
explanation could be that incubation with HQNO aects growth of the strains dierently
and so in future it would be useful to transduce the mutations into either the hemB or
menD SCV to determine if this is the case.
5.5 Resistance to oxidative stress in the SCVs does not seem to be
due to dierences in the expression of perR, katA or fur
PerR is a negative transcriptional regulator of numerous genes involved in metal home-
ostasis and oxidative stress resistance [606]. If endogenous ROS levels of perR are altered
within SCVs, this could lead to the up-regulation of genes such as katA and mntB that
were shown to be important for resistance to H2O2 in the oxidative stress screen (Figure
5.7). This could explain why SCVs are more resistant to ROS and thus, their increased
survival within human blood.
To test whether levels of perR were altered within SCVs, GFP reporter constructs
were made, with the perR promoter cloned upstream of the gene encoding GFP. Re-
porters were also constructed for the PerR-regulated genes, katA and fur, as this would
provide an indirect way of measuring perR oxidation in the SCVs. The use of GFP
reporter constructs was chosen on the basis of the previous experiments, described in
Chapter 3, that made use of P3-GFP reporters (Figure 3.13). These experiments
demonstrated that GFP was a reliable and sensitive marker of gene expression, enabling
transcription to be detected even at very low levels. Since GFP uorescence is not
bleached substantially by H2O2 alone, the reporter constructs could also be used to
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measure expression levels of these genes after exposure to H2O2 and potentially be used
in ow cytometry experiments [614].
To construct the GFP reporters, the gfp gene was amplied along with plasmid
pCL55 from the P3-GFP reporter construct, excluding promoter P3 (Figure 5.8 for
schematic). Primers were designed to amplify the promoters of fur, katA and perR and
plasmid pCL55 containing the gfp gene using previously designed sequences, with over-
hangs added to the 5' and 3' ends of each primer [606]. This enabled each promoter to be
cloned upstream of the gfp gene in pCL55 using the NEB Gibson assembly kit. Imme-
diately after Gibson assembly, the assembled reporter constructs were transformed into
E. coli DC10B and transformants were selected on ampicillin LB agar plates. Colonies
with ampicillin resistance were screened by PCR using primers that amplied the pro-
moter and gfp gene. Colonies with a PCR product of the expected size were then grown
and plasmid extracted by midiprep. The three reporter constructs (pCL55 pperR-GFP,
pCL55 pfur -GFP and pCL55 pkatA-GFP) were then transformed into USA300 WT S.
aureus and the hemB and menD SCVs by electroporation. S. aureus transformants
were selected for on TSA plates containing chloramphenicol and colony PCRs were car-
ried out with these transformants to ensure that the reporter constructs were present
and of the expected size (Figure 5.8). The gfp gene was sequenced in each of reporter
constructs for each of the strains and this was found to be intact (data not shown).
162
Figure 5.8: Construction of the oxidative stress GFP reporter constructs. The pro-
moter sequences of fur, katA and perR were amplied by PCR using primers with overhangs
corresponding to pCL55-gfp. The plasmid pCL55-gfp was amplied by primers containing over-
hangs corresponding to each of the dierent promoters. Plasmid pCL55-gfp was then assembled
with its corresponding promoter using Gibson assembly and immediately transformed into E.
coli DC10B. Transformants were selected on ampicillin and checked by colony PCR and se-
quencing. Each of the conrmed constructs were then transformed into S. aureus WT and the
hemB and menD SCVs. Transformants were selected for on chloramphenicol plates and checked
by colony PCR and sequencing.
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Fluorescence and OD600 of USA300 WT and the hemB and menD SCVs con-
taining pCL55 pperR-GFP, pCL55 pfur -GFP or pCL55 pkatA-GFP was then measured
simultaneously every 30 min for 17 hours, as described for the P3 reporters (Figure
3.13). Fluorescence in these strains was compared to the corresponding strains contain-
ing empty pCL55 plasmid and WT bacteria containing the P3-GFP reporter. However,
uorescence was only detected in WT bacteria containing the P3-GFP reporter, with no
uorescence detected for any of the other strains at any time point (data not shown).
Since expression of these genes may only be detected upon exposure to oxidative stress,
with expression levels only high for a brief period, uorescence for each of the strains
was measured every 15 min for 2 hours, after a stationary phase culture was exposed
to sub-lethal concentrations of H2O2 (10 mM, 1 mM or 0.1 mM). Unfortunately, no
uorescence was detected at any of the timepoints (data not shown).
The reason why the GFP-reporters did not report katA, perR or fur is unknown
but it may have been that this method was not sensitive enough to detect expression.
To address this, quantitative real-time PCR (qPCR) was adopted as this enables the
detection of even very low transcript levels. RNA was extracted from stationary phase
WT, hemB and menD bacteria and reverse-transcribed into complementary DNA
(cDNA) using Oligo(dt) primers, which hybridise to the poly(A) tract of mRNA. The
cDNA was then amplied by qPCR using primers that annealed to the 3' end of the
genes for katA, perR, fur and the housekeeping gene encoding 16S rRNA. Fold-change
in gene expression for each of the genes in the hemB and menD SCV compared to
the WT could then be determined by relative quantication using the  technique,
normalising expression to the housekeeping 16S rRNA gene [615]. Using this method,
no signicant dierences were found for the expression levels of katA, perR or fur in
the hemB and menD SCVs compared to the WT (Figure 5.9). These results were
variable between replicates, which could be explained by the non-standard use of the
polyA mRNA extraction method. The PCR reactions for each of the genes could also
have been further optimised to decrease the variability. Overall, it is not conclusive
from these results whether dierences in the gene expression levels of katA, perR or fur
contribute to SCV resistance to oxidative stress.
5.6 Catalase activity is higher in the menD SCV than the WT
S. aureus produces ahpC and katA that catalyse the breakdown of H2O2 to oxygen and
water. AhpC is responsible for the breakdown of low concentrations of H2O2, whilst KatA
is responsible for higher concentrations [351]. This was also evident from the genetic
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Figure 5.9: Gene expression levels of katA, perR and fur do not vary in the
hemB and menD SCVs compared to the WT. Gene expression levels of the katA,
perR and fur were measured by quantitative real-time PCR using RNA prepared from
stationary phase bacteria. Fold-change in expression levels compared to the WT set to
1 are shown. The graphs represent the mean of three experiments (with RNA extracted
separately each time) repeated in triplicate and error bars represent SEM.
screen for oxidative stress genes (Figure 5.7) where KatA was essential for resistance
against 15 mM H2O2 with no increased killing of the ahpC ::Tn mutant. Although
expression of the katA gene appeared to be no dierent in the SCVs compared to the WT
based on the qPCR results, it was possible that protein levels were dierent. Therefore,
the ability of each of the strains to breakdown H2O2 was assessed to see if this could
explain why SCVs are more resistant to H2O2. The agrC strain was also included
to see whether the Agr regulon had any role in breaking down H2O2, as a previous
publication has shown that oxidative stress can cause AgrA to dissociate from DNA,
resulting in expression of the antioxidant glutathione peroxidase [357].
To measure the breakdown of H2O2 by USA300 WT, the hemB and menD SCVs,
and agrC cultures were grown for 18 h and 107 CFU were added to 100 M H2O2.
Bacteria were incubated at 37C in the dark. Catalase activity was indirectly deter-
mined by measuring H2O2 concentration over one hour using the Thermo-Fisher Pierce
quantitative peroxide assay. In this assay, peroxide was measured by the conversion of
ferrous ion to ferric ion, which is triggered after peroxyl radicals are generated when
peroxide reacts with the chemical sorbitol, found within one of the kit reagents. When
ferric ion complexes with xylenol orange, another chemical supplied with the kit, this
results in a colour change to purple when H2O2 is present. Samples were read at the
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wavelength 595 nm in a microplate reader and the H2O2 concentration was determined
by the use of a standard curve generated from standards of known H2O2 concentrations
(data not shown).
The ability of each of the strains to break down H2O2 is shown in Figure 5.10.
In the absence of bacteria, there was no decrease in the concentration of H2O2. This
was also the case when the hemB SCV was incubated with 100 M H2O2, which was
expected as the hemB SCV is auxotrophic for haem and KatA requires haem for its
activity [352]. WT S. aureus, the agrC mutant and the menD mutant were able to
break down the H2O2 over the course of the assay, with no H2O2 detected after one
hour. In each case, both the WT and agrC mutant broke down H2O2 at a similar rate,
with no signicant dierence between the strains. However, the menD SCV broke down
H2O2 at a signicantly faster rate than the WT, with 3-fold less H2O2 detected after 5
min when 100 M was incubated with the menD SCV compared to the WT. Therefore,
despite there being no evidence by qPCR that katA expression was any dierent in the
menD SCV compared to the WT, this assay revealed higher catalase activity in the
menD SCV.
As catalase activity diered in both of the SCVs compared to the WT, this result
was conrmed by testing the ability of the genetically complemented hemB and menD
SCVs to break down H2O2 (Figure 5.11). Transformation of the hemB SCV with
pCL55 containing a copy of the WT hemB gene restored catalase activity in this strain,
enabling it to break down H2O2 at a similar rate to the WT. By contrast, the hemB
SCV transformed with pCL55 as a plasmid control was unable to break down H2O2,
with levels remaining as high as H2O2 samples not incubated with bacteria. When the
menD SCV was complemented with pCL55 containing the WT menD gene, catalase
activity was reduced to WT levels. This was signicantly dierent to the menD SCV
transformed with a plasmid control, with no H2O2 detected even 5 min into the assay.
This clearly shows that the dierences in catalase activity between the WT and SCVs
are due to the mutations within either hemB or menD. Whilst loss of the hemB gene
leads to loss of catalase activity and an inability to break down H2O2, loss of the menD
gene increases the rate of H2O2 breakdown.
5.7 Oxidative stress resistance genes inuence survival of S. aureus in
human blood, in a strain-dependent manner
To test if resistance to oxidative stress contributes to S. aureus survival in human blood,
some of the oxidative stress mutants identied as important for H2O2-resistance in the
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Figure 5.10: Catalase activity is higher in the menD SCV but not the hemB
SCV compared to WT S. aureus. The ability of USA300 WT, the hemB and menD
SCVs and the agrC mutant to breakdown H2O2 was measured. Bacteria (10
7 CFU)
or a PBS no bacteria control were added to 100 M H2O2 in PBS and samples were
incubated for one hour at 37C in the dark. The concentration of H2O2 in the samples
was quantied over one hour using the Thermo-Fisher Pierce quantitative peroxide assay
and the use of a standard curve. Results in the graph represent the mean of at least ve
experiments done in duplicate. Error bars represent SEM.
genetic screen were tested in the ex vivo whole blood survival assay. As resistance to
H2O2 is signicantly increased in a perR::Tn mutant, survival of a JE2 strain in human
blood was compared to that of the JE2 perR::Tn mutant (Figure 5.12A). As with
USA300 WT, the JE2 WT was killed signicantly in blood over six hours (Figure 4.1),
with only 5.4% of the inoculum viable at the 6 hour timepoint. However, loss of perR led
to a signicant increase in JE2 survival in blood (P < 0:0023), with 23.1% of the bacteria
viable after 6 hours when perR was disrupted. Loss of PerR leads to up-regulation of
several oxidative stress resistance genes such as KatA and as resistance to H2O2 by
the JE2 strain was dependent on the KatA enzyme (Figure 5.7), survival of the JE2
strain in human blood was compared to that of the JE2 katA::Tn mutant. Surprisingly,
despite the importance of katA for resistance to H2O2, the katA::Tn mutant survived
signicantly better than the JE2 WT in human blood (P < 0:0001 at 6 h) with 10-fold
more bacteria viable at 6 hours. As loss of KatA can aect the expression of other
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Figure 5.11: Genetic complementation of the hemB and menD SCV restores
catalase activity back to WT levels. H2O2 (100 M in PBS) was incubated with
107 CFU of either USA300 WT, the hemB SCV containing pCL55 with or without the
hemB gene, the menD SCV containing pCL55 with or without the menD gene or a PBS
(no bacteria) control. The concentration of H2O2 was measured over one hour using the
Thermo-Fisher Pierce quantitative peroxide assay and a standard curve. Results shown
are the result of at least four independent experiments done in duplicate and error bars
represent SEM.
oxidative-stress genes, bovine catalase activity was added to human blood in addition to
JE2 WT bacteria to explore further the role of catalase. However, there was no benet
to S. aureus of adding catalase to blood, with no signicant dierence between survival
of JE2 incubated with or without catalase. As S. aureus produces a second enzyme,
AhpC, that can break down H2O2 and potentially compensate for KatA, the survival of
an ahpC ::Tn mutant in human blood was then examined. Loss of ahpC however, did
not signicantly aect JE2 survival. Overall, these results suggest that the ability of S.
aureus to break down H2O2 may not be important for JE2 survival in blood and that
other oxidative stress resistance genes are involved.
As S. aureus strains vary in their expression of virulence factors and oxidative stress
defences such as STX pigment, it was determined whether H2O2-degrading enzymes
were important for the survival of strains other than USA300. Therefore, the survival
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of the MSSA strain SH1000, and SH1000 mutants decient in katA, ahpC and a katA
ahpC double mutant were tested during incubation in blood (Figure 5.12B). As shown
previously in Figure 4.2, SH1000 survives better than USA300 in blood, with 22% of
the bacteria viable at the 6 h timepoint. Paradoxically, unlike USA300, loss of katA
did not aect survival of SH1000, with 28% of the bacteria surviving at 6 h, i.e. no
signicant dierence was detected between SH1000 and the SH1000 katA::Tn mutant.
However, when ahpC was deleted, survival was signicantly reduced compared to the
WT, with only 2.8% of the bacteria viable after 6 h (P < 0:003). Survival of the katA::Tn
ahpC ::tet double mutant was similar to the katA::Tn mutant, which suggests that ahpC
but not katA is important for survival of SH1000 in blood, with katA not contributing
to survival even in the absence of ahpC. This experiment demonstrates that dierent S.
aureus strains utilise dierent mechanisms to cope with oxidative stress in blood.
Figure 5.12: The importance of oxidative stress resistance genes in human
blood depends on the strain of interest. Survival of (A) JE2 WT with or without
catalase and oxidative stress mutants JE2 katA::Tn, perR::Tn, ahpC ::Tn and (B) SH1000
WT and oxidative stress mutants SH1000 katA::Tn, ahpC ::tet and katA::Tn ahpC ::tet
after incubation with human blood is shown. Survival was measured by CFU plating
and is presented as a percentage of the inoculum. Data shown is the mean of at least
three experiments repeated in duplicate and error bars represent SEM.
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5.8 Catalase contributes to SCV survival in human blood
Previously, it was shown that the menD SCV has signicantly higher catalase activity
than WT S. aureus (Figure 5.10). As catalase was important for resistance against
H2O2, the role of catalase in SCV survival in blood was tested. Survival of a menadione-
auxotrophic SCV, SCV1072, after incubation in human blood was tested alongside
SCV1072 katA::Tn and SCV1072 katA::Tn ahpC ::Tn. As can be seen in Figure 5.13,
SCV1072 survived well in blood, with 75% of the bacteria viable at the 6 h timepoint,
similar to the 67% survival seen for the USA300 menD SCV (Figure 4.6). However,
when katA was disrupted, survival dropped to 40% at the 6 h timepoint, which was
statistically signicant (P < 0:041). In the double katA::Tn ahpC ::tet mutant, less than
30% of the inoculum was viable after 6 h, although the dierence between SCV1072 and
the mutant was not signicant (P = 0.052). This result indicates that KatA but not
AhpC production contributes to survival of SCV1072.
Figure 5.13: Loss of catalase decreases survival of SCV1072 in human blood.
Survival is shown as a percentage of the inoculum after SCV1072, SCV1072 katA::Tn
and SCV1072 katA::Tn ahpC ::tet were incubated with human blood for up to 6 h. Data
shown represents the mean of at least three experiments repeated in duplicate and error
bars represent SEM.
In Chapter 4, it was shown that co-incubation of USA300 WT with the menD SCV
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led to increased survival of the WT, suggesting that the menD SCV was able to protect
the WT from killing (Figure 4.10B). As increased catalase activity was detected in the
menD SCV and KatA appears to contribute to its survival in blood, it was hypothesised
that this might protect the WT from killing. To test this, the USA300 WT strain
was mixed with either SCV1072 or SCV1072 katA::Tn at a 1:1 ratio and human blood
was inoculated with 104 CFU in total. Survival of USA300 WT at 2, 4 and 6 h post-
incubation was measured by plating onto oxacillin CBA plates. This enabled the survival
of only the WT strain to be determined as both SCV1072 strains were sensitive to
oxacillin. No signicant dierence was detected when USA300 was co-incubated with
either SCV1072 or SCV1072 katA::Tn, with around 17% of the USA300 WT viable at 6 h
regardless of whether SCV1072 had an intact katA gene or not (Figure 5.14). However,
survival of USA300 WT was also not aected by the presence of SCV1072 as survival
of a WT only control was not signicantly dierent (data not shown). Therefore, KatA
production by SCV1072 does not protect the WT from killing in human blood. However,
it cannot be ruled out that the menD SCV in the USA300 background might protect
the WT via KatA production or an alternative mechanism that is strain-dependent as
SCV1072 is derived from SH1000.
5.9 Metal levels vary in the hemB and menD SCVs compared to the
WT
Susceptibility of bacteria to oxidative stress is partly determined by intracellular metal
levels in the bacterial cell. It was hypothesised that metal levels such as iron might be
reduced within the SCVs due to loss of the TCA cycle that utilises a number of proteins
containing iron-sulfur clusters [547]. This would then, in turn, be expected to make
SCVs less susceptible to H2O2. To test this, USA300 WT and the hemB and menD
SCVs were grown in TSB for 18 h. Approximately 109 CFU were lysed by treatment
with lysostaphin for one hour and bacterial lysates were then analysed by Inductively
Coupled Plasma Mass Spectrometry (ICP-MS). This was done in collaboration with
Barry Sampson and Nicholas Martin at the SAS Trace Element Laboratory in Charing
Cross Hospital.
The bacterial lysates were analysed undiluted or diluted 1:10 in MilliQ water for
levels of manganese, iron, copper and zinc. Lysates were compared to the lysis buer
and TSB to check the levels of metal that the lysates would obtain from the preparation
buers or growth medium. Values calculated were then corrected based on CFU counts
and the results are shown in Figure 5.15.
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Figure 5.14: Catalase production by SCV1072 does not protect JE2 S. aureus
from killing in human blood. JE2 was co-incubated with either SCV1072 (grey line)
or SCV1072 katA::Tn at a 1:1 ratio before inoculating human blood with 104 CFU in
total. Percentage survival of JE2 at 2, 4 and 6 hours post-incubation is shown and was
measured by plating on oxacillin plates to select for JE2. Data shown represents the
mean of at least three experiments repeated in duplicate with error bars representing
SEM.
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Figure 5.15: The intracellular levels of iron and manganese vary in SCVs compared to the WT. The concen-
tration of manganese, iron, copper and zinc was measured in USA300 WT and the hemB and menD SCV. Bacteria (109
CFU) were lysed using lysostaphin and bacterial lysates were analysed undiluted or diluted in carrier wash solution using
ICP-MS in helium mode. Data presented represent the corrected metal concentrations of 109 CFU from three independent
experiments. Asterisks show signicance as measured by the Student's T-test (* P  0.05; ** P  0.01; *** P  0.001) and
error bars represent SEM.
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In the hemB and menD SCVs, manganese levels were higher than the WT (2186
nmol in 109 CFU), with 3580 nmol of manganese detected in 109 CFU of the hemB
SCV and 5271 nmol in the menD SCV (Figure 5.15A), although these dierences
were not statistically signicant. Manganese levels were also higher in the bacterial
lysates than the lysis buer (278 nmol ml 1) or growth medium TSB (449 nmol ml 1).
In contrast, iron levels in the SCVs were signicantly reduced compared to the WT
(Figure 5.15B), with iron levels similar to that of the TSB growth medium, which did
not contain bacteria. Copper levels appeared to be reduced in both SCVs compared to
the WT, whilst zinc levels were similar across all of the strains (Figure 5.15 C,D).
However, both copper and zinc levels were extremely low in the bacteria, with the
undiluted samples falling outside of the target range (10{100 mol L 1). Therefore,
these results are not reliable and cannot be used to determine if dierences in copper
and zinc production exist between the WT and SCVs.
5.10 Discussion
It was hypothesised that SCVs might be more sensitive to oxidative stress on the basis of
decreased pigmentation and reduced katA activity [343, 543]. However, in this chapter,
experiments were conducted that demonstrate the opposite is true, with both the hemB
and menD SCVs signicantly more resistant to 15, 20 and 25 mM H2O2. This increased
resistance to H2O2 may explain the ability of SCVs to survive within blood as ROS
production appears to be the main mechanism of killing within blood, as inhibition of
the NADPH oxidase using DPI blocked the majority of killing of WT S. aureus. Whilst
treatment of blood with DPI did lead to a slight increase in survival of the hemB SCV,
there was no increase in survival with the menD SCV.
The increased resistance of the menD SCV to oxidative stress and killing within
human blood could be attributed in part to the up-regulation of KatA. Although a couple
of reports have shown decreased expression of katA in SCVs, a transcriptomics study
by Moisan et al. (2006) also reported increased katA in a hemB SCV and three clinical
SCVs, with expression 2{4-fold higher than the WT Newbould strain [432, 543, 611].
However, no signicant increase in katA expression was detected in either the hemB or
menD SCVs using qPCR. This may be due to the large amount of variation within the
qPCR results, which could have obscured small dierences in katA expression between
the strains. Alternatively, it may be that protein levels of KatA are more stable within
the SCVs, enabling the higher KatA activity within the menD SCV.
However, up-regulation of KatA can only partially explain the reduced susceptibility
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of the menD SCV to killing in human blood as loss of KatA in SCV1072 did not reduce
survival to the same levels as the WT. In addition, the hemB SCV lacks KatA activity
due to loss of haem biosynthesis, yet it survives just as well as the menD strain in
human blood. Activation of the major regulator PerR, which controls the expression of
a number of oxidative stress genes, was not signicantly dierent in the SCVs compared
to the WT and thus could not explain why SCVs were more resistant.
In this chapter, it was shown that dierences in the intracellular levels of various
metal ions in the SCVs compared to the WT could be an important mechanism that
might enable SCVs to survive H2O2 stress and neutrophil killing. In the hemB and
menD SCVs, iron levels were reduced compared to the WT. This was unsurprising as
loss of the ETC and reduced TCA activity in SCVs would be expected to reduce the
amount of iron-sulfur proteins in the cytoplasm. As iron can react with H2O2 to produce
damaging OH , reduction in the levels of iron could benet S. aureus under oxidative
stress conditions. In the genetic screen, it was observed that the JE2 fur ::Tn mutant
cultured with HQNO was signicantly more susceptible to H2O2 than the fur ::Tn mutant
grown without HQNO. As Fur acts to repress iron transporters, loss of fur in the SCVs
could lead to increased acquisition of iron that increases susceptibility of the SCVs back
to WT levels.
In addition to decreased levels of iron, the SCVs had higher levels of manganese,
although this was not statistically signicant. Manganese is an important co-factor of
SodA and SodM and is less susceptible to oxidation than iron due to a higher reducing
potential [347, 600]. The importance of manganese to S. auerus is highlighted by the
fact that neutrophils restrict the levels of manganese in the phagosome using calprotectin
and Nramp1 [591, 616]. S. aureus attempts to respond to this by scavenging manganese
via the MntABC transporters, with mntABC mutants shown to be more susceptible to
neutrophil killing [349, 617]. The results shown in this chapter conrm the importance
of mntABC for the survival of S. aureus in H2O2, as loss of mntA, mntB or mntC
led to reduced survival of the JE2 strain cultured with or without HQNO. Although
manganese does not degrade H2O2, O2 can liberate iron, which can react with H2O2
[275, 594]. Therefore, the increased manganese in the SCVs might promote SOD activity
and protect the strains from neutrophil killing in human blood.
Mutants decient in key oxidative-stress resistance mechanisms were tested within
human blood to identify genes that contribute to the survival of WT S. aureus. KatA and
AhpC have previously been shown to not be important for survival during incubation
with neutrophils [351]. However, these mutants were only tested with neutrophils in
isolation and not within human blood. Interestingly, JE2 katA::Tn survived signicantly
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better than the WT JE2 strain, despite KatA being essential for survival in the H2O2
genetic screen. It is also surprising based on the results that show that KatA contributes
to SCV survival. However, previous work has shown that loss of katA leads to up-
regulation of the PerR regulon, which could explain why loss of katA leads to increased
survival [351]. To support this, a perR::Tn mutant, which has increased expression
of oxidative stress genes, was signicantly less susceptible to killing in blood than the
WT strain. However, survival of the perR::Tn mutant was not as high as the katA::Tn
mutant, which could suggest that loss of katA leads to additional changes that enable S.
aureus survival within blood [351].
Loss of ahpC had no eect on survival of JE2 in blood despite reports that loss
of ahpC can also increase the expression of PerR-regulated genes [351]. Although this
corresponds well with the H2O2 genetic screen where AhpC did not contribute to S.
aureus survival, when the same oxidative stress mutants were tested in SH1000, results
contradicted those found with JE2. In SH1000, loss of katA did not aect survival in
human blood, whilst loss of ahpC was detrimental for survival. These results suggest
that JE2 and SH1000 both resist killing in human blood by resisting oxidative stress but
that the proteins utilised to provide oxidative stress resistance are dierent. As shown
in Chapter 3 and this chapter, SH1000 is signicantly more resistant to killing in blood
compared to the MRSA strains, JE2 and USA300, which suggests that SH1000 either
expresses the same genes more strongly or that it has developed alternative mechanisms
to resist oxidative stress and avoid killing in human blood.
To summarise, SCVs are able to resist H2O2 and this resistance may enable them to
survive the neutrophil oxidative burst and explain why SCVs survive so well in blood.
In the menD SCV, KatA activity was higher than WT S. aureus and this contributed
to its survival in blood and H2O2. However, catalase is not the whole story as the
hemB SCV lacks catalase activity and loss of katA in a menadione-auxotrophic SCV
did not reduce survival to WT levels. The reduced levels of iron and elevated levels of
manganese provides an alternative explanation as to why SCVs are more resistant to
oxidative stress.
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6 Discussion
6.1 Agr dysfunction and persistent SAB
The aim of this project was to assess the importance of Agr in the survival of WT and
SCV S. aureus in the bloodstream. Agr has been shown to be important for bacterial
survival in a number of animal models, with agr mutants less virulent in infections
such as endocarditis, keratitis, pneumonia, arthritis and endophthalmitis [4, 62{69]. In
addition, in vivo data from studies that have assessed the survival of S. aureus after
incubation with isolated neutrophils, have shown that Agr is important [334, 355, 356].
However, clinical studies have reported that strains defective in Agr are often isolated
from patients with persistent SAB, which suggests that Agr is not important for S.
aureus survival in blood [385, 386, 404{415]. Therefore, to assess the role of Agr during
bacteraemia, an ex vivo whole human blood model was used to better represent the
in vivo environment. These results correlated well with the in vivo data, with loss of
agr associated with increased killing, demonstrating that Agr is necessary for maximal
survival of WT S. aureus in human blood.
The reason for the discrepancy between the clinical data and the in vivo data is not
fully understood. However, it is now known that in many of the clinical studies, agr
dysfunction is overestimated as functionality is usually tested using the CAMP assay.
The CAMP assay is a semi-quantitative test that lacks sensitivity and many strains
that are reported as agr -defective in this assay are still capable of producing toxins that
can lyse phospholipid vesicles [415]. This new method, named the vesicle lysis test, is a
more accurate way to test agr functionality and is substantially less time-consuming than
alternatives such as Northern blotting and quantitative reverse transcriptase PCR that
measure RNAIII, as well as being much cheaper than methods such as MALDI-TOF
mass spectrometry [415]. With the cost of whole genome sequencing now becoming
aordable, this could also be utilised by hospitals to quickly assess agr functionality
[419].
Although agr dysfunction does appear to be overestimated in the clinical studies,
there is evidence that some clinical isolates lose Agr function during the course of infec-
tion, with these strains incapable of lysing the phospholipid vesicles [415]. This suggests
that in certain circumstances, Agr expression does not benet S. aureus survival and so
there is no selection to maintain a functional Agr operon. Alternatively, loss of Agr may
facilitate persistent SAB via other phenotypic properties. For example, it may promote
increased colonisation and biolm formation and/or intracellular survival. These two
scenarios will be discussed in further detail below.
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6.1.1 The importance of Agr for survival in blood depends on the host
environment
Transmission of S. aureus between dierent hosts has been linked to its high level of
virulence [618]. Patients infected with a highly virulent strain of S. aureus are more likely
to display symptoms and have increased contact with healthcare workers, both of which
encourage transmission. Some of the virulence of S. aureus can be attributed to Agr
expression, with Agr responsible for controlling numerous toxins that enable it to lyse
host immune cells and overcome host defences. Therefore, Agr expression also promotes
transmission. The importance of Agr in transmission means that agr mutations are
often short-lived and transmission of agr mutants between healthy individuals are rare
as loss of Agr function is disadvantageous to the bacterium [407].
However, in a hospital or healthcare setting, a large proportion of the patients have
a weakened immune system and some patients may have signicantly lower numbers of
immune cells than healthy individuals. Patients within healthcare settings are normally
the most susceptible to S. aureus infections [256{258, 261]. When the respiratory burst
is defective, neutrophils cannot kill S. aureus eciently and this result was supported in
this thesis by the data showing that DPI-treated blood was unable to cause a signicant
amount of killing [268]. Certain individuals, such as the elderly and diabetics, cannot
generate the same strength of respiratory burst as healthy individuals and, due to their
increased visits to healthcare settings, they are much more likely to get an infection
[220, 619, 620]. Although Agr is important for transmission amongst healthy individuals,
loss of agr can be tolerated in individuals with lowered immune systems as the normal
defences that prevent S. aureus establishing an infection are lost. This is supported by
studies that have shown that agr mutants tend to be associated with individuals that
have had a recent stay within hospital or who have been in very close contact with a
hospital patient [407]. In addition, a study by Chong et al. (2013) reported a case
of clonal spread of an agr mutant within a tertiary hospital within Korea [413]. As
agr expression is very costly for the bacterium, with S. aureus frequently acquiring agr
mutations in vitro after repeated subculture, it may be that loss of agr could increase
the tness of the bacteria in the bloodstream of immunocompromised patients [400].
In many infections, agr mutants are isolated as a mixed population, with agr -positive
bacteria also detected [401, 404, 405, 407, 412]. These agr mutants might be able to
exploit this situation, beneting from the nutrients released from host cells after toxin
production by agr -functional strains, without the cost of agr expression. Therefore,
it would be interesting to test how an agr mutant would survive in the ex vivo whole
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human blood model during a co-infection with the agr -functional WT strain.
Consequently, the importance of Agr is dependent on the environment that the bac-
teria is in. This is supported by the fact that most community-associated strains of S.
aureus, which are capable of infecting healthy individuals, tend to have high levels of
Agr expression. By contrast, hospital-associated strains that do not require a high level
of virulence for transmission, are more likely to have lower Agr expression or acquire
mutations that inactivate the Agr system [54, 413, 618].
6.1.2 The balance between Agr expression and antibiotic resistance
In addition to hospital-associated strains not requiring high levels of Agr expression for
transmission, the hospital environment may also select for reduced Agr expression. For
example, it has been shown that the antibiotic pressures that S. aureus encounters in the
hospital select for a reduction in agr expression and a concomitant increase in resistance
to antibiotics such as methicillin and vancomycin [54, 403, 411, 414, 420, 421, 579, 581,
582, 621]. Resistance to -lactam antibiotics is often attributed to the presence of the
SCCmec element and in health-care associated strains, this element also acts to reduce
levels of Agr and toxin expression through the fudoh gene and the PSM-mec element
[580, 622]. The use of the alternative transpeptidase, PBP2a/PBP2', which is encoded by
mecA on the SCCmec element and provides resistance to -lactams, may also modify the
cell wall and prevent agr activation [421]. Cell wall modication also aects resistance to
the antibiotic vancomycin and this, again, may select for agr mutants [623]. To determine
whether loss of agr is benecial for S. aureus after exposure to antibiotics, survival of
WT S. aureus and agr mutants could be tested in blood containing antibiotics such as
methicillin and vancomycin at the MIC for the strain in question. It would be useful to
do this with a selection of HA- and CA-MRSA strains to see if the background in question
aects survival. It has been noted that loss of agr is associated with the acquisition of
mutations that render S. aureus more resistant to vancomycin [411, 414, 420, 581, 582].
It would be interesting to test whether sub-culturing S. aureus agr mutants in blood, or
broth as a comparison, would result in an increased MIC to vancomycin. These strains
could then be sequenced if resistance did occur, to test which mutations were responsible.
By testing the agr mutants alongside WT S. aureus, the mutation rate for the acquisition
of mutations conferring resistance to vancomycin could also be determined and compared
to see if loss of agr predisposes S. aureus to vancomycin resistance, as has been proposed
by Sakoulas et al. (2002) [624].
Increased resistance to vancomycin and Agr dysfunction is also associated with in-
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creased resistance to tPMPs [403, 420, 583]. Most of this association seems to be linked
to the reduction in autolysis of agr mutants. Autolysis is also linked to bacterial killing
after exposure to -lactams [584]. Previous studies have shown that Agr positively regu-
lates autolysis and therefore, agr mutants have reduced autolysis [420, 584]. It would be
interesting to see if the USA300 agr mutants constructed in this study are less susceptible
to autolysis by other environmental triggers. This could be easily tested by measuring
the change in optical density after incubation of the strains with Triton X-100 [625].
6.1.3 Loss of Agr may be important for other phenotypes that help promote
S. aureus survival during bacteraemia
S. aureus is able to form biolms on materials such as intravenous catheters and pros-
thetic devices [586]. As bacteria within a biolm are less susceptible to antibiotics, this
provides a means for S. aureus to persist within the hospital [139]. This niche also pro-
vides the opportunity for S. aureus to cause recurrent bacteraemia, as the bacteria can
easily disperse from the biolm and seed into the bloodstream [140]. Although not com-
pletely understood, loss of agr generally results in the increased formation of biolms
[475, 572, 626]. The use of antibiotics can select for reduced agr expression and thus,
increased biolm formation [588]. Biolms formed by agr mutants have also been shown
to be denser and more compact than biolms formed by strains with functional Agr. It
is known that the increased production of adhesins such as FnbpA, Spa and SasG, by the
agr mutants, helps promote biolm formation [572]. Agr expression, on the other hand,
tends to be associated with dispersal, with the production of Agr-regulated proteases
and surfactants, such as -toxin and the PSMs, able to disrupt bacterial adhesion [626].
Therefore, Agr dysfunction might be associated with persistence in the bloodstream due
to the increased ability of the bacteria to form biolms.
Loss of Agr has also been linked to intracellular persistence within a range of host
cells, including endothelial cells, and this might oer another explanation as to why
agr mutants are associated with persistent SAB [126, 127, 379, 573, 578, 627, 627{
630]. Once inside the bloodstream, S. aureus can rapidly adhere to the endothelium
and this adherence is promoted by the down-regulation of Agr, due to the up-regulation
of genes that encode adhesins [380, 384, 631, 632]. This means that higher rates of
invasion tend to be observed for agr mutants compared to Agr-functional strains [376].
In addition, loss of agr results in down-regulation of toxin expression and this reduces
the cytotoxicity of the strains, preventing them from lysing the host cell and facilitating
intracellular persistence [633, 634]. As cells such as endothelial cells are not well adapted
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to killing bacteria, this would provide a niche that S. aureus could use to escape killing
by professional phagocytes such as macrophages and neutrophils [635].
6.1.4 The use of Agr inhibitors to prevent SAB
Due to the importance of Agr for virulence in many dierent types of S. aureus infec-
tions, much work has been undertaken to develop Agr inhibitors that could be used
therapeutically to prevent serious outcomes. The benet of these inhibitors is that they
oer an alternative to antibiotics, which S. aureus is becoming increasingly resistant to.
In addition, these inhibitors are less likely to place bacteria under such strong selec-
tive pressure, such as after antibiotic treatment, with it reported that bacteria are less
likely to develop resistance mechanisms to these inhibitors. After the discovery of agr
interference, it was recognised that Agr could be inhibited in S. aureus by subjecting
the bacteria to AIP of a dierent agr type [85]. For example, Agr could be inhibited
in an agr type II strain with either AIP1, AIP3 or AIP4. As these molecules can be
produced synthetically, this enables additional modications to the molecules, which
could facilitate their therapeutic use. Although blocking agr through this method has
been shown to reduce virulence in a mouse dermonecrosis model, the problem with using
AIP to interfere with agr is that the strain of question needs to be agr typed before the
molecule can be used [636, 637]. Agr typing is a time-consuming process however, and
for Agr inhibitors to be eective, it is likely that the treatment would need be given soon
after an S. aureus infection is identied. Therefore, alternative inhibitors might be more
suitable within the hospital and over the years, an increasing number of molecules have
been identied that aect Agr function in a variety of ways. These include the RNase
protein RnaP, that blocks Agr expression by reducing levels of RNAIII; Savirin that
binds to AgrA and blocks it from binding DNA and Solonamide B, which competitively
binds AgrC and blocks its activation by AIP [355, 637, 638].
In this thesis, AIP3 was used to inhibit Agr expression of USA300, which is of the agr
type I. This led to reduced survival of S. aureus within the bloodstream and lends support
to using Agr inhibitors as a therapeutic aid in patients with staphylococcal bacteraemia.
In this experiment, bacteria were cultured with the inhibitory AIP prior to incubation
with blood. However, in real-life, Agr expression is likely to only be important after
uptake by host cells such as neutrophils, as Agr is already blocked by the action of host
molecules such as haemoglobin and apolipoprotein B [360, 361, 395, 396]. Therefore, to
ensure that Agr expression was prevented inside host cells, the inhibitor of choice would
either need to be cell-permeable or it would need to block Agr activation before uptake
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and be long-lived.
The use of Agr inhibitors is controversial however, with it thought that inhibiting
Agr could promote persistence [637]. As loss of Agr might benet S. aureus in the host,
use of these inhibitors could actually be detrimental. In addition, it might select for
Agr-independent methods of survival, such as the SCV phenotype that is described in
the next section.
6.2 The Agr-independent survival of SCVs
Previous publications have shown that SCVs are associated with persistent infections
and that they are often isolated from patients with bacteraemia [431, 490, 491, 496, 507].
The work from this thesis supports these studies, with it shown that the SCV phenotype
is benecial for survival in an ex vivo whole human blood model. Although it has been
previously hypothesised that the low level of Agr expression in the SCVs is the reason for
their increased survival during infection, in this work, it was found that the mechanism
for SCV survival was Agr-independent as agr mutants were more susceptible to killing
[454, 503]. Despite their low level of Agr expression, SCVs were able to survive much
better than even WT S. aureus.
The mechanism for the increased survival of the SCVs in human blood is at least
partly due to their decreased susceptibility to oxidative stress, as the SCVs tested were
also more resistant to H2O2 than WT bacteria. This result conicts with previous studies
that have suggested that SCVs might actually be more susceptible to oxidative stress due
to their decreased pigmentation and a couple of studies that have shown that catalase
expression is reduced in SCVs [343, 497, 543, 611].
6.2.1 Elevated catalase expression in the menD SCV contributes to survival
in blood
In this thesis no catalase activity was detected for the hemB SCV. This ts in with pre-
vious studies and was expected on the basis that the hemB SCV lacks haem biosynthesis
[352, 543]. However, surprisingly, the menD SCV had much higher catalase activity than
even WT S. aureus. This may be due to increased levels of the KatA protein as the
transcription of KatA was not signicantly dierent from the WT or hemB SCV.
The elevated catalase activity contributes to survival of the menadione-auxotrophic
SCV within blood as disrupting KatA signicantly reduced the survival of the SCV in
the ex vivo whole human blood model. This can, however, only explain partly why SCVs
are less susceptible to killing in blood, as the hemB SCV was still able to survive just as
182
well as the menD SCV despite lacking catalase activity. In addition, disruption of katA
in WT USA300 actually led to increased survival of the strain in blood, whilst loss of
katA had no aect on SH1000. Interestingly, AhpC (another enzyme capable of breaking
down H2O2) did contribute to survival in blood for strain SH1000, which suggests that
in certain strains this enzyme can protect S. aureus from killing. As loss of genes such
as katA often lead to up-regulation of alternative oxidative stress mechanisms, it would
be interesting to see if other members of the PerR regulon can compensate. This could
be achieved by measuring transcript levels of the PerR-regulated genes in the strains
where katA or ahpC had been deleted.
6.2.2 Do low iron and high manganese levels in the SCVs lead to ROS
resistance?
Since the hemB SCV survives just as well as the menD SCV in blood and H2O2, it
seemed likely that there was an alternative explanation that could apply to both SCVs.
One way that H2O2 kills bacteria is by reacting with iron found in proteins and, via
the Fenton reaction, this can generate damaging O {2 and OH that along with H2O2
can damage proteins and DNA [272, 274, 639]. By analysing culture lysates of bacteria
by mass spectrometry, it was found that levels of iron within the hemB and menD
SCVs was much lower than for the WT. In addition, it was found that SCVs had much
higher levels of manganese and this could also contribute to oxidative stress resistance
as manganese acts as a natural SOD and is required for the function of enzymes such
as SodA and SodM, which defend against O {2 stress [346{348]. Manganese has been
shown to be important in S. aureus to defend against neutrophil killing, with mutants
decient in manganese transport signicantly more susceptible to killing [349, 617]. To
conrm the mass spectrometry result, it would be useful to test whether levels of iron
and manganese in the complemented hemB and menD strains are similar to WT levels
compared to the plasmid only controls.
Using mass spectrometry, it was possible to test total levels of iron associated within
the dierent strains. However, the Fenton reaction targets specically free iron [272].
To test whether the Fenton reaction is a major contributor to cell damage in the WT
bacteria, the levels of free iron in the dierent strains could be measured using electron
paragmagnetic resonance (EPR) spectroscopy. Previous studies assessing free iron levels
in E. coli have utilised EPR spectroscopy, using desferrioxamine or H2O2 to convert free
iron to its ferric state to enable detection [275]. To determine whether SCVs are more
resistant to oxidative stress due to reduced free iron levels, the levels of free iron could
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be altered within the WT and the SCVs and susceptibility to H2O2 could be tested. One
way this could be achieved, would be to incubate WT bacteria with iron chelators such as
dipyridyl, o-phenanthroline, and desferrioxamine, which can penetrate the bacterial cell.
Alternatively, WT bacteria could be grown under iron-limited conditions. Susceptibility
of the WT (grown with or without the iron chelators or grown in iron-limited or rich
media) to H2O2 could then be assessed. Alternatively, free iron levels could be increased
within the SCV by disrupting iron storage molecules such as Ftn or Bcp, or the iron
chelator MrgA by mutagenesis. Mutagenesis of the fur gene also leads to increased levels
of free iron as loss of Fur relieves repression of iron transporters leading to an increase
in the import of iron [368, 595, 640]. In the oxidative stress screen in Chapter 5, loss
of Fur appeared to lead to decreased survival of HQNO-treated JE2 after exposure to
H2O2. Therefore, it would be interesting to test free iron levels in this strain. Bacteria
with higher levels of free iron could also be tested in the ex vivo whole blood model to
test if they are more susceptible to killing in the bloodstream.
Under iron-rich conditions, haem has been shown to accumulate in the bacterial
membrane [641]. This haem is able to react with oxygen to generate haemin and O {2 ,
which could contribute to killing of the bacteria in addition to neutrophil killing. Mena-
dione biosynthesis can also contribute to this stress, with menaquinone able to donate
electrons to haemin, leading to the formation of semiquinone. Semiquinone can then
react with oxygen to generate O {2 . Therefore, SCVs that lack menadione or haemin
biosynthesis are likely to be subject to reduced haem stress and this could contribute to
survival against H2O2. Levels of haem could be measured in the SCVs alongside the WT
to assess whether levels are reduced in the SCV. It has been suggested previously that
a menadione-auxotrophic SCV also has reduced haemin biosynthesis so it is plausible
that both SCVs would not be subject to the same amount of haem stress as the WT
[544, 545]. To see if this internally generated stress might contribute to SCV survival
against external stresses such as blood and H2O2, the amount of internal ROS produced
by the SCVs could be compared. This could be carried out by comparing the amount of
ROS produced by WT bacteria with mutations in katA and ahpC, with SCVs containing
the same mutations. These mutations would prevent the bacteria from breaking down
the H2O2, enabling the amount of internally-generated ROS to be measured.
To determine if manganese contributes to the SCVs increased resistance to H2O2
and blood, the SCVs could be grown in medium with minimal amounts of manganese
or grown in the presence of calprotectin, which sequesters manganese [349]. It is likely
however, that both reduced iron and increased manganese levels contribute to oxida-
tive stress resistance. This mechanism has been adopted by the organism Lactobacillus
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plantarum, which requires a high degree of oxidative stress resistance as the organism
consumes oxygen to generate H2O2, which may be used to kill competing organisms
[642]. L. plantarum protects itself against the H2O2 by having a high rate of manganese
uptake, resulting in intracellular levels of manganese as high as 30{35 mM. In addition,
the bacterium has extremely low levels of iron, which reduces the amount of damaging
ROS generated.
ROS can kill bacteria by damaging DNA and generating deleterious mutations, or by
oxidising amino acids or proteins, leading to protein aggregation and the disruption of
the protein's function [352]. It would be useful to assess whether reduced iron levels and
increased manganese levels leads to decreased levels of DNA damage, protein damage,
or both. DNA damage could be assessed using PCR, the TUNEL assay or the bacterial
comet assay [643, 644]. Whilst, protein damage could be assessed using a kit such as
the OxyBlot kit, which detects the carbonyl groups that are formed by the oxidation of
protein side chains. The amount of DNA or protein damage would need to be assessed
before and after exposure to H2O2. To understand how important levels of iron and
manganese are to oxidative stress resistance, oxidative damage could be measured in
the WT and SCV where levels of these metals have been altered. Once the mechanism
and/or pathways are understood, it may then be possible to design novel therapeutics
that promote the eradication of SCVs [645].
6.2.3 Do the metabolic dierences between the WT and the SCV phenotype
account for why levels of metal ions vary?
As SCVs are decient in the ETC, it is likely that their need for iron is greatly reduced
as many of the proteins that require iron perform in the ETC, such as cytochromes
and proteins involved in the TCA cycle [646]. Instead, SCVs utilise substrate-level
phosphorylation to obtain energy, and the enzymes that participate in this process do
not require iron [646]. SCVs are likely to be unable to acquire iron in blood to the
same extent as WT due to their reduced expression of agr and inability to produce
haemolysins [434]. It would be worth testing whether iron and manganese uptake is
altered in the SCVs compared to the WT to see whether this explains why intracellular
levels of these metals vary.
It is not known how metal homeostasis is regulated in the SCVs, although one protein
that may be involved is the ClpC protein, which belongs to a family of proteases that are
involved in S. aureus stress resistance [647]. These proteases have also been previously
linked to the persister phenotype [605, 648]. ClpC is known to be important during late
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growth phase, when bacteria start to become depleted of nutrients, with ClpC involved in
enabling S. aureus to switch on the TCA cycle and resist the oxidative stress generated
from oxidative phosphorylation [605]. Interestingly, it has been found that levels of clpC
are reduced in a thymidine-decient SCV [436]. Loss of clpC leads to a reduction in
the TCA cycle and metal homeostasis is aected, with decreased iron levels seen in a
clpC mutant after 24 and 48 hours growth and increased expression of the mntABC
operon that encodes the manganese transporters [648]. Levels of iron did appear higher
at 72 and 96 h of growth in the clpC mutant however and protein levels of MntC were
higher in the WT despite the reduced transcription of the operon. Nevertheless, it would
be interesting to see whether clpC levels vary in the hemB and menD SCVs, as seen
for the thyA SCV, and whether this may explain why metal ion levels are dierent in
the SCVs. It would also be useful to test whether other members of the Clp family are
involved or whether other regulators that are involved in metabolism might be involved
in regulation of metal homeostasis.
6.3 Building a more realistic model system
The ex vivo whole human blood model was a good system to use to determine whether
Agr or the SCV phenotype contributed to S. aureus survival in blood. S. aureus has
adapted to cause infections in humans and produces a number of molecules that speci-
cally target human cells and molecules [179, 194, 548, 552]. This model, therefore, more
accurately reects the situation in humans than a mouse or rabbit model. In addition,
in the ex vivo whole human blood model, S. aureus survival is tested with all of the com-
ponents found in blood, unlike in the neutrophil killing model, where S. aureus survival
is tested in isolation with neutrophils [278, 290, 320, 343, 364, 554]. This model was also
cost-eective, with results obtained in less than two days, enabling more information to
be obtained than would have been possible with animal models, which are more costly.
However, there are a number of ways that this model could be enhanced to provide
a more realistic model of the human host. It has been shown that once inside the
bloodstream, the majority of S. aureus rapidly adheres to the endothelium [380]. S.
aureus may then release toxins that damage the endothelium and cause the release of
cytokines and chemokines that signal for the activation and recruitment of immune cells
such as neutrophils [261]. Interactions with the endothelium may be exploited by S.
aureus as the bacterium can invade endothelial cells and persist intracellularly, or by the
process of extravasation, S. aureus can penetrate the surrounding tissue [384]. These two
mechanisms may enable S. aureus to persist during SAB, with bacteria able to escape
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the surrounding tissue and/or endothelium, and seed back into the blood.
As mentioned earlier, loss of Agr promotes intracellular survival of S. aureus, and
this could be another explanation for why agr mutants and SCVs are associated with
persistent bacteraemia. Loss of Agr expression initially promotes invasion of host cells,
as this leads to an increase in the expression of bacterial adhesins and a down-regulation
of proteases that act to degrade surface-bound adhesins [376]. Once inside the host
cell, it is thought that loss of agr supports intracellular persistence, as toxin expres-
sion is down-regulated, and this reduces the ability of S. aureus to lyse the host cell
[454]. However, some studies have shown that agr is also important for persistence
in non-professional phagocytes, with agr mutants unable to escape acidication of the
phagolysosome [171, 376, 379, 383, 577, 649]. Therefore, it would be worth testing the
survival of the agr mutants and SCVs used in this study, after incubation of the strains
with human endothelial cell lines such as HUVEC and HMEC-1. If this conrmed stud-
ies showing that loss of Agr is benecial for S. aureus intracellular survival, the strains
could be incubated with human blood in combination with a human endothelial cell
line to try to delineate whether intracellular persistence contributes to the survival of
S. aureus in the bloodstream and whether this enables agr mutants to avoid killing. It
would be interesting to do this under ow conditions, both with and without the cell
line to see how this aects survival, as this would better mimic the situation within the
host. In addition, it would be useful to understand how biolm formation contributes
to the persistence of S. aureus in blood. This could be investigated by incorporating
devices, such as a ow cell, that S. aureus could form biolms on, and then measuring
bacterial survival (Figure 6.1).
To assess whether S. aureus extravasation into the surrounding tissue and survival
in dierent organs provides a means for the bacteria to seed back into the bloodstream
and cause persistent SAB is dicult to test. This would require the use of animal mod-
els, which do not accurately reect the situation in the human host, due to dierences
in their immune system and the species-specicity of some of the molecules S. aureus
produces to persist [179, 194, 548, 552]. Furthermore, this result would likely be ex-
tremely organ-dependent as dierent organs would support S. aureus growth dierently.
Organs such as the kidney are for example replete with haem and this could restore
the haem-auxotrophic SCV to the WT phenotype [460]. In vivo imaging methods that
enable bacteria to be tracked within the animal models such as the mouse are becoming
more sensitive and could one day be used to to try to answer this question.
In the whole blood killing model, EDTA was used as the anticoagulant. This was
necessary to prevent blood clotting and to enable accurate CFU counts so that the
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Figure 6.1: Using a ow cell to achieve a more realistic model system of
bacteraemia. A ow chamber could be incubated with or without an endothelial cell
line to study the interactions of S. aureus with the endothelium and biolm formation,
respectively. Flow conditions could be created by using a peristaltic pump.
survival of S. aureus could be measured. However, it is known that S. aureus can hijack
the coagulation cascade to avoid killing by immune cells. By activating coagulation, S.
aureus can hide within a thrombus to avoid being phagocytosed by neutrophils [320].
Unfortunately, as coagulation was prevented, it is unknown whether this mechanism is
important for the survival of S. aureus in the bloodstream and whether Agr or the SCV
phenotype inuences this process. To enhance the model, it would be worth testing
some of the conditions using an alternative anti-coagulant such as heparin. Although,
each anticoagulant has each drawbacks, for example, heparin is known to chelate iron
and copper and this could therefore reduce the amount of ROS generated after oxidation
catalysed by these metals [650].
The H2O2-killing assay was used to test the resistance of the WT and SCVs to
oxidative stress, to understand whether this might explain why the SCVs survived well
in the bloodstream. It has been shown that ROS is responsible for the majority of
S. aureus killing in the neutrophil and that H2O2 is one of the ROS produced in the
phagosome. It would be useful to build on these results and to test the SCVs against
a range of ROS, such as HOCl and O 2 . This would also help determine whether SCVs
are resistant to a broad range of ROS or whether resistance is specic to H2O2.
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6.4 Summary
Overall, S. aureus has evolved at least two mechanisms to survive and persist during
bacteraemia (Figure 6.2). After neutrophil uptake of WT S. aureus, the bacteria are
able to produce a number of cytolytic toxins to escape the phagosome and avoid the
ROS burst. Bacteria that are exposed to ROS can also resist some of the eects via
the production of the antioxidant pigment, STX [343]. In an alternative mechanism,
S. aureus can acquire mutations that result in the SCV phenotype, which produces
no toxins (due to reduced agr expression) or STX, but is able to survive neutrophil
killing due to increased resistance to oxidative stress. This is partially explained by
elevated catalase activity within menadione-auxotrophic SCVs, but this is not the whole
story. Loss of the ETC in the SCVs leads to reduced amounts of intracellular iron and
increased amounts of manganese, providing a plausible explanation as to why SCVs are
less susceptible to oxidative stress.
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Figure 6.2: A model for S. aureus survival within the bloodstream. Neu-
trophils phagocytose S. aureus located within the bloodstream and the bacteria are
tracked to the phagosome. Here, bacteria are exposed to neutrophil defence molecules
such as ROS, AMPs and nitrous oxide. WT S. aureus can avoid these molecules by pro-
ducing Agr-regulated toxins that enable it to lyse the neutrophil before exposure (A).
agr mutants are unable to escape in this manner and therefore, they are more susceptible
to neutrophil killing (B). Although SCVs lack Agr and therefore toxin production, they
are able to survive within the phagosome due to their increased resistance to ROS (C).
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